Document:

Exhibit 10.3

*Represents language for which confidential treatment has been requested.

ROW TERRITORY LICENSE AGREEMENT 

 

BY AND AMONG 

SHIRE PHARMACEUTICALS IRELAND LIMITED 

SHIRE PHARMACEUTICALS PLC 

AND 

NEW RIVER PHARMACEUTICALS INC. 

 

DATED AS OF MARCH 31, 2005 

TABLE OF CONTENTS  

	 	 	 	 	Page
	 	 	 	 	 
	
ARTICLE 1
        	 
        	
          DEFINITIONS
        	 
        	
2
        
	
ARTICLE 2
        	 
        	
          MANAGEMENT OF COLLABORATION
        	 
        	
11
        
	
2.1
        	 
        	
General
        	 
        	
11
        
	
2.2
        	 
        	
Joint Development Committee (JDC)
        	 
        	
11
        
	
2.3
        	 
        	
Joint Supply Committee (JSC)
        	 
        	
12
        
	
2.4
        	 
        	
Joint Intellectual Property Committee (JIPC)
        	 
        	
14
        
	
2.5
        	 
        	
General Committee Membership and Procedures
        	 
        	
14
        
	
2.6
        	 
        	
Committee Decision-Making
        	 
        	
16
        
	
ARTICLE 3
        	 
        	
          DEVELOPMENT AND REGULATORY RESPONSIBILITIES
        	 
        	
17
        
	
3.1
        	 
        	
Overview
        	 
        	
17
        
	
3.2
        	 
        	
Development Plans
        	 
        	
17
        
	
3.3
        	 
        	
Regulatory Activities
        	 
        	
18
        
	
3.4
        	 
        	
Development in the ROW Territory for ADHD and Other Indications
        	 
        	
18
        
	
3.5
        	 
        	
Shared Expenses
        	 
        	
20
        
	
3.6
        	 
        	
Use of Third Parties
        	 
        	
21
        
	
3.7
        	 
        	
Assistance
        	 
        	
21
        
	
3.8
        	 
        	
Compliance with Laws
        	 
        	
21
        
	
ARTICLE 4
        	 
        	
          COMMERCIALIZATION OF COLLABORATION PRODUCTS
        	 
        	
21
        
	
4.1
        	 
        	
Principles of Commercialization
        	 
        	
21
        
	
4.2
        	 
        	
Sales and Distribution of Collaboration Products to Third Parties
        	 
        	
21
        
	
4.3
        	 
        	
Marketing Plans for ROW Territory
        	 
        	
22
        
	
4.4
        	 
        	
Regulatory Obligations During Commercialization
        	 
        	
22
        
	
4.5
        	 
        	
Diligence in Commercialization
        	 
        	
22
        
	
4.6
        	 
        	
Cost of Commercialization
        	 
        	
22
        
	
4.7
        	 
        	
Use of Third Parties
        	 
        	
22
        
	
4.8
        	 
        	
Promotional Materials
        	 
        	
22
        
	
4.9
        	 
        	
Compliance with Laws
        	 
        	
23
        
	
ARTICLE 5
        	 
        	
          MANUFACTURE OF COLLABORATION PRODUCTS
        	 
        	
23
        
	
5.1
        	 
        	
Manufacture and Supply
        	 
        	
23
        

i 

TABLE OF CONTENTS

(continued) 

	 	 	 	 	Page
	 	 	 	 	 
	
5.2
        	 
        	
Specifications and Terms of Supply; Multiple Sources
        	 
        	
24
        
	
5.3
        	 
        	
Manufacture by Shire; Commercial Supply by Shire
        	 
        	
24
        
	
5.4
        	 
        	
Supply Terms
        	 
        	
25
        
	
ARTICLE 6
        	 
        	
          FINANCIAL TERMS
        	 
        	
25
        
	
6.1
        	 
        	
Licensing Fee
        	 
        	
25
        
	
6.2
        	 
        	
Milestone Payment
        	 
        	
25
        
	
6.3
        	 
        	
Royalties on Net Sales in ROW Territory
        	 
        	
25
        
	
ARTICLE 7
        	 
        	
          PAYMENT TERMS
        	 
        	
26
        
	
7.1
        	 
        	
Payment Method
        	 
        	
26
        
	
7.2
        	 
        	
Payment Schedules; Reports
        	 
        	
27
        
	
7.3
        	 
        	
Currency Conversion
        	 
        	
27
        
	
7.4
        	 
        	
Legal Restrictions
        	 
        	
27
        
	
7.5
        	 
        	
Taxes
        	 
        	
28
        
	
7.6
        	 
        	
Records Retention; Audit
        	 
        	
28
        
	
ARTICLE 8
        	 
        	
          LICENSES
        	 
        	
29
        
	
8.1
        	 
        	
Licenses to Shire
        	 
        	
29
        
	
8.2
        	 
        	
Licenses to New River
        	 
        	
30
        
	
8.3
        	 
        	
Sublicensing
        	 
        	
30
        
	
8.4
        	 
        	
Scope of Licenses
        	 
        	
30
        
	
8.5
        	 
        	
No Implied Licenses
        	 
        	
30
        
	
8.6
        	 
        	
Exclusivity
        	 
        	
30
        
	
8.7
        	 
        	
Nonassertion
        	 
        	
30
        
	
8.8
        	 
        	
[*]
        	 
        	
30
        
	
ARTICLE 9
        	 
        	
          CONFIDENTIALITY
        	 
        	
31
        
	
9.1
        	 
        	
Confidential Information
        	 
        	
31
        
	
9.2
        	 
        	
Publicity; Filing of this Agreement
        	 
        	
33
        
	
9.3
        	 
        	
Publication
        	 
        	
33
        
	
9.4
        	 
        	
Use of Names
        	 
        	
34
        
	
9.5
        	 
        	
Confidentiality of this Agreement
        	 
        	
34
        

ii 

TABLE OF CONTENTS

(continued)

	 	 	 	 	Page
	 	 	 	 	 
	
                    9.6
        	 
        	
Disclosures Under Existing NDA
        	 
        	
34
        
	
                    9.7
        	 
        	
Survival
        	 
        	
34
        
	
ARTICLE 10
        	 
        	
          OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT
        	 
        	

        
	

        	 
        	
          RIGHTS
        	 
        	
34
        
	
                    10.1
        	 
        	
Ownership
        	 
        	
34
        
	
                    10.2
        	 
        	
Disclosures; Disputes Regarding Inventions
        	 
        	
35
        
	
                    10.3
        	 
        	
Patent Filings
        	 
        	
35
	
                    10.4
        	 
        	
Third-Party Patent Rights
        	 
        	
37
        
	
                    10.5
        	 
        	
Enforcement and Defense of Patents
        	 
        	
37
        
	
                    10.6
        	 
        	
Notice of Certification
        	 
        	
40
        
	
                    10.7
        	 
        	
Patent Term Extensions
        	 
        	
40
        
	
                    10.8
        	 
        	
Listing of Patents
        	 
        	
40
        
	
                    10.9
        	 
        	
Trademarks and Copyrights
        	 
        	
41
        
	
ARTICLE 11
        	 
        	
          REPRESENTATIONS AND WARRANTIES; EXCLUSIVITY
        	 
        	
43
        
	
                    11.1
        	 
        	
Representations, Warranties and Covenants
        	 
        	
43
        
	
                    11.2
        	 
        	
Limitation on Representations or Warranties
        	 
        	
48
        
	
                    11.3
        	 
        	
Performance by Affiliates
        	 
        	
48
        
	
                    11.4
        	 
        	
Disclaimer of Warranty
        	 
        	
48
        
	
                    11.5
        	 
        	
Limitation of Liability
        	 
        	
48
        
	
                    11.6
        	 
        	
Essential Basis
        	 
        	
49
        
	
ARTICLE 12
        	 
        	
          TERM AND TERMINATION
        	 
        	
49
        
	
                    12.1
        	 
        	
Term
        	 
        	
49
        
	
                    12.2
        	 
        	
Breaches (General)
        	 
        	
49
        
	
                    12.3
        	 
        	
Allegations of Material Breach
        	 
        	
49
        
	
                    12.4
        	 
        	
Other Termination by Shire
        	 
        	
51
        
	
                    12.5
        	 
        	
Other Termination By New River
        	 
        	
52
        
	
                    12.6
        	 
        	
Termination for Government Action
        	 
        	
52
        
	
ARTICLE 13
        	 
        	
          EFFECTS OF TERMINATION
        	 
        	
53
        
	
                    13.1
        	 
        	
Post-Termination Activities by Shire
        	 
        	
53
        

iii 

TABLE OF CONTENTS

(continued) 

	 	 	 	 	Page
	 	 	 	 	 
	
                    13.2
        	 
        	
Post-Termination Activities by New River
        	 
        	
55
        
	
                    13.3
        	 
        	
Accrued Rights
        	 
        	
57
        
	
                    13.4
        	 
        	
Confidential Information
        	 
        	
57
        
	
                    13.5
        	 
        	
Survival
        	 
        	
57
        
	
                    13.6
        	 
        	
Liability Following Termination
        	 
        	
57
        
	
ARTICLE 14
        	 
        	
          INDEMNIFICATION; INSURANCE
        	 
        	
57
        
	
                    14.1
        	 
        	
Indemnification
        	 
        	
57
        
	
                    14.2
        	 
        	
Notice of Claim
        	 
        	
58
        
	
                    14.3
        	 
        	
Control of Defense
        	 
        	
58
        
	
                    14.4
        	 
        	
Right to Participate in Defense
        	 
        	
58
        
	
                    14.5
        	 
        	
Settlement
        	 
        	
58
        
	
                    14.6
        	 
        	
Cooperation
        	 
        	
59
        
	
                    14.7
        	 
        	
Expenses of the Indemnified Party
        	 
        	
59
        
	
                    14.8
        	 
        	
Treatment of Certain Losses
        	 
        	
59
        
	
                    14.9
        	 
        	
Insurance
        	 
        	
60
        
	
                    14.10
        	 
        	
Guaranty
        	 
        	
60
        
	
ARTICLE 15
        	 
        	
          DISPUTE RESOLUTION
        	 
        	
60
        
	
                    15.1
        	 
        	
Disputes
        	 
        	
60
        
	
                    15.2
        	 
        	
Litigation
        	 
        	
60
        
	
                    15.3
        	 
        	
Injunctive Relief
        	 
        	
61
        
	
                    15.4
        	 
        	
Governing Law
        	 
        	
61
        
	
ARTICLE 16
        	 
        	
          MISCELLANEOUS
        	 
        	
61
        
	
                    16.1
        	 
        	
Entire Agreement; Amendment
        	 
        	
61
        
	
                    16.2
        	 
        	
Force Majeure
        	 
        	
61
        
	
                    16.3
        	 
        	
Notices
        	 
        	
62
        
	
                    16.4
        	 
        	
Independent Contractors
        	 
        	
63
        
	
                    16.5
        	 
        	
Non-Solicitation
        	 
        	
63
        
	
                    16.6
        	 
        	
Maintenance of Records
        	 
        	
63
        
	
                    16.7
        	 
        	
United States Dollars
        	 
        	
63
        

iv 

TABLE OF CONTENTS

(continued) 

	 	 	 	 	Page
	 	 	 	 	 
	
16.8
        	 
        	
No Strict Construction
        	 
        	
63
        
	
16.9
        	 
        	
Assignment
        	 
        	
63
        
	
16.10
        	 
        	
Counterparts
        	 
        	
63
        
	
16.11
        	 
        	
Further Actions
        	 
        	
64
        
	
16.12
        	 
        	
Severability
        	 
        	
64
        
	
16.13
        	 
        	
Ambiguities
        	 
        	
64
        
	
16.14
        	 
        	
Headings
        	 
        	
64
        
	
16.15
        	 
        	
No Waiver
        	 
        	
64
        

  

  v

  

Exhibits 

	
EXHIBIT A
        	
DETERMINATION OF CERTAIN ACCOUNTING TERMS
        
	
EXHIBIT B
        	
ADDITIONAL SUPPLY TERMS
        
	
EXHIBIT C
        	
JOINT PRESS RELEASE
        
	
EXHIBIT D
        	
TECHNICAL TRADE SECRETS
        
	
EXHIBIT E
        	
CERTAIN PRODUCTS OF SHIRE
        

- 1 - 

ROW TERRITORY LICENSE AGREEMENT 

      THIS ROW TERRITORY LICENSE AGREEMENT (the “Agreement”) is dated as of March 31, 2005 by and among SHIRE PHARMACEUTICALS IRELAND LIMITED , an Irish resident
company having a principal place of business at 2nd Floor, Unit 1A, Citylink Business Park, Old Naas Road, Dublin 12, Ireland (“Shire”), SHIRE PHARMACEUTICALS GROUP PLC, a British public limited company having a principal place of business at Hampshire International Business Park, Chineham, Basingstoke, England RG24 8EP, solely for purposes of the provisions of
Section 14.10 of this Agreement, and NEW RIVER PHARMACEUTICALS INC., a Virginia corporation having a principal place of business at 1881 Grove Avenue, Radford, Virginia 24141 (“New River”). Shire and New River are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 

      WHEREAS, New River is a specialty pharmaceutical company focused on developing novel pharmaceuticals that are safer and improved versions of widely-prescribed
pharmaceutical products, and is clinically developing a proprietary amphetamine conjugate for the treatment of attention deficit/hyperactivity disorder in pediatric and adult patients;

      WHEREAS, Shire is a worldwide, specialty pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical products; and 

      WHEREAS, on January 31, 2005 (the “Effective Date”), New River and Shire LLC entered into that
certain Collaboration Agreement (the “January Agreement”) that established a broad collaboration for the further development and commercialization of Compound in both the US
Territory and ROW Territory, with the objective of utilizing the areas of expertise of both New River and Shire and its Affiliates to provide products to patients; 

      WHEREAS, pursuant to Section 17.16 of the January Agreement, New River and Shire LLC agreed to divide the January Agreement into two separate agreements: one relating to
the US Territory and the other relating to the ROW Territory; 

      WHEREAS, as contemplated by Section 17.16 of the January Agreement, New River and Shire LLC, an Affiliate of Shire, are entering into that certain US Territory
Collaboration Agreement (the “US Agreement”) simultaneously with the execution of this Agreement; and

      WHEREAS, this Agreement, together with the ROW Agreement, supercede and replace the January Agreement in its entirety. 

      NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the Parties, intending to be legally bound, agree as follows:

ARTICLE 1

DEFINITIONS 

The following terms shall have the following meanings as used in this Agreement: 

     1.1 “Act” means the United States Federal Food, Drug and
Cosmetics Act, as amended from time to time, and the rules, regulations and guidelines promulgated thereunder. 

     1.2 “ADHD” means attention deficit/hyperactivity disorder in human beings. 

     1.3 “Adolescent” means a human being that has attained the
age of thirteen (13) but is less than eighteen (18) years of age. 

     1.4 “Adult” means a human being that has attained the age of eighteen (18). 

     1.5 “Affiliate” means a Person that controls, is controlled
by or is under common control with a Party.  For the purposes of this definition, the word “control” (including, with correlative meaning, the terms “controlled by” or “under common control with”) means the actual
power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person, whether by the ownership of at least fifty percent (50%) of the voting stock of such Person (it being understood that the
direct or indirect ownership of a lesser percentage of such stock shall not necessarily preclude the existence of control), or by contract or otherwise. 

     1.6 “Business Day” means any day other than (i) Saturday or
Sunday or (ii) any other day on which banks in New York, New York, United States, Dublin, Ireland or London, England are permitted or required to be closed. 

     1.7 “cGCP” means the current Good Clinical Practice
standards for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials, including the requirements in 21 C.F.R. Parts 11, 50, 54, 56, 312, and 314, that provide assurance that the data and
reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected. 

     1.8 “cGLP” means current Good Laboratory Practices (i) as
promulgated under the Act at 21 C.F.R. Part 58, as the same may be amended or re-enacted from time to time and (ii) as required by Law in countries other than the United States where non-clinical laboratory studies are conducted. 

     1.9 “cGMP” means all applicable standards relating to
manufacturing practices for fine chemicals, active pharmaceutical ingredients, intermediates, bulk products or finished pharmaceutical products, including (i) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts
210 and 211 and The Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for Medicinal Products as each may be amended from time to time, (ii) the principles detailed in the ICH Q7A guidelines, (iii) if
Shire notifies New River that Shire intends to Commercialize a Collaboration Product in a country, Laws promulgated by any Governmental Authority in such country having jurisdiction over the Manufacture of Compound or Collaboration Product, or (iv)
if Shire notifies 

 - 2 - 

New River that Shire intends to Commercialize a Collaboration Product in a country, guidance documents promulgated by any Governmental Authority in such country having jurisdiction over the Manufacture of Compound or Collaboration
Product (including but not limited to advisory opinions, compliance policy guides and guidelines), which guidance documents are being implemented within the pharmaceutical manufacturing industry. 

     1.10 “Child” means a human being that has not attained the age of thirteen (13).

     1.11 “Collaboration Product” means a pharmaceutical product
containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

     1.12 “Combination Product” means any Collaboration Product
that contains the Compound and one or more pharmaceutically active ingredients in addition to Compound, and any and all Improvements thereto. 

     1.13 “Commercialization” means any and all activities
directed to the commercial Manufacturing, marketing, offering for sale and selling of a Collaboration Product, including advertising, educating, planning, marketing, promoting, distributing and conducting market and product support studies and
post-marketing safety surveillance and reporting. 

     1.14 “Committee” means the JDC, JSC or JIPC, as the case may be. 

     1.15 “Compound” has the meaning set forth on Exhibit
D. 

     1.16 “Control” means, with respect to any intellectual
property right or other intangible property, that a Party or one of its Affiliates owns or has a license or sublicense to such item or right, and has the ability to grant access, license or sublicense in or to such right without violating the terms
of any agreement or other arrangement with any Third Party.

     1.17 “Cost of Goods” has the meaning as set forth in Exhibit
A. 

     1.18 “Development” means all activities relating to
obtaining Regulatory Approval of a Collaboration Product, including all test method development, stability testing, toxicology, formulation, process development, cGMP audits (but only those performed prior to Regulatory Approval and excluding any
audits for commercial Manufacture), cGLP audits, cGCP audits, validation, quality assurance/quality control development, preclinical and clinical testing and studies, regulatory affairs and outside counsel regulatory legal services relating to any
of the foregoing, and any activities relating to the Manufacture of Collaboration Products other than commercial quantities thereof. For the avoidance of doubt, the conduct of Phase III-B Clinical Studies will be considered Development. 

     1.19 “Development Expenses” means the expenses incurred by a
Party that are consistent with a Development Plan and are specifically attributable or reasonably allocable to the Development of a Collaboration Product. Development Expenses shall include, but are not limited to, the following costs incurred for
the Development of a Collaboration Product: the cost of studies on the toxicological, pharmacokinetic, metabolic or clinical aspects of a Collaboration Product directed to obtaining Regulatory Approval of a Collaboration Product; the cost of Phase

 - 3 - 

III-B Clinical Trials, and costs (and related fees) for preparing, submitting, reviewing or developing data or information for the purpose of submission to a Governmental Authority to obtain Regulatory Approval of a Collaboration
Product; and manufacturing process development and scale-up for Collaboration Products in bulk and finished form. Development Expenses shall exclude any [*] incurred by a Party in connection with the Development of a Collaboration
Product.

     1.20 “Diligent Efforts” means the carrying out of
obligations or tasks consistent with the reasonable best practices of the pharmaceutical industry for the development or commercialization of a pharmaceutical product having similar market potential, profit potential or strategic value as the
applicable Collaboration Product, based on conditions then prevailing. Diligent Efforts requires that the Party, at a minimum: (a) determine the general industry practices with respect to the applicable activities; (b) reasonably promptly assign
responsibility for such obligations to specific employee(s) who are held accountable for progress and monitor such progress on an on-going basis; (c) set and consistently seek to achieve specific and meaningful objectives for carrying out such
obligations; and (d) make and implement decisions and allocate resources designed to advance progress with respect to such objectives. 

     1.21 “Drug Approval Application” means an application for
Regulatory Approval required before commercial sale or use of a Collaboration Product as a drug in a regulatory jurisdiction, including a new drug application (“NDA”) or
supplemental new drug application (“SNDA”) or any amendments thereto submitted to the FDA. 

     1.22 “FDA” means the United States Food and Drug
Administration or any successor federal agency thereto. 

     1.23 “Field” means all human and veterinary pharmaceutical uses. 

     1.24 “First Commercial Sale” means, with respect to a
Collaboration Product and on a country-by-country basis, the first commercial sale after receipt of Regulatory Approval of such Collaboration Product in such country. Sales for clinical studies, compassionate use, named patient programs, sales under
a treatment IND, test marketing, any nonregistrational studies, or any similar instance where the Collaboration Product is supplied with or without charge shall not constitute a First Commercial Sale.

     1.25 “Generic Product” means, with respect to a
Collaboration Product and on a country-by-country basis, a product that includes an active ingredient that is the same as the Compound, including without limitation, any product which is submitted for Regulatory Approval through an abbreviated NDA
(“ANDA”), an application under Section 505(b)(2) of the Act or foreign equivalent of the foregoing that references any NDA or SNDA or any foreign equivalent thereof for the
Collaboration Product. 

     1.26 “Governmental Authority” means any court, tribunal,
arbitrator, agency, legislative body, commission, official or other instrumentality of (i) any government of any country, (ii) a federal, state, province, county, city or other political subdivision thereof or (iii) any supranational body, including
without limitation the European Agency for the Evaluation of Medicinal Products. 

 - 4 - 

     1.27 “Improvement” means any enhancement or modification of
(i) a Collaboration Product, (ii) the Compound’s or Collaboration Product’s use, dosage form, indication, line extension, presentation or formulation or (iii) the process or method for the Manufacture of the Compound or Collaboration
Product, in each case whether or not patentable, that is developed by or for, invented or acquired by, or comes under the Control of, New River or Shire during the Term. 

     1.28 “IND” means an Investigational New Drug Application
filed with FDA or a similar application filed with an applicable Regulatory Authority outside of the United States such as a clinical trial application (CTA) or a clinical trial exemption (CTX). 

     1.29 “Invention” means any discovery (whether patentable or
not) conceived during the Term and potentially useful for the Manufacture, use, Development or Commercialization of the Compound or a Collaboration Product. 

     1.30 “Joint Invention” means an Invention that is conceived
jointly by an employee of, or person under an obligation of assignment to, each of New River and Shire. 

     1.31 “Know-How” means any non-public information, results
and data of any type whatsoever, in any tangible or intangible form whatsoever, including without limitation, databases, ideas, discoveries, inventions, trade secrets, practices, methods, tests, assays, techniques, specifications, processes,
formulations, formulae, knowledge, know-how, skill, experience, materials, including pharmaceutical, chemical and biological materials, products and compositions, scientific, technical or test data (including pharmacological, biological, chemical,
biochemical, toxicological and clinical test data), analytical and quality control data, stability data, studies and procedures, drawings, plans, designs, diagrams, sketches, technology, documentation, and patent-related and other legal information
or descriptions. 

     1.32 “Law” or “Laws” means all laws, statutes, rules, codes, regulations, orders, judgments and/or ordinances of any Governmental Authority. 

     1.33 “Licensed Know-How” means all Know-How that is
Controlled by New River as of the Effective Date or at any time during the Term and that is potentially useful for the Development, Manufacture, use and/or Commercialization of the Compound, a Collaboration Product and/or a New River Invention;
provided, however, that Know-How Controlled by New River disclosing New River’s proprietary CarrierwaveTM technology shall not be included in Licensed Know-How except to the extent
necessary for Shire to exercise its rights and perform its obligations under this Agreement. Notwithstanding anything herein to the contrary, Licensed Know-How shall exclude Licensed Patents. 

     1.34 “Licensed Patent” means a Patent that (i) claims the
Manufacture, use, Development, Commercialization and/or export of the Compound, a Collaboration Product and/or a New River Invention, and (ii) is Controlled by New River as of the Effective Date or at any time during the Term. For the avoidance of
doubt, all New River Collaboration Patents shall be considered Licensed Patents. 

     1.35 “Losses” means any and all amounts paid or payable to
Third Parties with respect to a Third Party Claim, including without limitation, damages (including all incidental and 

 - 5 - 

consequential damages), deficiencies, defaults, awards, settlement amounts, assessments, fines, dues, penalties, costs, liabilities, obligations, taxes, liens, losses, lost profits, fees and expenses (including, without
limitation, court costs, interest and reasonable fees of attorneys, accountants and other experts). 

     1.36 “Major EU Market” means each of France, Germany, the
United Kingdom, Italy and Spain. 

     1.37 “Manufacture” means all activities related to the
manufacturing of a pharmaceutical product, or any ingredient thereof, including but not limited to manufacturing Compound or supplies for Development, manufacturing Collaboration Product for commercial sale, packaging, in-process and finished
product testing, release of product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of product, ongoing stability tests and regulatory activities related to any of the foregoing. 

     1.38 “Net Sales” means, with respect to a Collaboration
Product, the amount invoiced by Shire, its Affiliates or sublicensees for sales of such Collaboration Product to a Third Party (“Invoiced Amount”) less: (i) transportation charges, freight and insurance (but only insurance related to protecting the particular shipment against physical
loss or damage); (ii) taxes (other than taxes based on income), tariffs, customs duty, excise or other duty and any other governmental charges, all to the extent imposed upon the sale, transportation or delivery of such Collaboration Product and
paid by the seller; (iii) Third Party distributor fees; (iv) trade discounts, quantity discounts, cash discounts, rebates, reimbursements, cooperative advertising allowances, credits or chargebacks actually granted, allowed or incurred in the
ordinary course of business in connection with the sale of such Collaboration Product, including any credits, volume rebates, charge-back and prime vendor rebates, fees, fees for services, reimbursements or similar payments granted or given to
wholesalers and other distributors, buying groups, health care insurance carriers, pharmacy benefit management companies, health maintenance organizations or other institutions or health care organizations; (v) adjustments, allowances or credits
(calculated on a per unit basis) to customers, not in excess of the selling price per unit of such Collaboration Product, including without limitation on account of price adjustments, governmental requirements, billing errors, rejection, damage,
recalls or return of such Collaboration Product; (vi) payments or rebates paid in connection with sales of Collaboration Products to any governmental or regulatory authority in respect of any state or federal Medicare, Medicaid or similar programs;
(vii) royalties or technology access fees paid to a Third Party in respect of the sale of such Collaboration Product; (viii) write-offs for bad debts incurred (net of any bad debts later recovered); and (ix) any item substantially similar in
character/substance to the foregoing.  Net Sales shall be accounted for in accordance with generally accepted accounting principles (“GAAP”) consistently applied in the
jurisdiction in which the sales occur, it being understood that bad debt write-off shall be deducted in arriving at Net Sales notwithstanding that such treatment may be inconsistent with GAAP, and it being further understood that Shire shall make
bad debt write-off decisions consistent with its usual business practices. 

For the purposes of determining Net Sales in the ROW Territory with respect to a Collaboration Product that (x) is sold as a Combination Product and (y) is also sold in the US Territory, the Net Sales in the ROW Territory of any
such Combination Product shall be determined by deducting 

 - 6 - 

from the Invoiced Amount the fully loaded acquisition cost per unit of the other active ingredient(s) included in such Combination Product. 

For the purposes of determining Net Sales in the ROW Territory with respect to a Collaboration Product that (x) is sold as a Combination Product and (y) is not also sold in the US Territory, the Net Sales in the ROW Territory of
any such Combination Product shall be determined in any accounting period by multiplying the Net Sales in the ROW Territory of the Combination Product by the fraction A/(A+B), where A is the average Invoiced Amount per unit of the Collaboration
Product when sold as a stand-alone Collaboration Product in finished form in the applicable country in the ROW Territory and B is the average invoice price of the other product(s) sold as stand-alone product(s) in finished form in the applicable
country in the ROW Territory.  In the event that such average Invoiced Amount or average invoice price, as applicable, cannot be determined for the Collaboration Product or the other product(s), Net Sales in the applicable country in the ROW
Territory for purposes of determining royalties shall be mutually agreed by the Parties based on the relative value contributed by each component. 

In addition, Net Sales in the ROW Territory shall be determined without regard to the deduction for royalties or technology access fees provided for in clause (vii) above to the extent that (1) such royalties or technology access
fees constitute Third Party Royalties and (2) the royalties payable by Shire to New River in respect of such Net Sales in the ROW Territory have been reduced by such Third Party Royalties in accordance with Section 10.5.1(a) . 

Notwithstanding the foregoing, in the ROW Territory, the disposition of a Collaboration Product or the use of the Collaboration Product without charge in excess of costs, including by means of clinical studies, compassionate use,
named patient programs, sales under a treatment IND, test marketing, any nonregistrational studies, patient assistance program, or any similar instance where the Collaboration Product is supplied without charge in excess of costs shall not result in
any Net Sales. Additionally, amounts received by Shire or its Affiliates or sublicensees for the sale of Collaboration Products among Shire and its Affiliates and sublicensees for resale shall not be included in the computation of Net Sales
hereunder. For the avoidance of doubt, no amount of cost, expense or other reduction or adjustment, whether or not specifically referred to in this definition of Net Sales, shall serve to adjust the Invoiced Amount more than once in arriving at Net
Sales. 

     1.39 “New River Invention” means an Invention that is
conceived, solely or jointly with a Third Party, by an employee of New River or a person under an obligation of assignment to New River.

     1.40 “Patent” means (i) valid and enforceable patents,
re-examinations, reissues, renewals, extensions, supplementary protection certificates and term restorations, any confirmation patent or registration patent or patent of addition based on any such patent, (ii) pending applications for patents,
including without limitation continuations, continuations-in-part, divisional, provisional and substitute applications, and inventors’ certificates, (iii) all foreign counterparts of any of the foregoing, and (iv) all priority applications of
any of the foregoing. 

 - 7 - 

     1.41 “Patent Expenses” means the fees and expenses of
outside counsel and payments to Third Parties incurred after the Effective Date in connection with the preparation, filing, prosecution and maintenance of the Licensed Patents, the Joint Collaboration Patents, and the Shire Patents covering Compound
and Collaboration Products, including the costs of patent interference and opposition proceedings, net of any reimbursement of such expenses by Third Parties.

     1.42 “Person” means any natural person, corporation, firm,
business trust, joint venture, association, organization, company, partnership or other business entity, or any government, or any agency or political subdivisions thereof.

     1.43 “Phase III-B Clinical Trials” means product support
clinical trials of a Collaboration Product (i.e., a clinical trial which is not required for receipt of initial Regulatory Approval but which may be useful in providing additional drug
profile data or in seeking a label expansion) commenced before receipt of Regulatory Approval for the indication for which such trial is being conducted.  For the avoidance of doubt, Phase III-B Clinical Trials shall be considered part of
Development.

     1.44 “Promotional Materials” means all written, printed,
video or graphic advertising, promotional, educational and communication materials (other than Collaboration Product labels and package inserts) for marketing, advertising and promotion of the Collaboration Products, including, without limitation,
copyrights in any such materials and all designs, industrial designs, design patents, design registrations, and design patent applications developed in connection with such materials, for use by (a) a sales representative or (b) advertisements, web
sites or direct mail pieces.  For clarity, it is understood and agreed that Promotional Materials shall not include corporate communications and general marketing or advertising by a Party or its Affiliate; provided, however, that to the extent that
such corporate communications or general marketing or advertising include or reference a Collaboration Product or related disease state and do not make any actual or implied claims, then such corporate communications or general marketing or
advertising shall be governed by the provisions of Section 9.2. 

     1.45 “Regulatory Approval” means all approvals [*], product
and/or establishment licenses, registrations or authorizations of any regional, federal, state or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacture, use, storage, import, export, transport, offer
for sale, or sale of a pharmaceutical product in a regulatory jurisdiction. 

     1.46 “ROW Territory” means the world, excluding the US Territory. 

     1.47 “Shire Background Know-How” means all Know-How
Controlled by Shire, other than Shire Collaboration Know-How, that is potentially useful for the Development, Manufacture, use and/or Commercialization of the Compound, a Collaboration Product and/or Shire Invention. Notwithstanding anything herein
to the contrary, Shire Background Know-How shall exclude Shire Background Patents. 

 - 8 - 

     1.48 “Shire Background Patent” means a Patent Controlled by
Shire, other than a Shire Collaboration Patent, that is potentially useful for the Development, Manufacture, use and/or Commercialization of the Compound, a Collaboration Product and/or Shire Invention. 

     1.49 “Shire Collaboration Know-How” means all Know-How that
is developed by Shire or its Affiliates during the Term pursuant to this Agreement or the US Agreement and that is potentially useful for the Development, Manufacture, use and/or Commercialization of the Compound, a Collaboration Product and/or
Shire Invention. Notwithstanding anything herein to the contrary, Shire Collaboration Know-How shall exclude Shire Collaboration Patents.

     1.50 “Shire Invention” means an Invention that is conceived,
solely or jointly with a Third Party, by an Affiliate or employee of Shire or a person under an obligation of assignment to Shire. 

     1.51 “Shire Know-How” means the Shire Background Know-How
and the Shire Collaboration Know-How. Notwithstanding anything herein to the contrary, Shire Know-How shall exclude Shire Patents. 

     1.52 “Shire Patents” means the Shire Background Patents and
the Shire Collaboration Patents. 

     1.53 “[*]” means [*].

     1.54 “Third Party” means any entity other than New River or
Shire or their respective Affiliates. 

     1.55 “US Territory” means the United States of America, its
territories and possessions. 

     1.56 “Valid
Claim” means: (a) a claim of an issued
Patent  that has not (i) expired or been canceled, (ii) been declared invalid
or unenforceable by a decision of a court or other appropriate body of competent
jurisdiction, from which no appeal is or can be taken, (iii) been admitted to
be invalid or  unenforceable through reissue, disclaimer or otherwise, or (iv)
been abandoned, disclaimed or dedicated to the public; and (b) a claim included
in a pending patent application that is being actively prosecuted in accordance
with this Agreement and  that has not been (i) canceled, (ii) withdrawn from
consideration, (iii) finally determined to be unallowable by the applicable governmental
authority (from which no appeal is or can be taken), or (iv) abandoned or disclaimed.
Notwithstanding the  foregoing clause (b), in the event that a pending claim
in a pending patent application is rejected and does not issue in an issued Patent
within [*] after the earliest date from which such claim was originally presented,
such a pending claim will  not be a Valid Claim, unless and until such pending
claim subsequently issues in an issued Patent, at which time such claim may again
be a Valid Claim as of the date of issuance of such Patent, if such claim also
meets the requirements of this  Section 1.56. 

Interpretation.  Unless the context of this Agreement otherwise requires, (a) words of one gender include the other gender; (b) words using the singular or plural number also include the plural or
singular number, respectively; (c) the terms “hereof,” “herein,” “hereby,” and other similar words refer to this entire Agreement; and (d) the terms “Article” and “Section” refer to 

 - 9 - 

the specified Article and Section of this Agreement.  Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days. 

Additional Definitions.  Each of the following definitions is set forth in the Section of this Agreement indicated below: 

	Definition	 	  Section 
	
Agreement
        	 
        	
Preamble
        
	
ANDA
        	 
        	
Section 1.25
        
	
Breaching Party
        	 
        	
Section 12.2.1
        
	
Confidential Information
        	 
        	
Section 9.1.1
        
	
Contractors
        	 
        	
Section 11.1.3(d)(i)
        
	
Development Plan
        	 
        	
Section 3.2.1
        
	
Disclosing Party
        	 
        	
Section 9.1.1
        
	
Dollars
        	 
        	
Section 16.7
        
	
Effective Date
        	 
        	
Recitals
        
	
Existing NDA
        	 
        	
Section 9.6
        
	
GAAP
        	 
        	
Section 1.38
        
	
Hatch-Waxman Certification
        	 
        	
Section 10.6
        
	
Indemnification Claim Notice
        	 
        	
Section 14.2
        
	
Indemnified Party
        	 
        	
Section 14.2
        
	
Indemnifying Party
        	 
        	
Section 14.2
        
	
Indemnitee
        	 
        	
Section 14.2
        
	
Indemnitees
        	 
        	
Section 14.2
        
	
Invoiced Amount
        	 
        	
Section 1.38
        
	
January Agreement
        	 
        	
Recitals
        
	
JDC
        	 
        	
Section 2.2.1
        
	
JIPC
        	 
        	
Section 2.4.1
        
	
Joint Collaboration Patents
        	 
        	
Section 10.1.1
        
	
Joint Press Release
        	 
        	
Section 9.2
        
	
JSC
        	 
        	
Section 2.3.1
        
	
Material Breach
        	 
        	
Section 12.3.1
        
	
NDA
        	 
        	
Section 1.21
        
	
New River
        	 
        	
Preamble
        
	
New River Collaboration Patents
        	 
        	
Section 10.3.1
        
	
New River Marks
        	 
        	
Section 10.9.3
        
	
Notice of Termination For Material Breach
        	 
        	
Section 12.3.3
        
	
Notifying Party
        	 
        	
Section 12.2.1
        
	
Parties
        	 
        	
Preamble
        
	
Party
        	 
        	
Preamble
        
	
[*]
        	 
        	
Section 8.8
        
	
Prior Consultants
        	 
        	
Section 9.6
        
	
Purchase Interest
        	 
        	
Section 12.3.5(a)
        
	
Purchase Notice
        	 
        	
Section 12.3.5
        
	
Purchase Price
        	 
        	
Section 12.3.5(a)
        

- 10 - 

	Definition	 	  Section 
	
Receiving Party
        	 
        	
Section 9.1.1
        
	
Recovery
        	 
        	
Section 10.5.2(c)(iv)
        
	
Representatives
        	 
        	
Section 15.1
        
	
Shared Expenses
        	 
        	
Section 3.5.1
        
	
Shire
        	 
        	
Preamble
        
	
Shire Collaboration Patents
        	 
        	
Section 10.3.2
        
	
Shire Marks
        	 
        	
Section 10.9.3
        
	
SNDA
        	 
        	
Section 1.21
        
	
Term
        	 
        	
Section 12.1
        
	
Third Party Claim
        	 
        	
Section 14.1.1
        
	
Third Party Manufacturers
        	 
        	
Section 2.3.2(a)
        
	
Third Party Royalty
        	 
        	
Section 10.5.1(a)
        
	
US Agreement
        	 
        	
Recitals
        
	
Withholding Taxes
        	 
        	
Section 7.5.1
        
	
Working Group
        	 
        	
Section 2.5.4
        
	
$
        	 
        	
Section 16.7
        

ARTICLE 2

MANAGEMENT OF COLLABORATION 

     2.1 General. The general purpose of the collaboration described in this Agreement will be to
Develop and Commercialize Collaboration Products. The Parties desire to establish three (3) specialized committees to oversee the Parties’ collaboration under this Agreement and to facilitate communications between the Parties with respect to
the Development, Manufacturing and intellectual property strategy of Collaboration Products hereunder and, where applicable, in the US Territory.  Each of such Committees shall have the responsibilities and authority allocated to it in this Article
2. Each of the Committees shall have the obligation to exercise its authority consistent with the respective purpose for such Committee as stated herein and any such decisions shall be made in good faith. For the avoidance of doubt, the Committees
described herein are the same committees as are described in the US Agreement, and each such Committee will have the responsibilities and authority set forth in this Agreement and in the US Agreement. 

     2.2 Joint Development Committee (JDC). 

          2.2.1 Formation and Purpose.  Promptly following the Effective Date, the Parties shall create a
joint development committee (the “JDC”) to oversee the Development of Collaboration Products hereunder.  The purposes of the JDC shall be (a) to determine the Development strategy
for the Collaboration Products in the US Territory and Major EU Markets, (b) to facilitate the management and implementation of the Parties’ Development activities hereunder, and (c) to approve plans and budgets for the Development by New River
of Collaboration Products for ADHD in the US Territory. The JDC shall have the membership and shall operate by the procedures set forth in Section 2.5. 

 - 11 - 

          2.2.2 Specific Responsibilities of the JDC.  In addition to its overall responsibilities
described in Section 2.2.1, subject to Section 2.6.1, the JDC shall, in particular: 

               (a) select Collaboration Products for research and Development under this Agreement in the US Territory and Major EU Markets;

               (b) prepare, approve and amend each Development Plan (including regulatory submission strategies and plans) for Collaboration
Products in the Major EU Markets; 

               (c) monitor the progress of the activities undertaken by the Parties pursuant to each Development Plan; 

               (d) review and approve proposals from the Parties to Develop Improvements and/or Combination Products; 

               (e) coordinate and oversee the Parties’ Regulatory Approval submission plans in the US Territory; 

               (f) design and approve all clinical trials of Collaboration Products proposed to be conducted anywhere in the world for
consistency and efficiency, including without limitation by creating the protocols, defining the end points, and selecting the primary investigators for such trials; 

               (g) have primary responsibility for establishing the objectives for all Phase IV Clinical Trials of Collaboration Products
proposed to be conducted for the US Territory, including without limitation by creating the protocols, defining the end points, and selecting the primary investigators for such trials; 

               (h) manage the flow of information with respect to Development being conducted for each Collaboration Product;

               (i) review and approve the statistical analysis plans and protocols for all Collaboration Product clinical studies conducted
worldwide, and any investigator’s brochure(s) and revisions thereto; 

               (j) work together with the other Committees during the Development of Collaboration Products to assure a smooth transition from
Development of such Collaboration Product to Commercialization of such Collaboration Product; 

               (k) review and approve compliance plans whereby the Parties prepare for or participate in a Governmental Authority inspection of
the preclinical or clinical data or preclinical sites/clinical sites or laboratories; and 

               (l) review and approve pharmacovigilance plans. 

     2.3 Joint Supply Committee (JSC). 

 - 12 - 

          2.3.1 Formation and Purpose. Promptly after the Effective Date, the Parties shall create a joint
supply committee (the “JSC”) to facilitate the management and implementation of the Parties’ activities with regard to the Manufacture and supply of Collaboration Products
worldwide. The JSC shall have the membership and shall operate by the procedures set forth in Section 2.5. 

          2.3.2 Specific Responsibilities of the JSC.  In addition to its overall responsibilities
described in Section 2.3.1, and subject to the provisions of Section 2.6.1 and Article 5, the JSC shall, in particular:

               (a) select which Party and/or Third Party(ies) to engage for the Manufacture and supply of Collaboration Products and components
thereof (“Third Party Manufacturers”), oversee auditing of Third Party Manufacturers, and approve contracts governing such Manufacture and supply; 

               (b) delineate requirements and responsibilities for development and licensure of manufacturing processes and facilities for
Collaboration Products and for worldwide supply of Collaboration Products; 

               (c) jointly develop a Manufacturing strategy for the ROW Territory to enable development and licensure of manufacturing processes
and facilities for Collaboration Products that includes all aspects of Manufacture and release, including but not limited to formulations, intermediate, dosage form, devices, product characterization studies, test methods and process validation
studies, stability studies and Manufacturing plans and forecasts and the implementation of Manufacturing Improvements; 

               (d) determine Manufacturing plans and budgets, including timelines and inventory strategies, and allocate responsibilities for
and oversee the implementation of such plans in accordance with this Agreement; 

               (e) oversee and approve process development plans prior to the Manufacture of registration batches of Collaboration Products;

               (f) oversee and approve plans to support Manufacture of commercial supply of Compound and Collaboration Products; 

               (g) review quality assurance efforts, including but not limited to those efforts with respect to the establishment of
specifications and quality standards for Collaboration Products; 

               (h) review and coordinate the drafting and contents of the Chemistry, Manufacturing and Controls section of a Drug Approval
Application for Collaboration Products; 

               (i) review and approve technology transfer plans for any changes in Manufacturing sites, testing sites, and responsibilities in
the supply chain for Collaboration Products, it being understood that decisions regarding the selection of which of a Party’s own Manufacturing and testing sites shall be used to manufacture any component of a Collaboration 

 - 13 - 

Product, if a Party Manufactures any component of a Collaboration Product pursuant to this Agreement or any related supply agreement, shall remain in the sole control of such Party; 

               (j) prepare for regulatory inspections and ensure adherence to compliance standards with respect to Collaboration Products;

               (k) ensure that future logistical strategies and capacity planning are consistent with the forecasts provided for the US
Territory and the ROW Territory, as well as inventory levels for Collaboration Products; 

               (l) review quality-related issues concerning the Collaboration Products or any component thereof; and 

               (m) review and approve compliance plans whereby the Parties prepare for or participate in a Governmental Authority inspection of
the Manufacturing or testing site of the Compound. 

     2.4 Joint Intellectual Property Committee (JIPC). 

          2.4.1 Formation and Purpose. Promptly after the Effective Date, the Parties shall create a joint
intellectual property committee (the “JIPC”) to facilitate the exchange of information between the Parties to the extent required by this Agreement regarding the prosecution,
maintenance and enforcement of the Licensed Patents, Licensed Know-How, Shire Collaboration Patents, Shire Collaboration Know-How, and Joint Inventions.  The JIPC shall have the membership and shall operate by the procedures set forth in Section
2.5. 

          2.4.2 Specific Responsibilities of the JIPC.  In addition to its overall responsibilities
described in Section 2.4.1, subject to Section 2.6.3 and Article 10, the JIPC shall, in particular:

               (a) Exchange information between the Parties regarding the Parties’ activities under this Agreement relating to the filing,
prosecution, maintenance and enforcement of the Licensed Patents, Licensed Know-How, Shire Collaboration Patents and Shire Collaboration Know-How; and 

               (b) Consult regarding the filing, prosecution, maintenance and enforcement of Joint Collaboration Patents and Joint Inventions.

     2.5 General Committee Membership and Procedures. 

          2.5.1 Membership. For the JDC, JSC and JIPC, each Party shall designate an equal number of
representatives who are employees of such Party or an Affiliate of such Party (not to exceed three (3) for each Party) with appropriate expertise to serve as members of such Committee; provided that a Party may designate outside legal counsel as a
representative to the JIPC. Each representative may serve on more than one Committee as appropriate in view of the individual’s expertise. Each Party may replace its Committee representatives at any time upon written notice to the other Party.
Each Committee shall have co-chairpersons. New River and Shire shall each select from their representatives a co-chairperson for each of the Committees.

 - 14 - 

The co-chairpersons of each Committee shall be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting of such Committee, and preparing and issuing minutes of each meeting within thirty
(30) days thereafter; provided, that a Committee co-chairperson shall call a meeting of the applicable Committee promptly upon the written request of the other co-chairperson to convene such a meeting. Such minutes will not be finalized until both
chairpersons review and confirm the accuracy of such minutes in writing. 

          2.5.2 Meetings. Each Committee shall hold meetings at such times as it elects to do so, but in
no event shall such meetings be held less frequently than once every four (4) months. Meetings of any Committee may be held in person or by means of telecommunication (telephone, video, or web conferences); provided, that at least one meeting per
year will be held in person.  The Parties will alternate in designating the location for in-person meetings, with New River selecting the first meeting location.  Other employees of each Party or any of its Affiliates involved in the Development,
Manufacture or Commercialization of Collaboration Products may attend meetings of such Committee as nonvoting participants, and, with the consent of each Party, consultants, representatives, or advisors involved in the Development, Manufacture or
Commercialization of Collaboration Products may attend meetings of such Committee as nonvoting observers; provided, that such Third Party representatives are under obligations of confidentiality and non-use applicable to the Confidential Information
of each Party and that are at least as stringent as those set forth in Article 9.  Each Party shall be responsible for all of its own expenses of participating in any Committee (including without limitation in any Working Group). 

          2.5.3 Meeting Agendas. Each Party will disclose to the other proposed agenda items along with
appropriate information at least seven (7) Business Days in advance of each meeting of the applicable Committee; provided, that under exigent circumstances requiring Committee input, a Party may provide its agenda items to the other Party within a
lesser period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a specific agenda for
such Committee meeting. 

          2.5.4 Working Groups. From time to time, each Committee may establish and delegate duties to
other committees, sub-committees or directed teams (each, a “Working Group”) on an “as-needed” basis to oversee particular projects or activities. Each such Working Group
shall be constituted and shall operate as the JDC, JSC or JIPC, as the case may be, determines; provided that each Working Group shall have equal representation from each Party. Working Groups may be established on an ad hoc basis for purposes of a
specific project for the life of a Collaboration Product, or on such other basis as the applicable Committee may determine. Each Working Group and its activities shall be subject to the oversight, review and approval of, and shall report to, the
Committee that established such Working Group.  In no event shall the authority of the Working Group exceed that specified for the relevant Committee in this Article 2. 

          2.5.5 Limitations of Committee Powers.  Each Committee shall have only such powers as are
specifically delegated to it hereunder and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, no Committee shall have 

 - 15 - 

any power to amend this Agreement.  Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 16.1 below. 

     2.6 Committee Decision-Making.  Subject to the terms of this Section 2.6, each Committee will
take action by unanimous vote with each Party having a single vote, irrespective of the number of representatives actually in attendance at a meeting, or by a written resolution signed by the designated representatives of each of the Parties. If a
Committee is unable to reach unanimous consent on a particular matter within thirty (30) days of its initial consideration of such matter, then either Party may provide written notice of such dispute to the Chief Executive Officer of the other
Party. The Chief Executive Officers (or their respective designees, provided that each such designee is not a member of the applicable Committee and occupies a position senior to the positions occupied by the applicable Party’s members of such
Committee) of each of the Parties will meet at least once in person or by means of telecommunication (telephone, video, or web conferences) to discuss the dispute and use their good faith efforts to resolve the dispute within thirty (30) days after
submission of such dispute to such officers.  If any such dispute is not resolved by the Chief Executive Officers or their designees within thirty (30) days after submission of such dispute to such officers, then the Chief Executive Officer or
designee of the Party specified in Section 2.6.1 or 2.6.12, as applicable, shall have the authority to finally resolve such dispute acting in good faith. 

          2.6.1 JDC Authority. 

               (a) If a dispute in the JDC is not resolved pursuant to Section 2.6 above and such dispute relates primarily to the Development
of Collaboration Products for ADHD in the US Territory (other than those relating to Phase IV Clinical Trials), the [*] or the [*], then the Chief Executive Officer of [*] shall have the authority to finally resolve such dispute. 

               (b) Notwithstanding anything to the contrary in subsection (a): 

                    (i) If a dispute in the JDC is not resolved pursuant to Section 2.6 above and such dispute (A) does not relate primarily to any
of the activities specified in subsection (a) above (including, without limitation [*] the [*] of [*] for [*] in the [*] or for any [*] in the [*] for [*] in the [*] or [*] or (B) relates primarily to [*] other than the [*] by [*] pursuant to the
[*] for which [*] has not [*] at the [*] or [*] the [*] to [*] of any [*] or [*] in the [*], then the Chief Executive Officer of Shire shall have the authority to finally resolve such dispute. 

                    (ii) If [*] for the first Collaboration Product for ADHD on or before [*], then, until such time as [*], the Chief Executive
Officer of [*] shall have the authority to finally resolve a dispute that relates primarily to the Development of Collaboration Products for ADHD in the US Territory. 

          2.6.2 JSC Authority.  If a dispute in the JSC is not resolved pursuant to Section 2.6 above,
then the Chief Executive Officer of [*] shall have the authority finally resolve such dispute; provided, however, that with respect to any matter over which [*] has approval (or other consent right) pursuant to Article 5 (including, without
limitation, Exhibit B), such 

 - 16 - 

resolution shall require the approval (or other consent) of [*] as set forth in Article 5 (including, without limitation, Exhibit B). 

          2.6.3 JIPC Authority.  If a dispute in the JIPC is not resolved pursuant to Section 2.6 above,
then [*] shall have the authority to finally resolve such dispute. The JIPC shall not have decision making authority under this Agreement and any dispute in the JIPC shall be resolved in accordance with the terms of Article 15. 

          2.6.4 Casting Vote.  Neither Party shall exercise its right to finally resolve a dispute at a
Committee in accordance with this Section 2.6 in a manner that excuses such Party from any of its obligations specifically enumerated under this Agreement. 

ARTICLE 3

DEVELOPMENT AND REGULATORY RESPONSIBILITIES 

     3.1 Overview. Subject to the roles of the various Committees described in Article 2 and the
terms of this Agreement, Shire will be primarily responsible for the Development of Collaboration Products for any indications in the ROW Territory. 

     3.2 Development Plans. 

          3.2.1 Scope. The Development of each Collaboration Product in the Major EU Markets under this
Agreement shall be governed by a development plan (each, a “Development Plan”).  Each Development Plan shall be developed in good faith in accordance with Shire’s standard
practices with the overall objective of achieving the commercial potential of such Collaboration Product. Each Development Plan shall describe the proposed overall program of Development for the Collaboration Product for each indication in each of
the Major EU Markets, including preclinical studies, toxicology, formulation, process development, clinical studies, pediatric exclusivity plans and regulatory plans and other elements of obtaining Regulatory Approval in each applicable country, as
well as timelines to key Governmental Authority meetings, Drug Approval Applications and Regulatory Approvals. Each Development Plan shall include a summary of estimated Development Expenses of the program expected during the Development process
through obtaining Regulatory Approval for each proposed indication and route of delivery, to the extent such expenses are to be shared by the Parties under the terms of this Agreement, and shall also include a detailed budget for all such shared
Development activities proposed for the following calendar year. 

          3.2.2 Preparation and Approval of Development Plans for the Major EU Markets. The Development
Plan for the Development by Shire of Collaboration Products for any indications in the Major EU Markets will be prepared by Shire and will be submitted to the JDC for review and approval. 

          3.2.3 Updates to the Development Plans. As early as necessary in each year beginning with the
first full calendar year after the Effective Date, Shire shall update and prepare the Development Plan for any such Collaboration Product for the following calendar year to take into account completion, commencement or cessation of Development
activities not contemplated by the then-current Development Plan, and submit such proposed Development Plan to the JDC no later than September 30 of such year for review and approval. 

 - 17 - 

          3.2.4 Diligence.  In addition to the specific diligence obligations of Shire pursuant to Section
3.4.1, Shire will use Diligent Efforts to carry out the activities for which it may agree to be responsible set forth in a Development Plan in the ROW Territory. 

     3.3 Regulatory Activities. 

          3.3.1 New River shall permit Shire access to and grant Shire the right to reference and use, for purposes of the Collaboration
Products, all data, regulatory filings and regulatory communications associated with any submissions for Regulatory Approval or other issues associated with any Collaboration Product, that is or would be relevant to Shire’s Development or
Commercialization of a Collaboration Product in the ROW Territory. To the extent that any such data, regulatory filings or regulatory communications are held by a Third Party, then New River shall arrange direct access to the portions of such data,
regulatory filings or regulatory communications that are relevant to the activities of Shire that are contemplated by this Agreement.  Any information obtained by a Party pursuant to this Section 3.3.1 shall be deemed Confidential Information for
purposes of Article 9. 

          3.3.2 Within thirty (30) days after the Effective Date, New River shall provide to Shire copies of all substantive or material
Manufacturing, pre-clinical and clinical data compiled as of the Effective Date with respect to the Collaboration Product, including any final versions of any study reports and any drafts then-outstanding of any study reports. Thereafter, New River
shall provide to Shire copies of all substantive or material Manufacturing, pre-clinical and clinical data compiled with respect to the Collaboration Product as soon as reasonably practicable after such data or results become available or compiled,
including any drafts and final versions of any study reports.  All disclosures under this Section 3.3.2 shall be delivered in electronic format.  For clarity, New River shall not be required to disclose New River’s proprietary
CarrierwaveTM technology under this Agreement, except to the extent necessary for Shire to exercise its rights and perform its obligations under this Agreement or as otherwise
specifically provided in this Agreement. 

     3.4 Development in the ROW Territory for ADHD and Other Indications. 

          3.4.1 Diligence. After receipt of Regulatory Approval in the US Territory for the first
Collaboration Product for ADHD, Shire will commence Diligent Efforts to Develop a Collaboration Product for ADHD in the Major EU Markets. Shire will use Diligent Efforts to carry out the activities set forth in the Development Plan for Collaboration
Products in each Major EU Market country where, [*], including preparing all reports necessary as part of a Drug Approval Application. 

          3.4.2 Costs of Development. Shire shall bear all expenses that are related to Developing and
obtaining Regulatory Approval of Collaboration Products in the ROW Territory, subject to the terms of Section 3.5.1 below.  The Parties recognize that Shire may desire to conduct clinical trials of Collaboration Products within the US Territory for
the purpose of obtaining Regulatory Approval within the ROW Territory, and agree that, prior to receipt of Regulatory Approval in the US Territory, Shire may conduct such trials with New River’s prior written consent, such consent not to be
unreasonably withheld, conditioned, or delayed; provided, that Shire is solely responsible for all costs of conducting any such trials.

 - 18 - 

          3.4.3 Regulatory Activities. 

               (a) Shire shall be responsible for preparing and filing Drug Approval Applications and seeking Regulatory Approvals for
Collaboration Products in the ROW Territory, including preparing all reports necessary as part of a Drug Approval Application. The Parties intend that [*] New River shall be responsible for providing to Shire, in the Common Technical Document format
(unless the FDA requires a different format or the Common Technical Document format would delay the filing of the Drug Approval Application), the data and information required to be submitted to the FDA, and such additional data and information
relating to the Development activities for which it was responsible, including all clinical trials performed by it and, if applicable, all manufacturing and controls information. Shire shall be responsible for prosecuting all such Drug Approval
Applications and shall have a right of cross-reference to the Drug Approval Applications filed by New River in the US Territory for such purpose. New River will take all such reasonable actions to allow such cross-reference. New River shall have the
right of cross-reference to all such Drug Approval Applications filed by Shire for the purpose of prosecuting Drug Approval Applications in the US Territory, and Shire shall, or shall cause its Affiliates to, take all such reasonable actions to
allow such cross-reference. 

               (b) In connection with all Drug Approval Applications being prosecuted by Shire hereunder, Shire agrees to provide New River with
a copy (which may be wholly or partly in electronic form) of all filings to regulatory agencies in each Major EU Market country that it makes hereunder.  Within thirty (30) days following the end of each calendar quarter, Shire shall report to New
River regarding the status of each pending and proposed Drug Approval Application in the ROW Territory. 

               (c) In the event that Shire desires New River to participate in any meeting, discussion or substantive telephone conference call
with any Governmental Authority relating to any Drug Approval Application or Regulatory Approval for Collaboration Products in the ROW Territory, Shire shall provide New River with reasonable advance notice of any such meeting, discussion or
conference call and New River shall participate with Shire. Shire shall promptly furnish New River with copies of all substantive documents or correspondence Shire has had with or receives from any Governmental Authority in the Major EU Markets, and
contact reports concerning substantive conversations or substantive meetings with any Governmental Authority in the Major EU Markets, in each case relating to any Drug Approval Application or Regulatory Approval (including without limitation any
minutes from a meeting with respect thereto). 

               (d) Shire shall provide to New River, on a timely basis, copies of all material Manufacturing, pre-clinical and clinical data
compiled in support of a Drug Approval Application in the ROW Territory for a Collaboration Product (but excluding any such data to the extent relating to the Manufacture of the Compound). 

               (e) In the event that any Governmental Authority threatens or initiates any action to remove a Collaboration Product from the
market in the ROW Territory, Shire shall notify New River of such communication immediately, but in no event later than one (1) Business Day, after receipt by Shire. Shire shall consult with New River prior to initiating a 

 - 19 - 

recall or withdrawal of Collaboration Product in a Major EU Market; provided that the final decision as to whether to recall or withdraw a Product in the ROW Territory shall be made by Shire in its sole discretion. In the event of
any recall or withdrawal for Collaboration Products sold in the ROW Territory, Shire shall implement any necessary action. 

          3.4.4 Reporting.  At each meeting of the JDC and the JSC, each Party will present a report
describing the Development and Manufacturing activities performed by such Party with respect to Collaboration Products in the ROW Territory since the last such report. 

     3.5 Shared Expenses. 

          3.5.1 Except as otherwise provided in Section 3.4.2, any Development Expenses incurred by either Party that, as determined by the
JDC, have worldwide application to the Development or Commercialization of the Collaboration Products will be borne [*] by Shire and [*] by New River, regardless of whether such work is conducted inside or outside of the United States
(“Shared Expenses”).  For clarity, Shire may use in the ROW Territory the results of Development of the first Collaboration Products for ADHD in each of Adults, Adolescents and
Children, without charge, but Shire shall be solely responsible for the performance and cost of any additional studies for the ROW Territory that do not have application in the US Territory.

          3.5.2 Quarterly Reconciliation of Development Expenses. 

               (a) Each Party shall calculate and maintain records of Shared Expenses incurred by it in accordance with procedures to be agreed
upon between the Parties. 

               (b) Within five (5) Business Days following the end of each calendar quarter, Shire shall submit to New River a written report
setting forth in reasonable detail, separately with respect to each Collaboration Product, the Shared Expenses it has incurred in such calendar quarter. 

               (c) Within five (5) Business Days following the end of each calendar quarter, New River shall submit to Shire a written report
setting forth in reasonable detail, separately with respect to each Collaboration Product, the Shared Expenses it has incurred in such calendar quarter. 

               (d) Within twenty-five (25) days following the end of each calendar quarter, Shire shall submit to New River a written report
setting forth in reasonable detail the calculation of all Shared Expenses for each Collaboration Product, and the calculation of any net amount owed by New River to Shire or by Shire to New River, as the case may be, in order to ensure the
appropriate sharing of Shared Expenses in accordance with the provisions of Section 3.5. The net amount payable shall be paid by Shire or New River, as the case may be, within thirty five (35) days following the end of each calendar quarter;
provided, that, in the event of a dispute, the disputing Party shall pay the amount not in dispute and provide written notice within five (5) Business Days after receipt of the written report in question to the other, specifying such dispute and
explaining the basis of the dispute.  New River and Shire shall promptly thereafter meet and negotiate in good faith a resolution to such dispute. If such dispute is not resolved within forty-five (45) days after delivery of a notice of dispute with
respect 

 - 20 - 

thereto to the other Party, the disputing Party may audit the other Party pursuant to the provisions of Section 7.6.2. 

          3.6 Use of Third Parties.  Either Party may retain Third Parties to perform Development
activities, subject to the terms provided in this Section 3.6 and in Section 8.3. Each Party shall remain liable for the performance of its obligations hereunder which it delegates to such Third Parties. Any Third Parties performing Development
activities hereunder shall be subject to confidentiality and non-use obligations at least as stringent as those set forth in Article 9 and must comply with the terms of Article 10. 

          3.7 Assistance. Subject to the terms of this Article 3, each Party agrees to provide the other
with all reasonable assistance and take all actions reasonably requested by the other Party that are necessary or desirable to enable the other Party to comply with any Law applicable to the Collaboration Products, including, but not limited to,
meeting, reporting and other obligations to maintain and update any Regulatory Approvals for the Collaboration Products. 

          3.8 Compliance with Laws. Each Party or its permitted Third Party contractors shall perform its
responsibilities under this Article 3, including those set forth in a Development Plan, in accordance with all applicable Laws, including without limitation cGLPs, cGCPs (or their non-US equivalents) and cGMPs. 

ARTICLE 4

COMMERCIALIZATION OF COLLABORATION PRODUCTS 

     4.1 Principles of Commercialization.  Shire will be solely responsible for Commercializing
Collaboration Products in the ROW Territory during the Term. 

     4.2 Sales and Distribution of Collaboration Products to Third Parties. 

          4.2.1 Terms of Sale to Third Parties.  For each Collaboration Product, including all
Improvements and Combination Products, Shire shall be solely responsible for handling all returns, recalls, order processing, invoicing and collection, distribution, and inventory and receivables arising from sales to Third Parties. New River may
not accept orders from a Third Party for a Collaboration Product or make sales for its own account (except to Shire) or for Shire’s account. If New River receives any order for a Collaboration Product, it shall refer such orders to Shire for
acceptance or rejection. Subject to Section 4.2.2, Shire shall have the right and responsibility for establishing and modifying the terms and conditions with respect to the sale of all Collaboration Products in the ROW Territory, including any terms
and conditions relating to or affecting the price at which the Collaboration Products will be sold, discounts available to managed care providers, any discount attributable to payments on receivables, distribution of the Collaboration Products, and
credits, price adjustments, or other discounts and allowances to be granted or refused. 

          4.2.2 [*]. If Shire or its Affiliates or sublicensees sell a Collaboration Product to a Third Party, [*] and at a [*] Shire or
its Affiliates or sublicensees for sales of such Collaboration Product [*], then Shire [*] in respect of such sale. 

 - 21 - 

     4.3 Marketing Plans for ROW Territory.  With respect to the ROW Territory, Shire will have full
authority and discretion over the content of any marketing plan. 

     4.4 Regulatory Obligations During Commercialization. 

          4.4.1 Shire Responsibilities.  Shire will maintain all regulatory filings and Regulatory
Approvals in the ROW Territory for each Collaboration Product Developed pursuant to this Agreement, including all INDs and Drug Approval Applications. As between the Parties, Shire will be solely responsible for all activities in connection with
maintaining Regulatory Approvals required for the Commercialization of Collaboration Product in the ROW Territory, including communicating and preparing and filing all reports (including adverse drug experience reports) with the applicable
Governmental Authorities, as described in further detail in Section 3.4.3. 

          4.4.2 Pharmacovigilance.  Shire shall be responsible for all processing of information related
to any adverse events, including, without limitation, any information regarding such adverse events that is received from a Third Party, related to a Collaboration Product after the First Commercial Sale of such Product.  The Party conducting any
clinical studies prior to such First Commercial Sale shall be responsible for all processing of information related to any adverse events associated with such studies. As soon as reasonably practicable following the date of this Agreement, the
pharmacovigilance departments of each of New River and Shire shall meet and determine the approach to be taken for the collection, review, assessment, tracking and filing of information related to adverse events associated with the Products,
consistent with the provisions of this Section 4.4.2.  Such approach shall be documented in a separate and appropriate written pharmacovigilance agreement between each of New River and Shire. Shire agrees to share relevant information it receives
(either directly or indirectly) with New River in a timely manner so as to allow New River to comply with its responsibility to report pharmacovigilance information under this Section 4.4.2. 

     4.5 Diligence in Commercialization. Shire will use Diligent Efforts in each of the Major EU
Markets to launch a Collaboration Product in each such country after receiving all Regulatory Approvals for such Collaboration Product in such country, and thereafter will use Diligent Efforts to Commercialize the Collaboration Product in such
country. 

     4.6 Cost of Commercialization. In the ROW Territory, Shire shall bear all costs in connection
with the Commercialization of Collaboration Products. 

     4.7 Use of Third Parties. Shire may retain Affiliates and/or Third Parties to perform
Commercialization activities in the ROW Territory.  Shire shall remain liable for the performance of its obligations hereunder that it delegates to such Affiliates and/or Third Parties. Shire covenants and agrees not to use any Third Parties to
perform promotional activities for Collaboration Products in the Major EU Markets without the prior written approval of New River, such approval not to be unreasonably withheld, conditioned, or delayed.  If the Parties agree to engage any such Third
Party sales force, such Third Party sales force will be directed, trained and controlled by Shire. 

4.8 Promotional Materials. 

 - 22 - 

          4.8.1 Creation of Promotional Materials.  Shire will create and develop Promotional Materials
for the ROW Territory. To the extent that Shire describes in any item of the Promotional Materials New River’s CarrierwaveTM proprietary technology, Shire shall include in such
Promotional Materials the New River trademark for such technology. New River hereby grants Shire a royalty-free license for such purpose. To the extent Shire shall include such description and trademark in the Promotional Materials, Shire shall
comply with New River’s then-current guidelines for trademark usage, a copy of which shall be provided to Shire from time to time. 

          4.8.2 Shire Ownership of Promotional Materials. Shire shall own all right, title and interest in
and to any Promotional Materials relating to the Collaboration Products, including without limitation applicable copyrights and trademarks, but excluding trademarks owned by New River in accordance with Section 10.9, and New River hereby assigns all
its right, title and interest to such Promotional Materials to Shire and agrees to execute all documents and take all actions as are reasonably requested by Shire to vest title to such Promotional Materials in Shire. 

          4.8.3 Use of Promotional Materials Exclusively for Collaboration Products. The Promotional
Materials, and any aspects of those uniquely tied to the Collaboration Products, shall be used exclusively in connection with the Collaboration Products in accordance with the terms of this Agreement. 

          4.8.4 Retention of Rights. Shire and New River, or their respective Affiliates, shall retain,
throughout the Term and following termination, all rights, including without limitation all copyrights and trademarks, to all of their respective programs and materials in all formats (print, video, audio, digital, computer, etc.) regarding sales
training, patient education and disease management programs owned by them as of the Effective Date or developed by them during the Term but outside of this Agreement, regardless of the fact that such programs or materials are shared with the other
Party, as well as any modifications of such programs or materials that they may develop in the future which are not specific to a Collaboration Product. In accordance with Section 4.8.2, Shire shall own any such modifications specific to a
Collaboration Product. 

     4.9 Compliance with Laws. Each Party or its permitted Third Party contractors shall perform its
responsibilities under this Article 4 in accordance with all applicable Laws. 

ARTICLE 5

MANUFACTURE OF COLLABORATION PRODUCTS 

     5.1 Manufacture and Supply. 

          5.1.1 Manufacturing Process. New River will use Diligent Efforts to develop a process for the
Manufacture of bulk Compound and to scale up such process to a level sufficient to Manufacture and supply clinical and commercial supplies of bulk Compound for the ROW Territory.  New River will undertake such development in consultation with the
JSC, including the preparation of filings necessary to obtain Regulatory Approval for the Manufacture of bulk Compound for the ROW Territory and the selection of any Third Party Manufacturer. In 

 - 23 - 

the event that New River includes the filings referred to in this Section 5.1.1 in Drug Master Files in the US Territory, Shire may reference such Drug Master Files for countries in the ROW Territory in which Shire seeks
Regulatory Approval of Collaboration Products; provided, however, that Shire will provide New River with assistance as reasonably requested by New River, and at no cost to New River, to ensure compliance with regulatory requirements in such
countries. Once such filings are made, no changes to the process for the Manufacture of bulk Compound for the ROW Territory shall be made without the written consent of Shire, such consent not to be unreasonably withheld, conditioned or delayed;
provided that New River will not require the prior written consent of Shire to make changes related to the process for the Manufacture of bulk Compound for the ROW Territory hereunder that are required by a Governmental Authority or applicable Law.
New River’s retention of any Third Party Manufacturer to perform any activities under this Section 5.1.1 shall be subject to the prior written approval of Shire, not to be unreasonably withheld, conditioned, or delayed. 

      All costs related to the foregoing activities set forth in this Section 5.1.1 that are additional to any activities set forth in Section 6.1.1 of the US Agreement shall be charged by New River to Shire at [*] 

          5.1.2 Development Supply.  New River will Manufacture, or arrange for a Third Party Manufacturer
to Manufacture, bulk Compound for Development activities to be performed by Shire under this Agreement. Any such supply will be provided by New River to Shire [*] (as determined in accordance with Exhibit
A). 

          5.1.3 Commercial Supply. New River will Manufacture, or arrange for a Third Party Manufacturer
to Manufacture, bulk Compound for use in the Manufacture of Collaboration Products by Shire or, at Shire’s direction, by a Third Party. Any such supply will be provided by New River to Shire [*] (as determined in accordance with Exhibit A). Shire will arrange for the Manufacture of Collaboration Products for sale in the ROW Territory using bulk Compound provided by New River under this Section 5.1.3. 

     5.2 Specifications and Terms of Supply; Multiple Sources.  New River, in consultation with the
JSC, shall establish the specifications, including any necessary documentation, certificates of analysis and test results, for the bulk Compound to be Manufactured under this Article 5, in each case subject to the prior written approval of Shire,
such approval not be unreasonably withheld, conditioned or delayed.  If a Governmental Authority in a country of the ROW Territory has promulgated any Laws or guidance documents that relate or will relate to the Manufacture of the Compound or a
Collaboration Product that are different from those promulgated in the US Territory or the European Union, Shire shall notify New River of such Laws or guidance documents.  The Parties shall endeavor to maintain compatible specifications for bulk
Compound on a worldwide basis, and to minimize the number of distinct specifications in different countries. New River shall establish at least [*] sources of supply for bulk Compound to be Manufactured under this Article 5. 

     5.3 Manufacture by Shire; Commercial Supply by Shire. Shire will have the right to act as, or to
appoint a Third Party to act as, a second source for Collaboration Products under terms and conditions to be established by the Parties and subject to reasonable commercial qualification by New River and applicable regulatory requirements.  In
connection with such 

 - 24 - 

right, Shire will prepare all specifications required for any facility at which Shire intends to Manufacture, or have Manufactured, Collaboration Products, including cGMP qualification guidelines, and any QA approved procedures to
be followed during the qualification of such facility, all consistent with the specifications and procedures approved in any existing Regulatory Approval, in each case at Shire’s sole expense. Following validation of such facility, the JSC will
task Shire with the production of quantities of Collaboration Products at least sufficient for Shire to maintain such validation as a second source and such quantities shall be available for distribution by Shire. In the event that [*] any agreement
with a Third Party Manufacturer for the Manufacture of Compound or otherwise [*] such that there is a reasonable likelihood of insufficient quantities of Compound to satisfy the need thereof for the Manufacture of Collaboration Products, then Shire
shall be entitled, but not be required, to assume in whole or in part New River’s rights and related obligations under such agreement (to the extent permissible thereunder) or otherwise direct the exercise of rights and performance of
obligations by New River under such agreement, including the establishment of additional Third Party Manufacturers or Manufacture by Shire, in each case upon the mutual agreement of the Parties, such agreement not to be unreasonably withheld,
delayed or conditioned. In such event the Parties shall meet and confer to devise the most effective supply plan for the bulk Compound and/or Collaboration Products and to consider amendments to this or other agreements, as necessary. 

     5.4 Supply Terms. The Parties, in consultation with the JSC, will establish the terms and
conditions applicable to the supply of Compound by New River to Shire under this Article 5, and enter into an appropriate supply agreement with respect thereto containing terms and conditions consistent with the terms of this Agreement, including
without limitation, this Article 5 and at a minimum those terms and conditions as set forth on Exhibit B, to the extent New River is able to obtain such terms from Third Party Manufacturers
having used Diligent Efforts to do so.  For the avoidance of doubt, such agreement will provide for the manufacture of bulk Compound only, notwithstanding the references in Exhibit B to the
manufacture of “Compound or Collaboration Product.” 

ARTICLE 6

FINANCIAL TERMS 

     6.1 Licensing Fee. As partial payment for the rights and licenses granted by New River pursuant
to this Agreement, Shire shall pay to New River a license fee equal to $1,200,000 within ten (10) Business Days after the Effective Date. This fee shall be non-creditable and non-refundable against any future obligations of Shire under this
Agreement, subject to Section 12.6. 

     6.2 Milestone Payment.  Within [*] after the [*] Shire shall pay New River $5,000,000, which
shall be non-creditable and non-refundable, subject to Section 12.6. For the avoidance of doubt, this milestone is paid only once regardless of the number of [*] in which a [*]. 

     The milestone is to be paid only once irrespective of the number of Collaboration Products Developed, Manufactured or Commercialized under this Agreement. 

     6.3 Royalties on Net Sales in ROW Territory. 

 - 25 - 

          6.3.1 Royalty Rates [*]. As further consideration for New River’s grant of the rights and
licenses to Shire hereunder, subject to the adjustments provided for in Section 6.3.3, Shire will pay, or cause to be paid, to New River, on a Collaboration Product-by-Collaboration Product basis, a royalty equal to:

               (a) [*] of aggregate Net Sales of such Collaboration Product [*], for that portion of the total amount of aggregate Net Sales of
such Collaboration Product [*] in any calendar year that is less than or equal to [*];

               (b) [*] of aggregate Net Sales of such Collaboration Product [*], for that portion of the total amount of aggregate Net Sales of
such Collaboration Product [*] in any calendar year that is greater than $[*] but less than or equal to $[*];

               (c) [*] of aggregate Net Sales of such Collaboration Product [*] for that portion of the total amount of aggregate Net Sales of
such Collaboration Product [*] in any calendar year that exceeds [*]. 

          6.3.2 [*].  As further consideration for New River’s grant of the rights and licenses to Shire hereunder, subject to the
adjustments provided for in Section 6.3.3, Shire will pay, or cause to be paid, to New River a royalty equal to [*] of Net Sales of each Collaboration Product in the [*] 

          6.3.3 Royalty Rate Adjustment. The rates set forth in Sections 6.3.1 and 6.3.2 shall be reduced
by [*] (to [*]%,[*]%, and [*]%, and [*]%, respectively) with respect to Net Sales of a Collaboration Product in a particular country in which, and during such time as, a Generic Product of such Collaboration Product has been launched and is then
offered for sale by a Third Party in such country. 

          6.3.4 Royalty Term.  Royalties due under Sections 6.3.1 and 6.3.2 will commence upon the First
Commercial Sale of a Collaboration Product in a particular country in the ROW Territory and will expire on a country-by-country basis upon the later of:  (a) the expiration of the last-to-expire Licensed Patent containing a Valid Claim that would be
infringed by the Manufacture, use, or sale of the Collaboration Product in such country by an unlicensed Third Party if such unlicensed Third Party were to Manufacture the Collaboration Product in such country of Manufacture, or use or sell the
Collaboration Product in such country of sale, and (b) [*] from the First Commercial Sale of the Collaboration Product in such country. 

ARTICLE 7

PAYMENT TERMS 

     7.1 Payment Method.  All amounts due to either Party hereunder will be paid in United States
Dollars by wire transfer in immediately available funds to an account designated by such Party. Any payments or portions thereof due hereunder that are not paid by the date such payments are due under this Agreement will bear simple interest at the
lower of (a) [*][*] the US Prime Rate, as reported in the Wall Street Journal, Eastern Edition, on the due date (or, if the due date is not a business day, on the last business day prior to
such due date), or (b) the maximum rate permitted by applicable Law, calculated on the number of days such payment is delinquent; provided that such interest shall not be due to the extent that a payment is 

 - 26 - 

inadvertently paid late (e.g., if such late payment is accompanied by reasonable evidence that the payor was not aware of the due date of the payment or reasonable
explanation that such payment due date was unintentionally missed) and if the payor acts in good faith in making payment as soon as it discovers that a required payment has not been made. 

     7.2 Payment Schedules; Reports. The payments due pursuant to Sections 3.5.2, 6.1, 6.2 and 10.3.5
are due and payable on the dates described therein.  Royalty payments due pursuant to Section 6.3 are due and payable within thirty-five (35) days of the end of each calendar quarter during the Term during which there were Net Sales of Collaboration
Products in the ROW Territory. Shire will accompany each payment of royalties under this Agreement with a report setting forth, on a country-by-country basis, the amount of gross sales of each Collaboration Product in such country, a calculation of
Net Sales, the currency conversion rate used and the United States Dollar-equivalent of such Net Sales, and a calculation of the amount of royalty payment due on such Net Sales.  Such report will be considered Confidential Information of Shire
subject to the obligations of Article 9 of this Agreement.  The Parties acknowledge that any expenses or costs reported or shared in any way under this Agreement may be based upon estimates, which estimates will be GAAP-compliant; provided that when
the actual results become known relative to any estimated amount, any difference between the actual results and the estimate is reported and the next payment due hereunder related to such estimated item is appropriately adjusted for such difference.
The Parties acknowledge and agree that any reports and payments relating to any cost, expense, or other financial amount shared pursuant to this Agreement for the fourth quarter of any calendar year shall reflect year-end reconciliations and
adjustments, if any, applicable to the previous three quarters’ reported results. 

     7.3 Currency Conversion. For any currency conversion required in determining the amount of
royalties due hereunder, such conversion will be made at the exchange rate used by Shire, consistent with its general internal corporate policies as they relate to its income statement, for its own consolidation purposes for the translation of such
currency into United States Dollars for any royalty payments due pursuant to this Agreement. Such policies will be made available to New River upon request and will be consistent with customary industry practices. 

     7.4 Legal Restrictions.  If at any time legal restrictions prevent the remittance by Shire of
all or any part of royalties on Net Sales in any country, Shire will have the right and option to make such payment by depositing the amount thereof in local currency to an account in the name of New River in a bank or other depository in such
country. Shire will consult with New River regarding, and promptly notify New River of, any and all such arrangements.

     7.5 Taxes. 

          7.5.1 Withholding Taxes.  New River will be responsible for any and all income or other taxes
owed by New River and required by applicable Law to be withheld or deducted from any of the royalty and other payments made by or on behalf of Shire to New River hereunder (“Withholding Taxes”), and Shire may deduct from any amounts that Shire is required to pay hereunder an amount equal to such Withholding Taxes; provided, however, that if New River is not able to claim a credit or reimbursement for such tax, in whole
or in part, as a result of Shire being a non-US entity, then Shire will deduct Withholding Taxes in accordance with this Section 7.5.1, but will, in addition to the sums otherwise payable under this Agreement, 

 - 27 - 

pay to New River such further sum as will ensure that, after deduction of Withholding Taxes on all such sums, the net amount received by New River equals the amount that New River would have received had the non-creditable or
non-reimbursable excess portion of such additional Withholding Taxes not been deducted. Shire will provide New River with reasonable advance notice of tax withholding obligations to which it reasonably believes that it is subject.  New River will
provide Shire any information available to New River that is necessary to determine the Withholding Taxes. Such Withholding Taxes will be paid to the proper taxing authority for New River’s account and evidence of such payment will be secured
and sent to New River within one (1) month of such payment. The Parties will do all such lawful acts and things and sign all such lawful deeds and documents as either Party may reasonably request from the other Party to enable New River and Shire or
its Affiliates or sublicensees to take advantage of any applicable legal provision or any treaty provisions with the object of paying the sums due to New River hereunder with the lowest legal amount of Withholding Taxes. 

          7.5.2 Additional Withholding Taxes.  If, as a result of any change in the corporate status or
location of Shire, or the permitted assignment of this Agreement by Shire, additional Withholding Taxes become due on payments from Shire or its permitted assignee to New River that would not have been due absent such change in corporate status or
location or permitted assignment, and New River is not able to claim a credit or reimbursement for such tax, in whole or in part, then Shire will deduct Withholding Taxes in accordance with this Section 7.5, but will, in addition to the sums
otherwise payable under this Agreement, pay to New River such further sum as will ensure that, after deduction of Withholding Taxes on all such sums, the net amount received by New River equals the amount that New River would have received had the
non-creditable or non-reimbursable excess portion of such additional Withholding Taxes not been deducted. To the extent that any such amount paid by Shire to New River in accordance with this Section 7.5 is in fact subsequently able to be claimed by
New River as a credit or reimbursement for such tax otherwise deducted, then New River will repay such amount to Shire. 

     7.6 Records Retention; Audit. 

          7.6.1 Record Retention.  Each Party will maintain complete and accurate books, records and
accounts used for the determination of expenses incurred in connection with the performance of Development or Commercialization activities or otherwise relevant for the calculation of Net Sales, in sufficient detail to confirm the accuracy of any
payments required under this Agreement, which books, records and accounts will be retained by such Party for three (3) years after the end of the period to which such books, records and accounts pertain, or longer as is required by applicable Law.

          7.6.2 Audit.  Each Party will have the right to have an independent certified public accounting
firm of internationally recognized standing, reasonably acceptable to the other Party, to have access during normal business hours, and upon reasonable prior written notice, to such of the records of the other Party as may be reasonably necessary to
verify the accuracy of any expenses shared or paid by the other Party under this Agreement or the calculation of Net Sales for any calendar year ending not more than three (3) years prior to the date of such request; provided, however, that, no
Party will have the right to conduct more than one such audit in any twelve (12) month period and that the auditing Party shall not be permitted to audit the same 

 - 28 - 

period of time more than once, unless evidence of fraud or gross negligence arises in a subsequent audit and the auditing Party reasonably believes that such evidence indicates the reasonable possibility of fraud or gross
negligence in any such prior period. The accounting firm will disclose to the Parties only whether the various expenses subject to being shared by this Agreement or Net Sales reported by the audited Party are correct or incorrect and the specific
details concerning any discrepancies. The auditing Party will bear all costs of such audit, unless the audit reveals a discrepancy in the auditing Party’s favor of more than [*], in which case the audited Party will bear the cost of the audit.
If the audited Party disputes the findings pursuant to this Section 7.6.2, the Parties shall meet and discuss such dispute. If such dispute is not resolved within forty-five (45) days, then it shall be subject to Article 15. Shire shall use Diligent
Efforts to obtain from any sub-licensee audit rights at least as favorable as the audit rights set forth in this Section 7.6.2 and the right to share the results of any such audit with New River. In the event that New River reasonably believes that
there is a material inaccuracy in the reporting by a sub-licensee of the Net Sales of such sub-licensee, then New River may direct Shire to exercise such audit rights in accordance with procedures reasonably requested by New River. New River shall
succeed to the rights and obligations of Shire in respect of any costs or expenses associated with a sub-licensee audit requested by New River. 

          7.6.3 Payment of Additional Amounts. If, based on the results of any audit, additional payments
are owed to either Party under this Agreement, then the paying Party will make such additional payments within five (5) Business Days after the accounting firm’s written report is delivered to the Parties. The provisions of Section 7.1 shall
apply to such payment. 

          7.6.4 Confidentiality. Each Party will treat all information subject to review under this
Section 7.6 in accordance with the provisions of Article 9. Prior to conducting any audit hereunder, the Party conducting such audit will cause its accounting firm to enter into a reasonably acceptable confidentiality agreement with the audited
Party obligating such accounting firm to maintain all such financial information in confidence with standards no less stringent that the terms of this Article 9 of this Agreement. 

ARTICLE 8

LICENSES 

     8.1 Licenses to Shire.  Subject to the terms of this Agreement, New River hereby grants to Shire
an exclusive license, with the right to grant sublicenses as provided in Section 8.3, under the Licensed Patents, the Licensed Know-How and New River’s interest in any Joint Collaboration Patents to (a) Develop and use Collaboration Products
for Commercialization in the Field in the ROW Territory and to Commercialize Collaboration Products in the Field in the ROW Territory, and (b) to make bulk and finished Collaboration Products (but not the Compound, except as otherwise provided in
Article 5) for Commercialization in the Field in the ROW Territory.  Notwithstanding the foregoing, New River shall retain the co-exclusive right under the Licensed Patents, Licensed Know-How and New River’s interest in any Joint Collaboration
Patents in the ROW Territory for the purpose of research and Development of Collaboration Products in the Field in accordance with a Development Plan. 

 - 29 - 

     8.2 Licenses to New River.  Subject to the terms of this Agreement, Shire hereby grants to New
River an exclusive (except as to Shire), paid-up license, without the right to grant sublicenses (except to Affiliates of New River), under the Shire Patents and Shire Know-How solely to conduct Development and Commercialization of Collaboration
Products in the Field in the US Territory pursuant to the US Agreement, and to supply Shire Collaboration Products and Compound for the ROW Territory in accordance with the terms of this Agreement. 

     8.3 Sublicensing.  Shire may grant sublicenses under Section 8.1: [*]; provided, however, that
the Development activities undertaken by any sublicensee of such rights will be subject to the oversight and authority of the JDC. The entry by Shire into a sublicense shall not relieve Shire of its obligations under this Agreement, including the
obligation to report the Net Sales of such sublicensee. 

     8.4 Scope of Licenses. As used in this Article 8, a license that is “exclusive except as
to” the granting Party means that the Party granting the license shall not grant any other entity (other than its Affiliates) any license under such patent rights with the right to practice within the Field, but that otherwise the granting
Party retains all its rights of ownership in such licensed rights, including without limitation the right to practice such patent rights, subject only to the license granted. 

     8.5 No Implied Licenses. Except as expressly provided in this Agreement, neither Party grants to
the other Party any right or license in any intellectual property right, whether by implication, estoppel or otherwise. No implied licenses are granted under this Agreement. Each Party hereby covenants and agrees not to use or sublicense any of its
rights under the licenses set forth in this Article 8 except as expressly permitted in this Agreement. 

     8.6 Exclusivity. During the Term, New River hereby covenants and agrees not to, itself or
through or with any Affiliate or Third Party, (a) develop, market, promote, sell, or otherwise commercialize any pharmaceutical products containing or comprising [*] or other compound where an active moiety of such compound is [*], other than
Collaboration Products, (b) or develop, market, promote, sell, or otherwise commercialize any pharmaceutical products containing [*] formulated for [*] for the treatment or prevention of ADHD, other than Collaboration Products, or (c) grant any
license to a Third Party to perform any activities described in the preceding clauses (a) or (b), in each case without the express prior written approval of Shire. 

     8.7 Nonassertion.  New River and its Affiliates hereby covenant and agree not to, alone or in
cooperation with any Third Party, [*], the manufacture, use, offer for sale, sale, distribution, import or export of which is done under and in accordance with the terms of this Agreement. This covenant will run with and attach to any and all
intellectual property owned or controlled, in whole or in part, by New River and shall be binding upon any assignee of any intellectual property from New River. 

     8.8 [*]. New River will be permitted to terminate this Agreement by written notice effective upon receipt if [*] (each such [*]).
 Shire will include provisions in all agreements granting sublicenses of Shire’s rights hereunder providing that if the sublicensee or its Affiliates undertake a [*] with respect to [*] under which the sublicensee is sublicensed, Shire will be

 - 30 - 

permitted to terminate such sublicense agreement. If a sublicensee of Shire (or an Affiliate of such sublicensee) undertakes a [*] [*] of any such [*] under which such sublicensee is sublicensed, then Shire upon receipt of notice
from New River of such [*] will terminate the applicable sublicense agreement. If Shire fails to so terminate such sublicense agreement, New River may terminate Shire’s right to sublicense in the countr(ies) covered by such sublicense agreement
and any sublicenses previously granted in such countr(ies) shall automatically terminate.  In connection with such sublicense termination, Shire shall cooperate with New River’s reasonable requests to cause such a terminated sublicensee to
discontinue activities with respect to the Collaboration Product in such countr(ies). 

ARTICLE 9

CONFIDENTIALITY 

     9.1 Confidential Information. 

          9.1.1 Confidential Information.  As used in this Agreement, the term “Confidential Information” means all secret, confidential or proprietary information or data, whether provided in written, oral, graphic, video, computer, electronic or other form, provided pursuant to
this Agreement or generated pursuant to this Agreement or the US Agreement by one Party or its Affiliates (the “Disclosing Party”) to the other Party or its Affiliates (the
“Receiving Party”), including but not limited to, information relating to the Disclosing Party’s existing or proposed research, development efforts, patent applications,
business or products, and any other materials that have not been made available by the Disclosing Party to the general public. Notwithstanding the foregoing sentence, Confidential Information shall not include any information or materials that:

               (a) were already known to the Receiving Party (other than under an obligation of confidentiality), at the time of disclosure by
the Disclosing Party, to the extent such Receiving Party has documentary evidence to that effect; 

               (b) were generally available to the public or otherwise part of the public domain at the time of disclosure thereof to the
Receiving Party; 

               (c) became generally available to the public or otherwise part of the public domain after disclosure or development thereof, as
the case may be, and other than through any act or omission of a Party in breach of such Party’s confidentiality obligations under this Agreement; 

               (d) were disclosed to a Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the
Disclosing Party not to disclose such information to others; or 

               (e) were independently discovered or developed by or on behalf of the Receiving Party without the use of the Confidential
Information belonging to the other Party, to the extent such Receiving Party has documentary evidence to that effect. 

          9.1.2 Confidentiality Obligations. Each of New River and Shire shall keep all Confidential
Information received from the other Party with the same degree of care it maintains 

 - 31 - 

the confidentiality of its own Confidential Information. Neither Party shall use such Confidential Information for any purpose other than in performance of this Agreement or disclose the same to any other Person other than to such
of its  and its Affiliates’ directors, managers, employees, independent contractors, agents or consultants who have a need to know such Confidential Information to implement the terms of this Agreement or enforce its rights under this
Agreement; provided, however, that a Receiving Party shall advise any of its and its Affiliates’ directors, managers, employees, independent contractors, agents or consultants who receives such Confidential Information of the confidential
nature thereof and of the obligations contained in this Agreement relating thereto, and the Receiving Party shall ensure (including, in the case of a Third Party, by means of a written agreement with such Third Party having terms at least as
protective as those contained in this Article 9) that all such directors, managers, employees, independent contractors, agents or consultants comply with such obligations as if they had been a Party hereto. Upon termination of this Agreement, the
Receiving Party shall return or destroy all documents, tapes or other media containing Confidential Information of the Disclosing Party that remain in the possession of the Receiving Party or its directors, managers, employees, independent
contractors, agents or consultants, except that the Receiving Party may keep one copy of the Confidential Information in the legal department files of the Receiving Party, solely for archival purposes. Such archival copy shall be deemed to be the
property of the Disclosing Party, and shall continue to be subject to the provisions of this Article 9. It is understood that receipt of Confidential Information under this Agreement will not limit the Receiving Party from assigning its employees to
any particular job or task in any way it may choose, subject to the terms and conditions of this Agreement. 

          9.1.3 Permitted Disclosure and Use.  Notwithstanding Section 9.1.2, a Party may disclose
Confidential Information belonging to the other Party only to the extent such disclosure is reasonably necessary to: (a) obtain Regulatory Approval of a Collaboration Product to the extent such disclosure is made to a Governmental Authority; (b)
comply with or enforce any of the provisions of this Agreement; (c) comply with Laws; or (d) comply with applicable stock exchange or Nasdaq regulation.  If a Party deems it necessary to disclose Confidential Information of the other Party pursuant
to this Section 9.1.3, such Party shall give reasonable advance notice of such disclosure to the other Party to permit such other Party sufficient opportunity to object to such disclosure or to take measures to ensure confidential treatment of such
information.  In addition, notwithstanding Section 9.1.2, the Parties shall prepare standardized responses to anticipated inquiries from the public or press, stockholders, investors and/or analysts with respect to the Compound, Collaboration Product
or other activities hereunder that may be disclosed.  Notwithstanding anything to the contrary in this Article 9, Shire shall not disclose to any Third Party Confidential Information of New River disclosing the Manufacture of Compound, without the
prior written consent of New River, not to be unreasonably withheld, delayed or conditioned. 

          9.1.4 Notification.  The Receiving Party shall notify the Disclosing Party promptly upon
discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information, and will cooperate with the Disclosing Party in any reasonably requested fashion to assist the Disclosing Party to regain possession of such
Confidential Information and to prevent its further unauthorized use or disclosure. 

 - 32 - 

     9.2 Publicity; Filing of this Agreement.  After the execution of the January Agreement, the
Parties announced the execution of the January Agreement using the form of the press release attached as Exhibit C (the “Joint Press Release”). Any other publication, news release or other public announcement relating to this Agreement or to the performance hereunder, shall first be reviewed and approved by both Parties; provided, however, that any disclosure which is
required by Law as advised by the disclosing Party’s counsel may be made without the prior consent of the other Party. To the extent practicable, the disclosing Party shall be given at least three (3) Business Days advance notice of any such
legally required disclosure, and the other Party shall provide any comments on the proposed disclosure during such period. To the extent that either Party determines that it or the other Party is required to file or register this Agreement or a
notification thereof to comply with the requirements of an applicable stock exchange or Nasdaq regulation or any Governmental Authority, including without limitation the U.S. Securities and Exchange Commission, the Competition Directorate of the
Commission of the European Communities or the U.S. Federal Trade Commission, such Party shall promptly inform the other Party thereof. Prior to making any such filing, registration or notification, the Parties shall agree on the provisions of this
Agreement for which the Parties shall seek confidential treatment, it being understood that if one Party determines to seek confidential treatment for a provision for which the other Party does not, then the Parties will use reasonable efforts in
connection with such filing to seek the confidential treatment of any such provision. The Parties shall cooperate, each at its own expense, in such filing, registration or notification, including without limitation such confidential treatment
request, and shall execute all documents reasonably required in connection therewith.  In furtherance of the foregoing, the Parties will agree as promptly as practicable after the Effective Date on the confidential treatment request to be filed with
the U.S. Securities and Exchange Commission and the redacted form of this Agreement related thereto.  In that connection, any redaction reasonably requested by either Party shall be included in such filing.  The Parties will reasonably cooperate in
responding promptly to any comments received from the U.S. Securities and Exchange Commission with respect to such filing in an effort to achieve confidential treatment of such redacted form; provided, however, that a Party shall be relieved of such
obligation to seek confidential treatment for a provision requested by the other Party if such treatment is not achieved after the second round of responses to comments from the U.S. Securities and Exchange Commission. 

     9.3 Publication.  Each Party shall submit copies of each proposed academic, scientific, medical
and other publication or presentation that contains or refers to the Licensed Patents, Licensed Know-How or otherwise relates to a Collaboration Product or any research or Development activities under this Agreement to the other Party at least sixty
(60) days in advance of submitting such proposed publication or presentation to a publisher or other Third Party.  Such other Party shall have the right to review, comment on and approve each such proposed publication or presentation for accuracy
and to ascertain whether such Party’s Confidential Information is being inappropriately utilized and/or released. The non-publishing Party shall have the right to remove any of its Confidential Information prior to submission for publication or
presentation. The publishing Party shall redact or otherwise modify the proposed publication or presentation to remove any such Confidential Information of the other Party. In addition, in the event that the document includes data, information or
material generated by a Party’s scientists, and professional standards for authorship would be consistent with including such Party’s scientists as co-authors of the document, the names of such scientists will be included as co-authors.  A
Party may publicly disclose without regard to the preceding 

 - 33 - 

requirements of this Section 9.3 any information that was previously disclosed in a public disclosure that was in compliance with such requirements. 

     9.4 Use of Names. Neither Party shall use the name of the other Party in relation to this
transaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may use the name of the
other Party in any document filed with any regulatory agency or authority, including the FDA and the Securities and Exchange Commission. 

     9.5 Confidentiality of this Agreement.  The terms of this Agreement shall be Confidential
Information of each Party and, as such, shall be subject to the provisions of this Article 9. 

     9.6 Disclosures Under Existing NDA. The Parties agree and acknowledge that New River and Shire
US, Inc. entered into that certain Existing NDA.  For purposes of this Section 9.6, the term “Existing NDA” means that certain Non-Disclosure and Confidentiality Agreement, dated as of July 16, 2002, as amended by letter agreements on July
13, 2004, October 29, 2004, November 12, 2004, November 15, 2004, by and among the Parties and various other Affiliates and independent contractors of Shire.  The Parties agree that “Confidential Information” (as such term is used in the
Existing NDA) disclosed to Shire Affiliates under the Existing NDA prior to the Effective Date shall be deemed to have been disclosed under this Agreement and, from and after the Effective Date, shall be held in confidence by such Shire Affiliates
in accordance with the terms of this Article 9. To the extent that Shire retains Prior Consultants to perform activities under this Agreement in connection with which such Prior Consultant is provided Confidential Information of New River, then such
Prior Consultant shall be made subject to the provisions of this Article 9 with respect to disclosures of “Confidential Information,” as such term is used in the Existing NDA.  The term “Prior
Consultants” means those persons added as parties to the Existing NDA pursuant to those amendments to the Existing NDA made as of November 12, 2004 and November 15, 2004. 

     9.7 Survival.  The obligations and prohibitions contained in this Article 9 shall survive the
expiration or termination of this Agreement for a period of ten (10) years. 

ARTICLE 10

OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS 

     10.1 Ownership. 

          10.1.1 New River shall solely own, and it alone shall have the right to apply for Patents, within and outside of the United
States for any New River Inventions and Shire shall solely own, and it alone shall have the right to apply for Patents, within and outside of the United States for any Shire Inventions.  New River and Shire will each own an undivided one-half
interest in any Joint Inventions and any Patents claiming such Joint Inventions (“Joint Collaboration Patents”), in each case without obligation to account to the other for the
exploitation thereof or to seek consent of the other for the grant of any licenses thereunder, subject to the licenses and rights granted by the Parties in this Agreement.  Each Party shall 

 - 34 - 

promptly disclose to the other Party all Inventions made by it during the Term.  The determination of inventorship for Inventions shall be made in accordance with applicable Laws relating to inventorship set forth in the patent
Laws of the United States (Title 35, United States Code). 

          10.1.2 Each Party will require all of its and its Affiliates’ employees to assign all Inventions that are the subject of
patent applications claiming Inventions that are developed, made or conceived by such employees according to the ownership principles described in this Section 10.1.  Each Party will require any agents or independent contractors performing an
activity pursuant to this Agreement to assign all Inventions that are the subject of patent applications claiming Inventions that are developed, made or conceived by such agents or independent contractors to New River and/or Shire according to the
ownership principles described in this Section 10.1. 

     10.2 Disclosures; Disputes Regarding Inventions. Each Party shall, before filing a new patent
application (including without limitation provisionals and continuations-in-part, but excluding continuations, divisionals, and requests for continued examinations) claiming an Invention, promptly disclose such Invention to the other Party,
including Joint Inventions, New River Inventions and Shire Inventions and shall provide the other Party with a copy of the proposed patent application at least ten (10) Business Days before filing such application or such shorter time as may be
required to preserve Patent rights, including, without limitation, the avoidance of a statutory bar.  If the non-filing Party believes that the filing Party’s proposed patent application discloses Confidential Information of the non-filing
Party, the non-filing Party shall so notify the filing Party within such ten (10) Business Days, and the filing Party shall amend its proposed application to comply with the confidentiality provisions of this Agreement. If the Parties are in
agreement as to the designation of the Invention as Joint Invention, New River Invention or Shire Invention, they can continue as set forth in Section 10.3 below. If the Parties disagree as to whether an Invention is a Joint Invention, New River
Invention or Shire Invention, and are unable to reach agreement within thirty (30) days after commencing discussions, then each Party will have the right to avail itself of any legally recognizable remedy in accordance with Article 15 of this
Agreement and applicable Law. 

     10.3 Patent Filings. 

          10.3.1 New River Responsibilities. New River shall prepare, file, prosecute and maintain Patents
to cover (a) New River Inventions (the “New River Collaboration Patents”), and (b) the Licensed Patents. New River shall keep Shire informed of the status of each such Patent and
shall give Shire a reasonable opportunity to provide comments to any communication from any patent office.  New River shall give reasonable consideration to any suggestions or recommendations of Shire concerning the preparation, filing, prosecution
and maintenance thereof, including suggestions of the JIPC pursuant to the terms set forth in Sections 2.4 and 2.6.3. Promptly after the Effective Date, New River shall provide Shire with copies of the file histories of all Licensed Patents and
shall update such file histories promptly upon receipt of any additional communications from any patent offices and patent counsel or agents pertaining thereto. New River shall also provide Shire with copies of any communications from any patent
offices and patent counsel or agents pertaining to any New River Collaboration Patents. New River, at Shire’s request, shall [*][*] in any New River Collaboration Patent, Licensed Patent or 

 - 35 - 

a continuation or divisional of either of the foregoing, the type of application being at New River’s discretion; provided, however, New River may refuse to [*] if New River reasonably believes, in good faith, that [*]  If
the [*] New River will [*] and shall give reasonable consideration to any suggestions or recommendations of Shire concerning [*]. The Parties shall cooperate reasonably in the prosecution of all Patents under this Section 10.3.1 and shall share all
material information relating thereto promptly after receipt of such information. If, during the term of this Agreement, New River intends to allow any Licensed Patent to expire or intends to otherwise abandon any Licensed Patent, New River shall
notify Shire of such intention at least sixty (60) days prior to the date upon which such Licensed Patent shall expire or be abandoned, and Shire shall thereupon have the right, but not the obligation, to assume responsibility for the preparation,
filing, prosecution or maintenance thereof. 

          10.3.2 Shire Responsibilities. Shire shall file, prosecute and maintain Patents to cover Shire
Inventions conceived pursuant to this Agreement or the US Agreement (the “Shire Collaboration Patents”). Shire shall keep New River informed of the status of each such Patent and
shall give reasonable consideration to any suggestions or recommendations of New River concerning the preparation, filing, prosecution and maintenance thereof, including the suggestions of the JIPC pursuant to the terms set forth in Sections 2.4 and
2.6.3. The Parties shall cooperate reasonably in the prosecution of all Shire Patents under this Section 10.3.2 and shall share all material information relating thereto promptly after receipt of such information. If, during the Term, Shire intends
to allow any Shire Patent to which New River has a license under this Agreement to expire or intends to otherwise abandon any Shire Patent, Shire shall notify New River of such intention at least sixty (60) days prior to the date upon which such
Shire Patent shall expire or be abandoned, and New River shall thereupon have the right, but not the obligation, to assume responsibility for the preparation, filing, prosecution or maintenance thereof. 

          10.3.3 Jointly Owned Patents. The responsibility for the filing, prosecution and maintenance of
Joint Collaboration Patents shall be determined by the Parties, including conducting related interference and opposition proceedings relating thereto, without prejudice to ownership, on behalf of both Parties based on a good faith determination of
the relative contributions of the Parties to the Invention and the relative level of interest of the Parties in the Invention; provided, however that the Parties may also decide not to file a Joint Collaboration Patent for any such Joint Invention.
At least ten (10) Business Days prior to the contemplated filing, the Party responsible for such activities for a Joint Collaboration Patent shall submit a substantially completed draft of such Joint Collaboration Patent to the other Party for its
approval.  Should the agreed upon Party elect not to prepare and/or file any such Joint Collaboration Patent, it shall (a) provide the other Party with written notice as soon as reasonably possible after making such election but in any event no
later than twenty (20) Business Days before the other Party would be faced with a possible loss of rights, (b) give the other Party the right, at the other Party’s discretion, to prepare, file, prosecute or maintain the Joint Collaboration
Patent, and (c) offer reasonable assistance in connection with such preparation, filing, prosecution or maintenance. 

          10.3.4 Cooperation.  The Parties agree to cooperate in the preparation, filing, prosecution and
maintenance of all Patents under this Section 10.3, including obtaining and executing necessary powers of attorney and assignments by the named inventors, providing 

 - 36 - 

relevant technical reports to the filing Party concerning the Invention disclosed in such Patent, obtaining execution of such other documents which shall be needed in the filing and prosecution of such Patent, and, as requested,
updating each other regarding the status of such Patent, and shall cooperate with the other Party so far as reasonably necessary with respect to furnishing all information and data in its possession reasonably necessary to obtain or maintain such
Patents. 

          10.3.5 Patent Expenses. Patent Expenses for the ROW Territory shall be borne [*]; provided,
however, if New River incurs any expenses for any country in which Shire has notified New River at least thirty (30) days advance notice in writing either that it does not intend to Commercialize a Collaboration Product in such country, or that it
has abandoned such Commercialization, any fee or expense incurred with respect to patents in such country shall be the sole responsibility of New River and shall not be deemed Patent Expenses effective as of the end of such notice period. Within
five (5) Business Days following the end of each calendar quarter, each Party shall deliver a report outlining its Patent Expenses for such quarter. Within thirty (30) days following the end of each such quarter, the Party incurring less than [*] of
such expenses during the quarter shall reimburse the other Party an amount sufficient to [*] each Party’s share of such costs.  In the event that Shire notifies New River that it does intend to Commercialize a Collaboration Product in any
country in which it has previously notified of an intention not to Commercialize or abandoned Commercialization, or so Commercializes such Collaboration Product in such country, then Shire shall reimburse New River for an amount equal to [*] of the
Patent Expense for the applicable country incurred from the effective date of such notification. 

     10.4 Third-Party Patent Rights.  Except as otherwise provided in Section 11.1 below, neither
Party makes any warranty with respect to the validity, perfection or dominance of any Patent or other proprietary right or with respect to the absence of rights in Third Parties which may be infringed by the Manufacture or Commercialization of any
Collaboration Product. Each Party agrees to bring to the attention of the other Party any patent or patent application it discovers, or has discovered, and which relates to the subject matter of this Agreement. 

     10.5 Enforcement and Defense of Patents. 

          10.5.1 Infringement of Third Party Patents. 

               (a) Third Party Claims; Third Party Royalties.  In the event of a Third Party Claim against
Shire, New River or their respective Affiliates alleging that the making, using, importing, selling or offering to sell a Collaboration Product infringes or will infringe claims in any patents of a Third Party, the Party first obtaining knowledge of
such Third Party Claim shall immediately provide the other Party notice of such Third Party Claim with the related facts in reasonable detail. Shire shall have the first right, but not the obligation, to control such defense with respect to the
Collaboration Product with an attorney of Shire’s choice if Shire or any of its Affiliates are named as a party to such Third Party claim and New River or any of its Affiliates are not.  In such case, New River shall have the right to be
represented by independent counsel at New River’s own expense. New River shall have the first right, but not the obligation, to control such defense with respect to the Collaboration Product with an attorney of New River’s choice if New
River or any of its Affiliates are named as a party to such Third Party claim and Shire or any of its Affiliates are not. In such case, Shire shall have the right to 

 - 37 - 

be represented by independent counsel at Shire’s own expense. If either Party refuses to accept control of the defense of a Third Party Claim for which it has the first right to control defense hereunder within [*] after
receiving or giving notice thereof, then the other Party shall have the right to defend against such Third Party Claim. In such case, such refusing Party shall have the right to be represented by independent counsel at its own expense.  If (1) Shire
or any of its Affiliates and (2) New River or any of its Affiliates are named as parties to such Third Party Claim, then the Parties will have the joint right, but not the obligation, to control such defense with respect to the Collaboration Product
with an attorney of their mutual agreement.  If the Parties are unable to agree on such joint defense, then the Parties will use good faith efforts to determine the Party to assume control of such defense and choice of counsel. In such case, the
other Party shall have the right to be represented by independent counsel at its own expense. If, as a result of a judgment in any litigation or settlement with a Third Party, Shire or its Affiliates are required to pay royalties to any Third Party
(“Third Party Royalty”), then, on a country-by-country basis and product-by-product basis, the royalty due to New River under this Agreement with respect to Net Sales in the ROW
Territory will be [*] of the Third Party Royalty, provided that the royalty due to New River will not be reduced to less than [*] of the royalty that would be due to New River in the absence of such Third Party Royalty. 

               (b) Cooperation. If a Party shall become engaged in or participate in any suit described in this
Section 10.5.1, the other Party shall cooperate, and shall cause its and its Affiliates’ employees to cooperate, with such Party in all reasonable respects in connection therewith, including giving testimony and producing documents lawfully
requested, and using its reasonable and diligent efforts to make available to the other, at no cost to the other (other than reimbursement of actually incurred, reasonable out-of-pocket travel and lodging expenses), such employees who may be helpful
with respect to such suit, investigation, claim, interference or other proceeding. 

          10.5.2 Prosecution of Infringers. 

               (a) Notice.  If either Party learns that a Third Party is infringing or allegedly infringing any
Patent within the Licensed Patents, the Shire Patents or the Joint Collaboration Patents or if any Third Party claims that any such Patent is invalid or unenforceable, it will promptly notify the other Party thereof including available evidence of
infringement or the claim of invalidity or unenforceability. The Parties will cooperate and use reasonable efforts to stop such alleged infringement or to address such claim without litigation. 

               (b) Enforcement and Defense of Licensed Patents, Joint Collaboration Patents and Shire Collaboration Patents. 

                    (i) Shire will have the first right (but not the obligation) to take the appropriate steps to enforce or defend any Patent within
the Shire Collaboration Patents. Shire may take steps including the initiation, prosecution and control any suit, proceeding or other legal action by counsel of its own choice. Each of New River and Shire will bear the costs of such enforcement or
defense [*]. Notwithstanding the foregoing, New River will have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

 - 38 - 

                    (ii) If, pursuant to Section 10.5.2(b)(i), Shire fails to take the appropriate steps to enforce or defend any Patent within the
Shire Collaboration Patents within [*] days of the date one Party has provided notice to the other Party pursuant to Section 10.5.2(a) of such infringement or claim, then New River will have the right (but not the obligation), at its own expense, to
bring any such suit, action or proceeding by counsel of its own choice and Shire will have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

                    (iii) New River will have the first right (but not the obligation) to take the appropriate steps to enforce or defend any Patent
within the Licensed Patents. New River may, in any such instance, take steps including the initiation, prosecution and control any suit, proceeding or other legal action by counsel of its own choice. Each of New River and Shire will bear the costs
of such enforcement or defense [*]. Notwithstanding the foregoing, Shire will have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

                    (iv) If, pursuant to Section 10.5.2(b)(iii), New River fails to take the appropriate steps to enforce or defend any Patent within
the Licensed Patents within [*] of the date one Party has provided notice to the other Party pursuant to Section 10.5.2(a) of such infringement or claim, then Shire will have the right (but not the obligation), at its own expense, to bring any such
suit, action or proceeding by counsel of its own choice, and New River will have the right, at its own expense, to be represented in any such action by counsel of its own choice.

                    (v) In the case of Joint Collaboration Patents, the Parties will decide whether Shire or New River will have the first right (but
not the obligation) to take the appropriate steps to enforce or defend any Patent within the Joint Collaboration Patents. The Party so selected may, in any such instance, take steps including the initiation, prosecution and control any suit,
proceeding or other legal action by counsel of its own choice. Each of New River and Shire will bear the costs of such enforcement or defense [*] and the Party that is not so selected will have the right, at its own expense, to be represented in any
such action by counsel of its own choice.

                    (vi) If, pursuant to Section 10.5.2(b)(v), the Party selected fails to take the appropriate steps to enforce or defend any Patent
within the Joint Collaboration Patents within [*] of the date one Party has provided notice to the other Party pursuant to Section 10.5.2(a) of such infringement or claim, then the other Party will have the right (but not the obligation), at its own
expense, to bring any such suit, action or proceeding by counsel of its own choice, and the Party so selected will have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

                    (vii) Notwithstanding
Sections 10.5.2(b)(i) -(vi), Shire will have the sole discretion whether to commence
[*] and the sole right  to commence [*] which may result in [*] [*] for such
Third Party. For the avoidance of doubt, New River shall not have the right to
commence [*] [*] which may result [*] for such Third Party. Any such [*] as may
be required by Law. 

 - 39 - 

               (c) Cooperation; Damages. 

                    (i) If one Party brings any suit, action or proceeding under this Section 10.5.2, the other Party agrees to be joined as party
plaintiff if necessary to prosecute the suit, action or proceeding and to give the first Party reasonable authority to file and prosecute the suit, action or proceeding; provided, however, that neither Party will be required to transfer any right,
title or interest in or to any property to the other Party or any other party to confer standing on a Party hereunder. 

                    (ii) The Party not pursuing the suit, action or proceeding hereunder will provide reasonable assistance to the other Party,
including by providing access to relevant documents and other evidence and making its employees available, subject to the other Party’s reimbursement of any out-of-pocket expenses incurred by the non-enforcing or defending Party in providing
such assistance. 

                    (iii) Neither Party will settle or otherwise compromise any such suit, action or proceeding in a way that adversely affects the
other Party’s intellectual property rights or its rights or interests with respect to the Collaboration Product without such Party’s prior written consent. 

                    (iv) Any settlements, damages or other monetary awards (the “Recovery”) recovered pursuant to a suit, action or proceeding brought pursuant to Section 10.5.2 will be allocated first to the costs and expenses of the Party taking such action, and second, to the costs and expenses (if any) of the other
Party, with any remaining amounts (if any) with respect to a country in the ROW Territory to be shared [*]. 

     10.6 Notice of Certification. New River and Shire each shall immediately give notice to the
other of any certification filed under the U.S. Drug Price Competition and Patent Term Restoration Act of 1984 (or its foreign equivalent) claiming that a Licensed Patent, Joint Collaboration Patent or a Shire Collaboration Patent is invalid or that
infringement of a Licensed Patent, Joint Collaboration Patent or Shire Collaboration Patent will not arise from the manufacture, use, offer for sale, sale or importation product by a Third Party (“Hatch-Waxman
Certification”). Nothing in this Section 10.6 shall prevent or otherwise limit New River’s right to take any and all such actions with regard to the matters described in this Section 10.6 as required by
applicable Law.

     10.7 Patent Term Extensions. New River and Shire shall cooperate in good faith in gaining patent
term extensions due to delay(s) in Regulatory Approval wherever applicable to the Licensed Patents, Joint Collaboration Patents and Shire Collaboration Patents.  However, Shire shall have the sole discretion in determining which Licensed Patent(s),
Joint Collaboration Patent(s), or Shire Collaboration Patent(s) to extend for any particular compound, composition, article, product, process, or use. 

     10.8 Listing of Patents. Shire shall have the right to determine which of the [*], if any, shall
be submitted for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S.C. Section 355, or any successor Law in the United States, together with any comparable Laws in any other country. Shire shall
notify New River at 

 - 40 - 

least ten (10) Business Days prior to the deadline for any such submission, and New River shall submit the designated Patents in accordance with applicable Law. In addition, New River may in its discretion, and to the extent
permitted by Law, submit any additional [*] that are not designated by Shire. Nothing in this Section 10.8 shall prevent or otherwise limit New River’s right to take any and all such actions with regard to the matters described in this Section
10.8 as required by applicable Law.

     10.9 Trademarks and Copyrights. 

          10.9.1 Product Trademarks. All Collaboration Products shall be marketed and sold worldwide under
and in connection with trademarks, trade dress, logos and slogans selected in accordance with this Section 10.9. 

          10.9.2 Trademark Selection.  Shire shall select trademarks, trade dress, logos and slogans for a
Collaboration Product for use in the ROW Territory.  Trademark(s), trade dress, logo(s) and slogan(s) under which Collaboration Products are marketed or sold (other than either Party’s corporate trademarks or trade names, and New River’s
CarrierwaveTM mark used in connection with technology related to the Compound) shall be used only pursuant to the terms of this Agreement to identify and in connection with the marketing
of Collaboration Products, and shall not be used by either Party to identify or in connection with the marketing of any other products. Each Party shall have a right to prior review and approval of all Promotional Materials incorporating any of its
trademarks, trade dress, logos or slogans sufficient to permit such Party to maintain quality control over its trademarks, trade dress, logos and slogans. All trademarks shall be registered by the Party owning such trademark in its name as owner in
all applicable countries. All trade dress, logos, slogans and designs may be registered by the Party owning such trade dress, logos or slogan, in the discretion of such Party, in its name as owner in all applicable countries. 

          10.9.3 Ownership of Trademarks. New River will continue to own, throughout the world, any
trademarks, trade dress, logos and/or slogans, and all registrations therefor, used or intended to be used for a Collaboration Product which New River owns as of the Effective Date (the “New River
Marks”).  Shire will own, throughout the world, all other trademarks, trade dress, logos and/or slogans, and all registrations therefor, used or intended to be used for a Collaboration Product (the
“Shire Marks”).  All goodwill attributable to a New River Mark generated by the Commercialization of a Collaboration Product bearing a New River Mark shall inure to the benefit of
New River. All goodwill attributable to a Shire Mark generated by the Commercialization of a Collaboration Product bearing a Shire Mark shall inure to the benefit of Shire.  If Shire determines to use a New River Mark for the Commercialization of a
Collaboration Product in the ROW Territory, New River shall grant to Shire, a non-exclusive, royalty-free license, with the right to grant sublicenses in accordance with Section 8.3, to use such New River Mark in the ROW Territory, solely in
conjunction with the Commercialization of the Collaboration Products. Shire shall comply with New River’s then-current guidelines for trademark usage, a copy of which shall be provided to Shire from time to time, in connection with Shire’s
use of such New River Mark. New River shall solely bear all costs of prosecution of applications to register and to record licenses (if applicable) for, and maintenance of, each New River Mark for each Collaboration Product. Shire shall solely bear
all costs of prosecution 

 - 41 - 

of applications to register and to record licenses (if applicable) for, and maintenance of, each Shire Mark for each Collaboration Product. 

          10.9.4 Infringement of Trademarks and Copyrights. Each Party shall take all reasonable and
appropriate steps to protect, defend and maintain each trademark and copyright owned by such Party hereunder for use in connection with a Collaboration Product, and all registrations therefor.  Each Party shall notify the other Party promptly upon
learning of any actual, alleged or threatened infringement of a trademark, trade dress, logo, slogan, copyright, or of any unfair trade practices, trade dress imitation, passing off of counterfeit goods, or like offenses. Upon learning of such
offenses, the Party owning such trademark or copyright shall have the obligation to, in consultation with the other Party, institute and control an appropriate action or proceeding to halt the offense, unless the Parties otherwise mutually agree.
All Recoveries in connection therewith will be allocated first to the costs and expenses of the Party taking such action, and second, to the costs and expenses (if any) of the other Party, with any remaining amounts (if any) with respect to a
country in the ROW Territory to be shared equally. Such other Party shall have the right to participate fully in all such actions or proceedings. During the Term, in the event that the Party owning such trademark or copyright does not undertake such
an infringement action then, in the case that such owning Party is New River, Shire shall be permitted to do so and all Recoveries in connection therewith will be allocated first to the costs and expenses of the Party taking such action, and second,
to the costs and expenses (if any) of the other Party, with any remaining amounts (if any) with respect to a country in the ROW Territory to be shared equally.  For the purposes of  this Section 10.9.4, the Party that brings suit to enforce a given
trademark or copyright shall also have the right to control settlement of such claim; provided, however, that no settlement shall be entered into without the written consent of the other Party, not to be unreasonably withheld, conditioned or
delayed. 

          10.9.5 Costs of Defense. All of the unrecovered costs, expenses and legal fees (including
internal costs, expenses and legal fees) incurred by the Parties in bringing, maintaining and prosecuting any action to maintain, protect or defend a trademark (or registration therefor) or copyright (or registration therefor) covering or used or
intended to be used in connection with the marketing or sale of a Collaboration Product in the ROW Territory will be [*]. 

          10.9.6 Acknowledgment of Ownership.  Each Party acknowledges the sole ownership by the other
Party and validity of all trademarks, trade dress, logos and slogans owned by the other Party and used or intended to be used on or in connection with the marketing or sale of a Collaboration Product.  Each Party agrees that it will not at any time
during or after the Term assert or claim any interest in or do anything which may adversely affect the validity or enforceability of any trademark, trade dress, logo or slogan owned by the other Party and used or intended to be used on or in
connection with the marketing or sale of a Collaboration Product. Neither Party will register, seek to register or cause to be registered any trademarks, trade dress, logos or slogans owned by the other Party and used or intended to be used on or in
connection with the marketing or sale of a Collaboration Product or any variation thereof, under any law providing for registration of trademarks, service marks, trade names, fictitious names or similar laws, as an Internet domain name, or in the
name of a corporation, partnership, limited liability company or other entity, without the other Party’s prior written consent, and neither Party will register, seek to register or cause to be registered any copyright, nor register or patent,
seek to 

 - 42 - 

register or patent or caused to be registered or patented, of the other Party, without the other Party’s prior written consent. 

ARTICLE 11

REPRESENTATIONS AND WARRANTIES; EXCLUSIVITY 

     11.1 Representations, Warranties and Covenants. 

          11.1.1 Each of the Parties hereby represents and warrants to the other Party that, as of the Effective Date:

               (a) Such Party has full corporate right, power and authority to enter into this Agreement and to perform its respective
obligations under this Agreement and that it has the right to grant the licenses and sublicenses granted pursuant to this Agreement. 

               (b) This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms. The
execution, delivery and performance of the Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it is bound, nor violate any Law of any Governmental Authority
having jurisdiction over it. 

               (c) Such Party has not granted any right to any Third Party that would conflict with the rights granted to the other Party
hereunder. 

               (d) Except for Regulatory Approvals, pricing and/or reimbursement approvals, manufacturing approvals and/or similar approvals
necessary for the Development, Manufacture or Commercialization of the Compound and Collaboration Products, such Party has obtained all necessary consents, approvals and authorizations of all Government Authorities and other Persons required to be
obtained by it as of the Effective Date in connection with the execution, delivery and performance of this Agreement; provided, that, for clarity, it is agreed that a termination by a Party in accordance with Section 12.6 shall not be deemed to
constitute evidence of a breach of this Section 11.1.1(d) . 

          11.1.2 Each Party hereby covenants to the other Party that, during the Term: 

               (a) Such Party will not grant any right to any Third Party that would conflict with the rights granted to the other Party
hereunder; 

               (b) In the course of the Development of the Compound and Collaboration Products, such Party will not use any employee or
consultant that is debarred by the FDA (or any foreign equivalent) or, to such Party’s knowledge, is the subject of debarment proceedings by the FDA (or any foreign equivalent). 

          11.1.3 New River hereby represents and warrants to Shire that, as of the Effective Date: 

               (a) There is no action or proceeding pending or, to New River’s knowledge, threatened, with respect to Collaboration
Products and/or the Compound, including 

 - 43 - 

without limitation the conduct of any clinical trials, manufacturing activities or other activities, or that questions the validity of this Agreement or any action taken by New River in connection with the execution of this
Agreement.  There are no material unsatisfied judgments or outstanding orders, injunctions, decrees, stipulations or awards (whether rendered by a court, an administrative agency or by an arbitrator) against New River with respect to Collaboration
Products and/or the Compound, including without limitation the conduct of any clinical trials, manufacturing activities or other activities.

               (b) IND #67482 and IND #70109 (i) have been filed in the name of New River and are in effect; and (ii) to New River’s
knowledge, constitutes all governmental approvals, permits and licenses required by New River in connection with the performance of clinical trials concerning the Collaboration Product or the Compound, as such clinical trials are conducted by New
River. Attached hereto as Schedule 11.1.3(b) is a true, correct and complete list of all INDs and Drug Approval Applications filed with a Governmental Authority relating to the Compound or a
Collaboration Product. 

               (c) Intellectual Property. 

                    (i) Schedule 11.1.3(c)(i)(I) sets forth a true and complete list of all Licensed Patents that
[*]. Schedule 11.1.3(c)(i)(II) sets forth a true and complete list of all Patents that [*].  Such schedules contain, where relevant, all application numbers and filing dates, registration
numbers and dates, jurisdiction, next action date with description for action to be taken, and notice of whether fees of any kind are yet to be paid. 

                    (ii) New River has submitted all information related to the Compound, Collaboration Product and/or Licensed Patents to the United
States Patent and Trademark Office required to be submitted in accordance with 37 C.F.R. 1.56, 1.97 and 1.98. 

                    (iii) The Licensed Patents and Licensed Know-How constitute all intellectual property Controlled by New River that is necessary
or useful to Manufacture, Develop, use or Commercialize the Compound and/or Collaboration Product for ADHD, and to the knowledge of New River there is not any other intellectual property necessary for such purposes that is not Controlled by New
River. 

                    (iv) Neither New River nor any of its Affiliates has received any written notice from any Third Party challenging or questioning
the right of New River to use or license any of the Licensed Know-How or Licensed Patents. 

                    (v) Each of New River and its Affiliates owns all right, title and interest in and to, or has a license, sublicense or otherwise
permission to use and license, all of the Licensed Know-How or Licensed Patents free and clear of all encumbrances and no person other than New River (including any current or former employee or consultant of New River) has any proprietary,
commercial or other interest in any of the Licensed Know-How or Licensed Patents. There are no existing agreements, options, commitments, or rights with, of or to any person to acquire or obtain any rights to, any of the Licensed Know-How or
Licensed Patents. 

 - 44 - 

                    (vi) The use or practice of the Licensed Know-How and Licensed Patents as it has been and is now being conducted do not, to the
knowledge of New River, infringe or misappropriate the intellectual property rights of a Third Party. Neither New River nor any of its Affiliates has received any written notice from any person, or has knowledge of, any actual or threatened claim or
assertion that the use or practice of the Licensed Patents or Licensed Know-How infringes or misappropriates the intellectual property rights of a Third Party. 

                    (vii) New River has the right to grant to Shire the licenses set forth in this Agreement under the Licensed Know-How or Licensed
Patents, free of any rights or claims of any Third Party and without payment of any royalties, license fees or other amounts to any Third Party. 

                    (viii) All Patents within the Licensed Patents are in full force and effect, valid, subsisting and, in the case of issued
Patents, enforceable, and inventorship of the Licensed Patents is properly identified on such Licensed Patents. None of the Licensed Patents is currently involved in any interference, reissue, reexamination, or opposition proceeding, and neither New
River nor any of its Affiliates has received any written notice from any person, or has knowledge, of such actual or threatened proceeding.

                    (ix) To
New River’s knowledge, [*] of any of the Licensed Know-How or Licensed Patents
by [*]. 

                    (x) There are no actions or proceedings (including any inventorship challenges) pending or, to the knowledge of New River,
threatened with respect to any of the Licensed Know-How, Licensed Patents, Compound or Collaboration Products nor have any such actions or proceedings been brought or, to the knowledge of New River, threatened during the past six (6) years, in each
case which have not been resolved without impairment of New River’s rights in and to any of the Licensed Know-How, Licensed Patents, Compound or Collaboration Products and without the obligation to pay any royalties or other amounts to any
Third Party with respect to the use of such technology or the sale of such products. 

                    (xi) Neither New River nor any of its Affiliates has entered into any contract (A) granting any Third Party the right to bring
infringement actions with respect to, or otherwise to enforce rights with respect to, any of the Licensed Know-How or Licensed Patents, or (B) expressly agreeing to indemnify any Third Party against any charge of infringement of any of the Licensed
Know-How or Licensed Patents. 

                    (xii) Neither New River nor any of its Affiliates has entered into any contract granting any Third Party the right to control the
prosecution of any of the Patents in the Licensed Patents. 

                    (xiii) All current and former employees and consultants of New River and its Affiliates who are or have been substantively
involved in the design, review, evaluation or development of the Licensed Know-How or Licensed Patents have executed written contracts or are otherwise obligated to protect the confidential status and value thereof 

 - 45 - 

and to vest in New River or its Affiliates exclusive ownership of the Licensed Know-How or Licensed Patents. 

                    (xiv) New River has made available to or provided Shire with copies of all material information and, as requested in writing by
Shire, with copies of all books, records and data, in each case with respect to Collaboration Products and/or the Compound. 

                    (xv) All official fees, maintenance fees and annuities for the Licensed Patents have been paid through the Effective Date.

                    (xvi) Schedule 11.1.3(c)(i)(I) and Schedule
11.1.3(c)(i)(II) set forth a true and complete list of all registration, application, maintenance, user, or renewal fees due within one hundred eighty (180) days after the Effective Date in connection with the Licensed
Know-How or Licensed Patents. Any necessary registration, application, maintenance, user or renewal fees due on or prior to the Effective Date in connection with the Licensed KnowHow or Licensed Patents have been paid in a timely manner.  All
applicable government requirements that must be met on or prior to the Effective Date in connection with the Licensed Know-How or Licensed Patents have been met in a timely manner with the relevant Governmental Authority. 

               (d) Compliance with Law. 

                    (i) New River and its Affiliates and any outsourcing company and contract research organization to which New River or its
Affiliates have subcontracted activities in connection with Compound and Collaboration Products (the “Contractors”) have complied with all applicable Laws, permits, governmental
licenses, registrations, approvals, concessions, franchises, authorizations, orders, injunctions and decrees, including the Act, in the research, Development, Manufacture and use of the Collaboration Product for ADHD and Compound, and neither New
River nor any of its Affiliates or, to the knowledge of New River, its Contractors, has received any written notice from any Governmental Authority claiming that any such activities as conducted by them are not in such compliance. 

                    (ii) Since January 1, 2002, no Governmental Authority has served notice on New River or any of its Affiliates that the Licensed
Know-How or Licensed Patents were or are in violation of any Law or the subject of any investigation. 

                    (iii) Since January 1, 2002, none of New River or any of its Affiliates have received written notice from any Governmental
Authority that there are any circumstances currently existing that might reasonably be expected to lead to any loss or refusal to renew any material governmental licenses, permits, registrations, concessions, franchises and authorizations relating
to the Collaboration Product for ADHD, Compound or any of the Licensed Know-How or Licensed Patents. 

                    (iv) New River and its Affiliates have complied in all material respects with all applicable Laws in connection with the
preparation and submission to the FDA of IND #67482 and #70109, and such INDs are in effect and good standing. IND #67482 and #70109 are the only INDs that New River or any of its Affiliates has filed with any Governmental Authority with respect to
the Compound or a Collaboration Product. New River 

 - 46 - 

and its Affiliates have filed with the applicable regulatory authority all required notices, supplemental applications and annual or other reports, including adverse experience reports, with respect to such INDs.  No Drug Approval
Application has been filed with any Governmental Authority with respect to the Compound or a Collaboration Product. 

                    (v) No Governmental Authority has commenced or, to New River’s knowledge, threatened to initiate any action to reject or
withdraw IND #67482 or #70109, or commenced or, to New River’s knowledge, threatened to initiate any action to enjoin production of the Compound or Collaboration Product at any facility, nor has New River or any of its Affiliates or, to the
knowledge of New River, any of its Contractors, received any notice to such effect since January 1, 2002. 

                    (vi) All manufacturing operations conducted by New River and its Affiliates and Contractors since January 1, 2002 relating to the
manufacturing of the Collaboration Product for ADHD and/or Compound have been conducted in compliance with all Laws, including without limitation all cGMPs. 

                    (vii) All Development activities conducted by New River and its Affiliates and Contractors since January 1, 2002 relating to the
Collaboration Product for ADHD and/or Compound have been conducted in compliance with all Laws, including without limitation all cGCPs and cGLPs. 

                    (viii) New River has delivered or otherwise made available to Shire copies of all substantive or material (A) reports of FDA Form
483 inspection observations, (B) establishment inspection reports, (C) warning letters, and (D) other documents that assert ongoing lack of compliance in any material respect with any applicable laws (including those of the FDA), in each case to the
extent received by New River or any of its Affiliates or, to the knowledge of New River, any of its Contractors from the FDA relating to a Collaboration Product and/or Compound. Neither New River nor any of its Affiliates has received any such
reports, letters or other documents from any other Governmental Authority relating to a Collaboration Product and/or Compound. 

                    (ix) To New River’s knowledge, no employee or agent of New River or any of its Affiliates or Contractors has made an untrue
statement of a material fact to any Governmental Authority with respect to the Collaboration Product for ADHD and/or Compound (whether in any submission to such Governmental Authority or otherwise), or failed to disclose a material fact required to
be disclosed to any Governmental Authority with respect to the Collaboration Product and/or Compound. 

                    (x) In the course of the Development of the Compound and Collaboration Products, New River has not used any employee or
consultant that is debarred by the FDA or, to New River’s knowledge, is the subject of debarment proceedings by the FDA. 

                    (xi) Representatives of New River and its Affiliates have disclosed to Shire any facts reasonably believed in good faith to be
material regarding:  (A) preclinical and clinical study results and protocols for the Collaboration Product for ADHD and/or Compound; (B) any communications to or from any Governmental Authority with respect 

 - 47 - 

to the Collaboration Product for ADHD and/or Compound, including IND submissions, any Governmental Authority minutes of meetings and telephone conferences; (C) any Governmental Authority requests for data and studies on the
Collaboration Product for ADHD and/or Compound; and (D) adverse drug experiences and other IND safety reports with respect to the Collaboration Product for ADHD and/or Compound. 

                    (xii) New River and its Affiliates do not have any knowledge of any preliminary or other results from any clinical trials
relating to the lack of efficacy of the Compound or Collaboration Product in human beings. 

For purposes of the foregoing sections, “New River” and “its Affiliates” shall in all cases include [*] 

     11.2 Limitation on Representations or Warranties. Notwithstanding anything to the contrary
herein, neither Party will be in breach of any representation or warranty made pursuant to this Article 11 to the extent that the Party alleged to have so breached can demonstrate that the Party alleging such breach had, on or prior to the Effective
Date, actual knowledge of such breach of such representation or warranty. 

     11.3 Performance by Affiliates. The Parties recognize that each may perform some or all of its
obligations under this Agreement through Affiliates; provided, however, that each Party shall remain responsible for and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement
in connection with such performance. Each Party hereby expressly waives any requirement that the other Party exhaust any right, power or remedy, or proceed against an Affiliate or subcontractor, for any obligation or performance hereunder prior to
proceeding directly against such Party.  Wherever in this Agreement the Parties delegate responsibility to Affiliates or local operating entities, the Parties agree that such entities may not make decisions inconsistent with this Agreement, amend
the terms of this Agreement or act contrary to its terms in any way. 

     11.4 Disclaimer of Warranty. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 11.1 OF THIS
AGREEMENT, NEW RIVER AND SHIRE MAKE NO REPRESENTATIONS AND GRANT NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND NEW RIVER AND SHIRE EACH SPECIFICALLY DISCLAIMS ANY OTHER REPRESENTATIONS AND
WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY
INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

     11.5 Limitation of Liability. IN NO EVENT WILL EITHER PARTY BE LIABLE FOR LOST PROFITS OR FOR
ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN ANY
WAY OUT OF THIS AGREEMENT. THE FOREGOING LIMITATIONS 

 - 48 - 

WILL NOT LIMIT EITHER PARTY’S OBLIGATIONS TO THE OTHER PARTY UNDER ARTICLE 9 AND ARTICLE 14. 

     11.6 Essential Basis.  The Parties acknowledge and agree that the disclaimers, exclusions and
limitations of liability set forth in this Article 11 form an essential basis of this Agreement, and that, absent any of such disclaimers, exclusions or limitations of liability, the terms of this Agreement, including, without limitation, the
economic terms, would be substantially different. 

ARTICLE 12

TERM AND TERMINATION 

     12.1 Term.  This Agreement shall commence as of the Effective Date and, unless sooner terminated
as provided herein, shall expire on a country-by-country basis upon expiration of all royalty obligations in such country for all Collaboration Products, pursuant to Section 6.3.4 (the “Term”). 

     12.2 Breaches (General). 

          12.2.1 If either Party (the “Breaching Party”) shall have
committed a breach of this Agreement, the other Party (the “Notifying Party”) shall provide written notice of such breach to the Breaching Party. For all allegations of breach
other than an allegation of Material Breach (as defined below), the Parties hereby agree that they shall seek to resolve the matter during the notice and cure period provided in Section 12.2.2 and may thereafter commence litigation pursuant to
Article 15. 

          12.2.2 Upon receipt of a notice of breach other than a Material Breach, the alleged Breaching Party shall have [*] within which
to cure such breach following receipt of such notice [*] in the event of non-payment unless such payment obligation is being disputed in good faith). If the matter is not resolved to the satisfaction of the Notifying Party during such cure period,
then either Party may invoke the provisions of Article 15 with respect to claims for damages and other requests for equitable relief, but neither Party shall have any right to terminate this Agreement for such breach. 

          12.2.3 The Parties may resort to the dispute resolution mechanisms of Article 15, and may seek all remedies in law or equity
other than termination of this Agreement, without invoking the mechanisms of Section 12.3. 

     12.3 Allegations of Material Breach. 

          12.3.1 The Parties intend that this Agreement shall survive breach, and shall not be terminable in the event of breach, unless
the breach is [*] under this Agreement [*] to such an extent that [*] for the [*] taken as a whole under [*], considered in the aggregate as a single transaction and as if set forth in a single agreement (“Material
Breach”).  The Parties acknowledge and agree that, so long as such breach satisfies the standard for Material Breach described in this Section 12.3.1, a Material Breach may result from a breach of this Agreement
only (irrespective of whether any breach, material or otherwise, has occurred with respect to the US Agreement), the US Agreement only (irrespective of whether any breach, material or 

 - 49 - 

otherwise, has occurred with respect to this Agreement), or both agreements. In the event there is a dispute as to whether a Material Breach has occurred, this Agreement and the US Agreement shall survive pending a determination
pursuant to Article 15 that a Material Breach has occurred. This Section 12.3 shall apply to any allegation of Material Breach, with consequences as set forth herein. 

          12.3.2 If a Party believes that a Material Breach has occurred, it shall give written notice to the Breaching Party of the nature
of the breach and the reason the Notifying Party believes it is a Material Breach. The alleged Breaching Party shall then have a period of [*] [*] following receipt of such notice [*] in the event of non-payment unless such payment obligation is
being disputed in good faith) in which to cure the breach; provided, however, that if the Material Breach is other than the payment of money and is capable of being cured but cannot be reasonably cured in such [*] period, then the right to terminate
this Agreement shall not arise if the allegedly Breaching Party has (a) during such period of time submitted a plan that, if successfully carried out, would be effective in curing such Material Breach, and has commenced its execution of such plan,
and (b) diligently pursues such plan thereafter for a period of up to an additional [*]. Any such notice of alleged Material Breach by the Notifying Party shall include a reasonably detailed description of all relevant facts and circumstances
demonstrating, supporting and/or relating to each such alleged Material Breach by the Breaching Party. 

          12.3.3 If the alleged Material Breach is not cured within the cure period specified in Section 12.3.2, the Notifying Party may
give notice of termination (“Notice of Termination For Material Breach”). If the Breaching Party agrees that a Material Breach has occurred, then the Parties shall proceed to
terminate this Agreement and the US Agreement in accordance with Section 12.3.5 and Article 13 of this Agreement and Section 13.3.5 and Article 14 of the US Agreement. If the Breaching Party does not agree that a Material Breach has occurred, then
this Agreement and the US Agreement shall survive, and the Parties shall continue to perform their obligations hereunder, until the issue of whether there has been a Material Breach by the Breaching Party is resolved in accordance with Article 15.

          12.3.4 If the Notifying Party gives Notice of Termination For Material Breach, and it is later determined by a court pursuant to
Article 15 that in fact there has not been a Material Breach by the Breaching Party, then this Agreement and the US Agreement shall continue in full force and effect. 

          12.3.5 If the Notifying Party gives Notice of Termination For Material Breach and this Agreement and the US Agreement terminate,
either because such notice is accepted by the Breaching Party or it is determined by a court pursuant to Article 15 that there has been a Material Breach by the Breaching Party, then the Notifying Party shall, within [*] after such determination,
deliver written notice (the “Purchase Notice”) to the Breaching Party of the purchase by the Notifying Party of the Purchase Interest (as such term is defined below).

               (a) The price (the “Purchase Price”) to be paid to purchase
the entire interests, rights and obligations of the Breaching Party and/or its Affiliates under this Agreement and the US Agreement (the “Purchase Interest”) shall be [*] [*], it
being understood and agreed that [*] shall be applied [*] and that all intellectual property rights and other assets licensed or 

 - 50 - 

otherwise made available by the Parties and their respective Affiliates under this Agreement and the US Agreement shall be [*]. 

               (b) Each Party shall, within [*] after the delivery of the Purchase Notice, retain an internationally recognized investment
banking firm to determine the Purchase Price. Each such investment banking firm shall set forth such determination in a written report and, on a mutually agreeable date no later than [*] after the delivery of the Purchase Notice, submit such report
to the other Party. 

               (c) The Purchase Price shall be the amount equal to [*] However, if [*], a third internationally recognized investment banking
firm (which is independent of both Parties) shall determine such fair market value by [*]. Such third investment banking firm shall be selected by the first two investment banking firms; provided, however, that, if the two investment banking firms
are unable to select a third investment banking firm within twenty (20) days following determination that [*], then each of the two initial investment banking firms shall within twenty (20) days thereafter submit the names of three internationally
recognized investment banking firms (which are independent of both Parties) willing to act as the third investment banking firm hereunder, one of which firms shall be selected by lot by the Parties. The cost of such third investment banking firm
shall be borne [*]. 

               (d) The purchase and sale of a Purchase Interest pursuant to this Section 12.3 shall be transferred free and clear of all liens
and other encumbrances and shall be consummated at closing at the principal offices of the Notifying Party, on a Business Day within forty-five (45) days following the final determination of the Purchase Price, and upon at least ten (10) Business
Days’ prior notice by the Notifying Party; provided that such period shall be extended for such period of time as shall be necessary in order to obtain requisite governmental or regulatory approvals. At such closing, the Notifying Party shall
pay the Breaching Party the Purchase Price by wire transfer of immediately available funds. The Parties shall execute and deliver appropriate documentation, in form and substance that is reasonably acceptable, to effect the transfer of the Purchased
Interest and each Party further agrees to reasonably cooperate to effect the orderly transition of any activities then being conducted by the Breaching Party and its Affiliates pursuant to this Agreement and the US Agreement. 

               (e) The rights of the Parties set forth in this Section 12.3 are not exclusive and are in addition to any other rights or
remedies available to such Party under this Agreement or the US Agreement, at law or in equity. 

     12.4 Other Termination by Shire.  At any time after the date of first Regulatory Approval of a
Collaboration Product in the US Territory, Shire may terminate this Agreement effective upon [*] advance written notice to New River. Termination by Shire pursuant to this Section 12.4 may be on the basis of the countries of the European Union
and/or the ROW Territory (other than the countries of the European Union). In the event of termination under this Section 12.4 no payment shall be due on account of such termination.  In addition, this Agreement shall be automatically terminated in
the event that Shire terminates the US Agreement pursuant to Section 13.4.2 of the US Agreement. 

 - 51 - 

     12.5 Other Termination By New River. New River may terminate this Agreement on the basis of (i)
the countries of the European Union and/or (ii) the ROW Territory (other than the countries of the European Union), in each case by [*] advance written notice to Shire [*], other than the following products: (i) any Collaboration Product, (ii) any
product marketed by or on behalf of Shire as of the Effective Date, as set forth on Exhibit E, and any additional dosage strengths or line extensions thereof, and (iii) those products
identified by Shire’s internal nomenclature as [*], each as described on Exhibit E, it being understood that each such product [*] [*] [*]. For avoidance of doubt, New River shall have
no right to terminate this Agreement pursuant to this Section 12.5 if Shire files for Regulatory Approval for, or Commercializes, that product identified by Shire’s internal nomenclature as [*] or any [*] as such products do not contain [*]
formulated for [*] [*] for the treatment or prevention of ADHD and are therefore outside the scope of this Section 12.5. In the event of termination under this Section 12.5, no payment shall be due by New River to Shire on account of such
termination. 

     12.6 Termination for Government Action. 

          12.6.1 During the period from the Effective Date and expiring on [*] [*], either Party may terminate this Agreement upon written
notice to the other Party at any time, if during such time there is a decree, judgment, injunction, order, or action that restricts, prevents or prohibits the transactions contemplated by this Agreement under applicable Law in the European Union;
provided that no such termination shall occur for a period of [*] following the entry of such decree, judgment, injunction, order or action (which period shall be reduced to [*] if [*] in the US Territory for a Collaboration Product for an ADHD
indication occurs after [*]), during which period of time the Parties shall cooperate and use reasonable commercial efforts to respond to any government requests for information, and to contest and resist any such decree, judgment, injunction, order
or action and to have vacated, lifted, reversed, stayed or overturned any such decree, judgment, injunction, order or action.  In addition, this Agreement may be terminated by either Party in the event that the US Agreement terminates pursuant to
Section 13.6 thereof, irrespective of whether there is any decree, judgment, injunction, order, or action that restricts, prevents or prohibits the transactions contemplated by this Agreement. 

          12.6.2 If
such termination is effective prior to the FDA acceptance of the first, and only
the first, Drug Approval Application for Collaboration Product for ADHD in the
Field in the US Territory, [*] [*], New River shall reimburse Shire [*] of the
amount paid by Shire pursuant to Section 6.1. Such payment shall be made within
one hundred twenty (120) days following termination; provided, that interest
shall accrue beginning on the thirty-first day after termination at the rate
provided for in Section 7.1. 

          12.6.3 If
such termination is effective after the FDA acceptance of the first, and only
the first, Drug Approval Application for Collaboration Product for ADHD in the
Field in the US Territory, [*] New River shall reimburse Shire (a) [*] of the
amount paid by Shire pursuant to Section 6.1, and (b) [*] [*] of all other amounts
paid by Shire pursuant to Section 6.2. Such payment shall be made within one
hundred twenty (120) days following termination; provided, that interest shall
accrue beginning on the thirty-first day after termination at the rate provided
for in Section 7.1. 

 - 52 - 

ARTICLE 13 

EFFECTS OF TERMINATION 

     13.1 Post-Termination Activities by Shire.  Without limiting any other legal or equitable
remedies that New River may have, if this Agreement is terminated in accordance with Sections 8.8, 12.4, 12.5 or 12.6, or if this Agreement is terminated in accordance with Section 12.3 and Shire is the Breaching Party, then the following provisions
shall apply: 

          13.1.1 Assignments.  Shire will promptly (and in each case within sixty (60) days of receipt of
New River’s request) and at no cost to New River (other than the Purchase Price, in the event of a termination pursuant to Section 12.3): 

               (a) upon New River’s request, assign to New River all of Shire’s right, title and interest in and to any agreements
between Shire and Third Parties that are freely assignable by Shire and that relate solely to the Development or Manufacture of any Compound or Collaboration Product in any territory for which such termination is effective; 

               (b) assign to New River all of Shire’s right, title and interest in and to any Shire Marks (including any goodwill
associated therewith), any registrations and design patents for any of the foregoing and any Internet domain name registrations for such trademarks and slogans, all to the extent solely related to a Collaboration Product in any territory for which
such termination is effective; 

               (c) assign to New River, to the extent freely assignable by Shire, the management and continued performance of any clinical
trials for the Collaboration Products ongoing as of the effective date of such termination in any territory for which such termination is effective; 

               (d) transfer to New River all of Shire’s right, title and interest in and to any and all regulatory filings and Regulatory
Approvals Controlled by Shire for the Collaboration Products in any territory for which such termination is effective, and grant New River the right to reference any regulatory filings and Regulatory Approvals Controlled by Shire for the
Collaboration Products elsewhere in the world for the purpose of Developing and Commercializing Collaboration Products in the territory for which such termination is effective; 

               (e) to the extent that any agreement or other asset described in this Section 13.1.1 is not assignable by Shire or does not
relate solely to Compound or a Collaboration Product, then such agreement or other asset will not be assigned, and upon the request of New River, Shire will take such steps as may be necessary to allow New River to obtain and to enjoy the benefits
of such agreement or other asset in the form of a license or other right to the extent Shire has the right and ability to do so; and 

               (f) provide copies of any other books, records, documents and instruments to the extent related to Compound or Collaboration
Product. 

 - 53 - 

          13.1.2 Manufacturing Activities. Shire will: 

               (a) upon New River’s request, if Shire is then Manufacturing a Collaboration Product, supply New River with clinical and
commercial quantities of such Collaboration Product for the shorter of (i) the period until New River or its designee has established and validated a manufacturing process for such Collaboration Product and is approved to Manufacture clinical trial
and commercial supplies of such Collaboration Product or (ii) eighteen (18) months from the effective date of such termination; provided, however, that New River will [*] (as determined pursuant to Exhibit
A hereof) with respect to such Collaboration Product; and 

               (b) if Shire is then Manufacturing a Collaboration Product, transfer the completed manufacturing process (together with any
unique mold or tooling used solely in connection therewith) for such Collaboration Product to New River or its designee upon New River’s request and at [*] cost and expense, and shall cooperate with New River to effect the transition of such
Manufacturing responsibilities. 

          13.1.3 License Grant.  Shire agrees to grant and hereby grants to New River, effective upon such
termination of this Agreement, an exclusive, royalty-free right and license, with the right to sublicense and authorize the grant of further sublicenses, under any Shire Collaboration Patents and Shire’s rights and interest in the Joint
Collaboration Patents to make, have made, use, sell, offer for sale, and import Compound or Collaboration Products affected by such termination in the Field and in the territory for which such termination is effective; provided, however, that New
River will be responsible for any payments associated with the grant of any license pursuant to the preceding sentence (including, without limitation, any royalty or other payment obligations to an upstream licensor of any such Patents). In
addition, if any Shire Know-How or technology claimed in a Shire Background Patent is then used in connection with the Manufacture, Development or Commercialization of Compound or a Collaboration Product in the applicable territory, Shire agrees to
grant and hereby grants to New River, effective upon such termination of this Agreement, a non-exclusive, royalty-free right and license, with the right to grant sublicenses, under such Shire Background Patents and Shire Know-How, to make, have
made, use, sell, offer for sale, and import Collaboration Products in the Field and in the territory for which such termination is effective. Finally, Shire agrees to grant and hereby grants to New River, effective upon such termination of this
Agreement, a non-exclusive, royalty-free right and license, with the right to grant sublicenses, under any copyright or Shire Confidential Information embodied in or relating to any marketing plan, package inserts, or other Promotional Materials
relating solely to Collaboration Products in the applicable territory.

          13.1.4 Disclosure and Delivery.  Shire will transfer to New River any Shire Collaboration
Know-How and Shire Background Know-How, to the extent then used in connection with the Manufacture, Commercialization or Development of the Collaboration Products; such transfer shall be effected by the delivery of documents, to the extent such
KnowHow is embodied in documents, and to the extent that such Know-How is not fully embodied in documents, Shire shall make its employees and agents who have knowledge of such Know-How in addition to that embodied in documents available to New River
for interviews, demonstrations 

 - 54 - 

and training to effect such transfer in manner sufficient to enable New River to practice such Know-How as theretofore practiced by Shire. 

          13.1.5 Sublicensees. Each of Shire’s sublicensees with respect to any affected
Collaboration Products in any affected country at such time will continue to have the rights and license set forth in their sublicense agreements, subject to the continued performance of the obligations thereunder; provided, however, that such
sublicensee agrees in writing that New River is entitled to enforce all relevant terms and conditions of such sublicense agreement directly against such sublicensee; and provided, further, that such sublicensee is not then in breach of its
sublicense agreement. 

          13.1.6 Disposition of Inventory. New River shall have the option, exercisable within thirty (30)
days following the effective date of such termination, to purchase any inventory of Collaboration Products affected by such termination at Shire’s Cost of Goods therefor. New River may exercise such option by written notice to Shire during such
thirty (30)-day period.  Upon such exercise, the Parties will establish mutually agreeable payment and delivery terms for the sale of such inventory. If New River does not exercise such option during such thirty (30)-day period, or if New River
provides Shire with written notice of its intention not to exercise such option, then Shire and its Affiliates and sublicensees will be entitled, during the period ending on the last day of the sixth (6th) full month following the effective date of
such termination, to sell any inventory of Collaboration Products affected by such termination that remain on hand as of the effective date of the termination, so long as Shire pays to New River the royalties applicable to said subsequent sales,
with respect to sales in the ROW Territory, in accordance with the terms and conditions set forth in this Agreement. 

          13.2 Post-Termination Activities by New River. Without limiting any other legal or equitable
remedies that Shire may have, if this Agreement is terminated in accordance with Section 12.3 and New River is the Breaching Party, then the following provisions shall apply: 

          13.2.1 Assignments.  New River will promptly (and in each case within sixty (60) days of receipt
of Shire’s request) and at no cost to Shire (other than the Purchase Price, in the event of a termination pursuant to Section 12.3): 

               (a) upon Shire’s request, assign to Shire all of New River’s right, title and interest in and to any agreements between
New River and Third Parties that are freely assignable by New River and that relate solely to the Development or Manufacture of any Compound or Collaboration Products; 

               (b) assign to Shire all of New River’s right, title and interest in and to any New River Marks (including any goodwill
therewith), including any registrations and design patents for the foregoing and any Internet domain name registrations for such trademarks and slogans, all to the extent solely related to a Collaboration Product; 

               (c) assign to Shire, to the extent freely assignable by New River, the management and continued performance of any clinical
trials for Collaboration Products ongoing as of the effective date of such termination; 

 - 55 - 

               (d) transfer to Shire all of New River’s right, title and interest in and to any and all regulatory filings and Regulatory
Approvals Controlled by New River for Collaboration Products; 

               (e) to the extent that any agreement or other asset described in this Section 13.2.1 is not assignable by New River or does not
relate solely to Compound or a Collaboration Product, then such agreement or other asset will not be assigned, and upon the request of Shire, New River will take such steps as may be necessary to allow Shire to obtain and to enjoy the benefits of
such agreement or other asset in the form of a license or other right to the extent New River has the right and ability to do so; and 

               (f) provide copies of any other books, records, documents and instruments to the extent related to Compound or Collaboration
Product. 

          13.2.2 Manufacturing Activities. New River will: 

               (a) upon Shire’s request, if New River is then Manufacturing Compound or Collaboration Product, supply Shire with clinical
and commercial quantities of such Compound or Collaboration Product for the shorter of (i) the period until Shire or its designee has established and validated a manufacturing process for such Compound or Collaboration Product and is approved to
Manufacture clinical trial and commercial supplies of such Compound or Collaboration Product or (ii) eighteen (18) months from the effective date of such termination; provided, however, that Shire [*] [*] (as determined pursuant to Exhibit A hereof) for such Compound or Collaboration Product; and 

               (b) if New River is then Manufacturing Compound or Collaboration Product, transfer the completed manufacturing process (together
with any unique mold or tooling used solely in connection therewith) for such Compound or Collaboration Product to Shire or its designee upon Shire’s request and at [*] cost and expense, and cooperate with Shire to effect the transition of such
Manufacturing responsibilities. 

          13.2.3 License Grant. Each license granted by New River to Shire pursuant to Section 8.1 shall,
effective upon such termination of this Agreement, become an exclusive, perpetual, non-terminable, royalty-free right and license, with the right to sublicense and authorize the grant of further sublicenses, and shall include the right to
Manufacture Compound. 

          13.2.4 Disclosure and Delivery. New River shall transfer to Shire any Licensed Know-How, to the
extent then used in connection with the Manufacture, Commercialization or Development of the Collaboration Products; such transfer shall be effected by the delivery of documents, to the extent such Know-How is embodied in documents, and to the
extent that such Know-How is not fully embodied in documents, New River shall make its employees and agents who have knowledge of such Know-How in addition to that embodied in documents available to Shire for interviews, demonstrations and training
to effect such transfer in manner sufficient to enable Shire to practice such Know-How as theretofore practiced by New River. 

          13.2.5 Sublicensees.  Each of New River’s sublicensees with respect to any affected
Collaboration Products at such time will continue to have the rights and license set forth in their sublicense agreements, subject to the continued performance of the obligations 

 - 56 - 

thereunder; provided, however, that such sublicensee agrees in writing that Shire is entitled to enforce all relevant terms and conditions of such sublicense agreement directly against such sublicensee; and provided, further, that
such sublicensee is not then in breach of its sublicense agreement. 

          13.2.6 Disposition of Inventory. Shire shall have the option, exercisable within thirty (30)
days following the effective date of such termination, to purchase any inventory of Compound or Collaboration Products at New River’s Cost of Goods therefor.  Shire may exercise such option by written notice to New River during such thirty (30)
day period. Upon such exercise, the Parties will establish mutually agreeable payment and delivery terms for the sale of such inventory. 

     13.3 Accrued Rights. Termination of this Agreement for any reason will be without prejudice to
any rights that will have accrued to the benefit of a Party prior to the effective date of such termination. Such termination will not relieve a Party from obligations that are expressly indicated to survive the termination of this Agreement.

     13.4 Confidential Information.  Any Confidential Information assigned pursuant to this Article
13 by the non-terminating Party shall thereafter be considered Confidential Information of the terminating Party and may be used by the terminating Party without regard to the restrictions otherwise imposed by Article 9. 

     13.5 Survival. The following Articles and Sections, together with any definitions used or
exhibits referenced therein, will survive any termination or expiration of this Agreement: Sections 4.8.2, 4.8.3, 4.8.4, 7.6, 10.1, 10.9.3, 10.9.6, 11.4, 11.5, 11.6, 12.3.5, 15.2, and 15.4, and Articles 9, 13, 14 (as to activities arising prior to
the termination), and 16. 

     13.6 Liability Following Termination. In the event that either Party has rights to a
Collaboration Product following termination of this Agreement, such Party shall be solely responsible for all liabilities associated with such Collaboration Product arising after the effectiveness of such termination. 

ARTICLE 14

INDEMNIFICATION; INSURANCE 

     14.1 Indemnification. 

          14.1.1 Indemnification
by Shire. Shire hereby agrees to save, defend
and hold New River, its  Affiliates, and their respective directors, agents and
employees harmless from and against any and all Losses arising in connection
with any and all charges, complaints, actions, suits, proceedings, hearings,
investigations, claims, demands,  judgments, orders, decrees, stipulations or
injunctions by a Third Party (each a “Third
Party Claim”) resulting directly from
[*] by [*] of any [*] pursuant to this Agreement [*] the  [*] by [*] or its [*]
or their [*] in [*] [*] under this Agreement [*] of Collaboration Products [*]
except for [*] [*] as [*] under [*], or [*] in connection with [*] hereunder;
in each case except to the extent that such Losses result from the  negligence
or willful misconduct of New River. 

 - 57 - 

          14.1.2 Indemnification
by New River.  New River hereby agrees to
save, defend and hold Shire,  its Affiliates, and their respective directors,
agents and employees harmless from and against any and all Losses arising in
connection with any and all Third Party Claims resulting directly from [*] by
[*] of any [*], [*] the [*] or [*] [*] by [*]  or its [*] or their [*], [*] in
[*] under this Agreement, [*], [*] or [*] of [*] [*] [*] or [*] [*] hereunder;
in each case except to the extent that such Losses result from the negligence
or willful misconduct of Shire. 

          14.1.3 The rights of indemnification under this Section 14.1 shall be subject to the provisions of Sections 14.2 through 14.8.

     14.2 Notice of Claim.  All indemnification claims in respect of any indemnitee seeking indemnity
under Section 14.1 (collectively, the “Indemnitees” and each an “Indemnitee”) will be made solely by the
corresponding Party (the “Indemnified Party”). The Indemnified Party will give the indemnifying Party (the “Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses or the discovery of any fact upon which such Indemnified Party intends to base a
request for indemnification under Section 14.1, but in no event will the Indemnifying Party be liable for any Losses that result from any delay in providing such notice which materially prejudices the defense of such Third Party Claim. Each
Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). Together with the Indemnification Claim Notice, the
Indemnified Party will furnish promptly to the Indemnifying Party copies of all notices and documents (including court papers) received by any Indemnitee in connection with the Third Party Claim. The Indemnifying Party shall not be obligated to
indemnify the Indemnified Party to the extent any admission or statement made by the Indemnified Party materially prejudices the defense of such Third Party Claim. 

     14.3 Control of Defense.  At its option, the Indemnifying Party may assume the defense of any
Third Party Claim subject to indemnification as provided for in Sections 14.1.1 and 14.1.2 by giving written notice to the Indemnified Party within [*] after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the
defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel it selects. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying Party
will not be liable to the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim.

     14.4 Right to Participate in Defense. Without limiting Section 14.3, any Indemnitee will be
entitled to participate in, but not control, the defense of a Third Party Claim for which it has sought indemnification hereunder and to employ counsel of its choice for such purpose; provided, however, that such employment will be at the
Indemnitee’s own expense unless (a) the employment thereof has been specifically authorized by the Indemnifying Party in writing, or (b) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 14.3
(in which case the Indemnified Party will control the defense). 

     14.5 Settlement. With respect to any Losses relating solely to the payment of money damages in
connection with a Third Party Claim and that will not result in the Indemnitee’s becoming subject to injunctive or other relief or otherwise adversely affect the business of the 

 - 58 - 

Indemnitee in any manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party will have the sole right to consent to the entry of
any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its reasonable discretion, will deem appropriate (provided, however that such terms shall include a complete and unconditional
release of the Indemnified Party from all liability with respect thereto), and will transfer to the Indemnified Party all amounts which said Indemnified Party will be liable to pay prior to the time of the entry of judgment. With respect to all
other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 14.3, the Indemnifying Party will have authority to consent to the entry of any judgment,
enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (which consent will be at the Indemnified Party’s reasonable discretion).  The Indemnifying Party that has
assumed the defense of the Third Party Claim in accordance with Section 14.3 will not be liable for any settlement or other disposition of a Loss by an Indemnitee that is reached without the written consent of such Indemnifying Party.  Regardless of
whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnitee will admit any liability with respect to, or settle, compromise or discharge, any Third Party Claim without first offering to the Indemnifying Party
the opportunity to assume the defense of the Third Party Claim in accordance with Section 14.3. 

     14.6 Cooperation.  If the Indemnifying Party chooses to defend or prosecute any Third Party
Claim, the Indemnified Party will, and will cause each other Indemnitee to, cooperate in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery
proceedings, hearings, trials and appeals as may be reasonably requested in connection with such Third Party Claim. Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by
the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and
explanation of any material provided hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket expenses incurred in connection with such cooperation. 

     14.7 Expenses of the Indemnified Party. Except as provided above, the reasonable and verifiable
costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim will be reimbursed on a calendar quarter basis by the Indemnifying Party, without prejudice to the
Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

     14.8 Treatment of Certain Losses.  New River shall be solely responsible for all Losses from
Third Party Claims resulting directly from either (a) the use or administration of the Compound by New River prior to the Effective Date or (b) the conduct of clinical testing of the Compound by New River (including such clinical tests that
commenced prior to and continuing after the Effective Date). 

 - 59 - 

     14.9 Insurance. Each Party will obtain and keep in force, through self insurance or otherwise,
in a form reasonably acceptable to the other Party hereto, insurance in scope and amount as required by law applicable to a Party’s activities hereunder and such additional amounts as may be reasonably necessary to cover such Party’s
indemnity obligations under this Agreement with scope and coverage as is normal and customary in the biotechnology/pharmaceutical industry generally for parties similarly situated. It is understood that such insurance will not be construed to limit
a Party’s liability with respect to its indemnification obligations under this Article 14.  Each Party will, except to the extent self insured, provide to the other Party upon request a certificate evidencing the insurance such Party is
required to obtain and keep in force under this Article 14. Such certificate will provide that such insurance will not expire or be cancelled or modified without at least thirty (30) days’ prior notice to the other Party. 

     14.10 Guaranty. In consideration of the rights granted to Shire under this Agreement, and to
induce New River to enter into this Agreement, Shire Pharmaceuticals Group PLC hereby unconditionally guarantees in favor of New River the full payment and performance by Shire of all obligations of Shire under this Agreement, in accordance with the
terms and conditions of this Agreement, including any applicable notice or cure periods. This guaranty shall be enforceable after the failure by Shire to perform any obligation it may have under this Agreement in accordance with its terms, and shall
be effective regardless of the solvency or insolvency of Shire at any time, the extension or modification of the obligations of this Agreement by operation of law, or the subsequent reorganization, merger, consolidation or other restructuring of
Shire. Shire Pharmaceuticals Group PLC hereby expressly waives any requirement that New River exhaust any right, power or remedy under Article 15, or proceed against any other Shire entity under Article 15, for any obligation or performance
hereunder prior to proceeding directly against Shire Pharmaceuticals Group PLC under this Section 14.10. 

ARTICLE 15 

DISPUTE RESOLUTION 

     15.1 Disputes. For all matters other than those delegated to the JDC or JSC under this
Agreement, the Parties hereby agree that the dispute shall be referred to a senior executive of New River and a senior executive of Shire (the “Representatives”). If any such
matter has not been resolved within [*] of such referral to the Representatives either Party may invoke the provisions of Section 15.2 for such dispute.  No dispute resolution procedure set forth in this Agreement shall be construed as an agreement
to arbitrate under any federal or state arbitration law, including but not limited to the Federal Arbitration Act, and shall not deprive a court of competent jurisdiction from resolving any dispute arising under, or related to, this Agreement. In
the event of any dispute between the Parties arising in connection with Article 10 of this Agreement, the Parties agree that the dispute resolution described under this Article 15 will be conducted with sufficient dispatch to prevent loss of patent
rights in the disputed subject matter. 

     15.2 Litigation.  Any dispute that is not resolved as provided in the preceding Section 16.1,
whether before or after termination of this Agreement, may be submitted by either Party only to any court of competent jurisdiction in the United States. 

 - 60 - 

     15.3 Injunctive Relief. Notwithstanding anything to the contrary in this Agreement, either Party
will have the right to seek temporary injunctive relief in any court of competent jurisdiction as may be available to such Party under the laws and rules applicable in such jurisdiction with respect to any matters arising out of the other
Party’s performance of its obligations under this Agreement. 

     15.4 Governing Law.  Resolution of all disputes arising out of or related to this Agreement or
the performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of New York, without regard to conflicts of law rules that would
provide for application of the law of a jurisdiction outside New York. 

ARTICLE 16 

MISCELLANEOUS 

     16.1 Entire Agreement; Amendment.  This Agreement, together with the US Agreement, including the
exhibits attached hereto and thereto (each of which is hereby and thereby incorporated herein and therein by reference), sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations,
conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements (including the January Agreement) and understandings between the Parties, except for the Existing NDA, which will continue to govern the
obligations of the Parties with respect to information disclosed thereunder with respect to periods prior to the Effective Date, and the Material Transfer Agreement between Shire Pharmaceuticals Inc. and New River dated January 7, 2005. There are no
covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein. No subsequent alteration, amendment, change or addition to this Agreement
shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. For the avoidance of doubt, the Parties agree that all covenants, promises, agreements, warranties, representations, conditions, and
understandings set forth herein are made and deemed effective as of the Effective Date, notwithstanding the execution of this Agreement and the US Agreement, and that the execution of this Agreement and the US Agreement shall not constitute a waiver
of any right or claim of either Party as of the Effective Date. 

     16.2 Force Majeure.  Each Party shall be excused from the performance of its obligations under
this Agreement to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party.  Such excuse shall be continued so long as the condition constituting force
majeure continues and the nonperforming Party takes reasonable efforts to remove the condition.  For purposes of this Agreement, force majeure shall include conditions beyond the control of the Parties, including without limitation, an act of God,
voluntary or involuntary compliance with any regulation, law or order of any government, war, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or
materials by fire, earthquake, storm or like catastrophe; provided, however, the payment of invoices due and owing hereunder shall not be delayed by the payer because of a force majeure affecting the payer, unless such force majeure specifically
precludes the payment process. 

 - 61 - 

     16.3 Notices. All notices or other communications that are required or permitted under this
Agreement will be in writing and delivered personally, sent by facsimile (and promptly confirmed by personal delivery or overnight courier as provided in this Agreement), or sent by internationally-recognized overnight courier to the addresses
below. Any such communication will be deemed to have been given (a) when delivered, if personally delivered or sent by facsimile on a Business Day (so long as promptly confirmed by personal delivery or overnight courier as provided in this
Agreement), and (b) on the second Business Day after dispatch, if sent by internationally-recognized overnight courier.  Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below. 

	 	
For New River:
        	 
        	
New River Pharmaceuticals Inc.
        
		

        	 
        	
The Governor Tyler
        
		

        	 
        	
1881 Grove Avenue
        
		

        	 
        	
Radford, VA 24141
        
		

        	 
        	
Phone: (540) 633-7978
        
		

        	 
        	
Fax: (540) 633-7939
        
		

        	 
        	
Attention: President
        
	 

        
	 	
with a copy to:
        	 
        	
Cooley Godward LLP
        
		

        	 
        	
5 Palo Alto Square
        
		

        	 
        	
3000 El Camino Real
        
		

        	 
        	
Palo Alto, CA 94306-2155
        
		

        	 
        	
Phone: (650) 843-5000
        
		

        	 
        	
Fax: (650) 849-7400
        
		

        	 
        	
Attention: Robert L. Jones
        
	 

        
	 	
For Shire:
        	 
        	
Shire Pharmaceuticals Group plc
        
		

        	 
        	
Hampshire International Business Park
        
		

        	 
        	
Chineham, Basingstoke
        
		

        	 
        	
Hampshire, RG24 8EP
        
		

        	 
        	
ENGLAND
        
		

        	 
        	
Fax: 011 44 125 689 4710
        
		

        	 
        	
Attention: General Counsel
        
	 

        
		

        	 
        	
Shire Pharmaceuticals
        
		

        	 
        	
725 Chesterbrook Boulevard
        
		

        	 
        	
Wayne, Pennsylvania 19087-5637
        
		

        	 
        	
Fax: (484) 595-8163
        
		

        	 
        	
Attention: General Counsel
        
	 

        
	 	
with a copy to:
        	 
        	
Morgan, Lewis & Bockius LLP
        
		

        	 
        	
502 Carnegie Center
        
		

        	 
        	
Princeton, NJ 08540
        
		

        	 
        	
Fax: (609) 919-6701
        
		

        	 
        	
Attention: Randall B. Sunberg
        

- 62 - 

     16.4 Independent Contractors. In making and performing this Agreement, Shire and New River shall
act at all times as independent contractors and nothing contained in this Agreement shall be construed or implied for any purpose to create an agency, partnership, limited partnership, joint venture or employer and employee relationship between
Shire and New River and this Agreement shall not be construed to suggest otherwise. At no time shall one Party make commitments or incur any charges or expenses for or in the name of the other Party. Except as otherwise provided in this Agreement,
each Party shall be solely responsible for its own costs and expenses associated with this Agreement. 

     16.5 Non-Solicitation. From and after the Effective Date until [*] the termination or expiration
of this Agreement, neither Party shall, and shall cause each of its Affiliates not to, directly or indirectly, without the other Party’s prior written consent, solicit the employment of any employee (or former employee bound by a
non-competition obligation) of the other Party or its Affiliates with whom it has come in contact in conducting activities under this Agreement; provided, however, that the foregoing provisions shall not apply to (a) a general advertisement or
solicitation program that is not specifically targeted at such persons or (b) the solicitation of any employee after such time as such employee’s employment has been terminated by the other Party or its Affiliate. 

     16.6 Maintenance of Records.  Each Party shall keep and maintain all records required by Law
with respect to Products and shall make copies of such records available to the other Party upon reasonable request. 

     16.7 United States Dollars. References in this Agreement to “Dollars” or “$”
shall mean the legal tender of the United States of America. 

     16.8 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly
construed against either Party. 

     16.9 Assignment.  Neither Party will sell, transfer, assign, delegate, pledge or otherwise
dispose of, whether voluntarily, involuntarily, by operation of Law or otherwise, this Agreement or any of its rights or obligations under this Agreement without the prior written consent of the other Party (which consent may be granted, withheld or
conditioned at such other Party’s sole and absolute discretion); provided, however, that either Party may assign or transfer this Agreement or any of its rights or obligations under this Agreement without the consent of the other Party (a) to
any Affiliate of such Party, or (b) to any Third Party with which it merges or consolidates, or to which it transfers all or substantially all of its assets. The assigning Party (unless it is not the surviving entity) will remain jointly and
severally liable with, and will guarantee the performance of, the relevant Affiliate or Third Party assignee under this Agreement, and the relevant Affiliate assignee, Third Party assignee or surviving entity will assume in writing all of the
assigning Party’s obligations under this Agreement. Any purported assignment or transfer in violation of this Section 16.9 will be void ab initio and of no force or effect. 

     16.10 Counterparts.  This Agreement may be executed in two counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same 

 - 63 - 

instrument.  Signatures provided by facsimile transmission shall be deemed to be original signatures. 

     16.11 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

     16.12 Severability. If any one or more of the provisions of this Agreement is held to be invalid
or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make
a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

     16.13 Ambiguities.  Ambiguities, if any, in this Agreement shall not be construed against any
Party, irrespective of which Party may be deemed to have authored the ambiguous provision. 

     16.14 Headings. The headings for each article and section in this Agreement have been inserted
for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 

     16.15 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver
as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as to a particular matter
for a particular period of time. 

[Signature Page Follows.]

 

 

 

 - 64 - 

 IN WITNESS WHEREOF, the Parties have executed this ROW Territory License Agreement in duplicate originals by their proper officers as of the date first written above.

	 	
NEW RIVER PHARMACEUTICALS INC.
        	 
	 	SHIRE PHARMACEUTICALS
                     IRELAND
          LIMITED  
	 	 

        	 	 	 
	By:	/s/ Randal J. Kirk
        	 
	By: 	/s/ Matthew Emmens
	 	
	 	 	

	 	
Randal J. Kirk
        	
          
        	 
        	
Name:   Matthew Emmens
        
	 	Chief Executive Officer	 	 	

	 	 
	  
        	 
        	
Title:     CEO
        
	 	 

        	 	 	

	 	 	 	 	 
	 	 

        	 	 	 
		

        	 
	 	SHIRE PHARMACEUTICALS
          GROUP PLC
	 	 

        	 	 	 
	 	 	  	By: 	/s/ Matthew Emmens
	 	 	 	 	

	 	 	          	  	 Name:   Matthew Emmens 
	 	 	 	 	

	 	 	  	  	 Title:     CEO 
		

        	 	 	 

EXHIBIT A 

DETERMINATION OF CERTAIN ACCOUNTING TERMS 

Upon the request of either Party from time to time, each Party will reasonably consider suggestions from the other Party to review and clarify and possibly expand any of the definitions in this Exhibit
A or any of the financial terms defined in Article 1, including financial terms whose definition is referred to in the table at the end of Article 1; provided that no changes shall be made without the written consent of
both Parties. 

1. COST OF GOODS SOLD 

     The provisions of this section shall govern the determination of the cost of a unit of Compound or Collaboration Product.  The accumulated costs of such unit as determined hereunder shall be referred
to as “Cost of Goods.” When such unit is sold or transferred to Shire, in the case of New River, or to a Third Party, in the case of Shire, the Cost of Goods of such unit shall become the unit’s Cost of Goods Sold, subject to the
selling Party’s inventory flow methods adopted. 

	 	1.1.	New River’s Cost of Goods. If
                    the Manufacture of Compound and/or Collaboration Product
                    is performed, in any part, by one or more Third Party Manufacturer(s)
                    on behalf of New River, New River’s Cost of Goods shall
          equal [*] 
	 	 	 
	 	1.2. 	Shire’s Cost of Goods. Relating
                    to Collaboration Product transferred to it from New River,
          Shire’s Cost of Goods shall equal [*] 
	 	 	 
	 	1.3.	Compound and/or Collaboration Product
                         Manufactured by a Party. If
                         the Manufacture of Compound and/or Collaboration Product
                         is performed directly by a Party, the Party conducting
                         such activities may propose to the other Party a methodology
                         to determine the Cost of Goods pursuant to a cost accounting
                         system based on standard costs, and the Parties shall
                         negotiate in good faith to agree upon such methodology.
                         The Parties agree and acknowledge that, if New River
                         undertakes to Manufacture Compound and/or Collaboration
                         Product directly, [*] by the Parties in determining
                         New River’s Cost of Goods. Similarly, if Shire
                         undertakes to Manufacture Collaboration Product directly
                         (pursuant to Shire’s rights under the Agreement),
                         [*] by the Parties in determining Shire’s Cost
          of Goods. 
	 	 	 
	 	1.4.	Cost Adjustments. If
                    any adjustment to New River’s Cost of Goods of a particular
                    quantity of Compound and/or Collaboration Product arises
                    by way of any adjustment to New River’s actual costs
                    incurred and payable to a Third Party Manufacturer subsequent
                    to the transfer of such quantity to Shire, New River shall
          promptly notify Shire of such adjustment and the

	 	 	Parties shall reflect such adjustment
          for all applicable purposes under this Agreement. 

2. ALLOCATION OF COSTS. 

     Except as it relates to appropriately allocating an item of expense or cost to more than one category of expense or cost under this Agreement, no item of expense or cost shall be treated as being a
part of more than one category of expense or cost under this Agreement. 

EXHIBIT B 

ADDITIONAL SUPPLY TERMS 

The following sets forth an outline of the principal terms of a supply agreement (the “Supply Agreement”) to be negotiated pursuant to Section 5.4 of the ROW Territory License Agreement. In each case, the terms hereof
and of the Supply Agreement will be subject to the Parties’ rights and obligations under the ROW Territory License Agreement. 

1.  Delivery. Compound or Collaboration Product supplied by New River to Shire shall be delivered to a facility designated by Shire and otherwise in accordance with the
applicable Third Party Manufacturer Agreement. 

2.  Shortage of Materials. 

	 	(a) 	In the event that the materials and/or
                    resources required to manufacture and deliver Compound or
                    Collaboration Product to Shire in a timely manner are, or
                    are reasonably anticipated to become, in short supply such
                    that New River may be unable to provide Shire with the quantities
                    of Compound or Collaboration Product forecast by Shire under
                    the Supply Agreement, New River shall notify Shire of such
                    shortage as promptly as practicable. If New River so notifies
                    Shire, New River and Shire shall promptly meet to discuss
          how to address the potential shortage.
	 	 	 
	 	(b)	In the event that New River, at any time,
                    has any information indicating that it may not be able to
                    supply Shire with all forecasted or ordered quantities of
                    Compound or Collaboration Product (whether or not New River
                    may be at fault), New River shall immediately provide Shire
          a written notice to that effect.

3. Quality Assurance.  The Parties shall enter into a Quality Agreement (the “Quality Agreement”) which shall set forth certain obligations of each Party
regarding the manufacture and supply of Compound or Collaboration Product. As more specifically set forth in the Quality Agreement, New River shall be responsible for all aspects of its supply chain regarding the Compound or Collaboration Product,
including without limitation quality control, quality assurance, release testing and stability testing. 

4. Specifications. The specifications for Compound or Collaboration Product, including the necessary documentation, certificates of analysis and test results, will be
established according to the procedures set forth in the Collaboration Agreement. 

5. Location of Manufacturing.  [*] Should New River desire to change any of the manufacturing sites for Compound or Collaboration Product, or any component thereof, to a
site other than those designated in the applicable Regulatory Approval, New River shall notify Shire in writing and the Parties shall thereafter meet to discuss the potential consequences of such a change. [*] 

6. Back-Up Manufacturing Rights. If New River fails to supply at least [*] [*] of Shire’s requirements for a Collaboration Product [*] [*] (a “Failure to
Supply”), then Shire may, by providing written notice [*] [*] of the occurrence of such Failure to Supply, elect to assume manufacturing of such Collaboration Product. If Shire elects to assume the manufacturing of a Collaboration Product (or
if Shire is a back-up manufacturer pursuant to Section 5.3), the following provisions shall be applicable: 

	 	(a) 	Transfer of Manufacturing Technology.
                    New River, [*], shall be responsible for providing Shire
                    with the documentation, know-how and technical assistance
                    necessary for the successful implementation of the manufacturing
                    process at a location to be designated by Shire. To the extent
                    practicable, New River shall continue to supply Shire with
                    its needs of Collaboration Product under the terms of the
          Supply Agreement until Shire is capable of doing so.
	 	 	 
	 	(b) 	Documentation to be Provided by New
                         River. In particular,
                         in connection with the transfer of the manufacturing
                         technology for a Collaboration Product, New River shall
          provide the following to Shire: 
	 	 	 	 
	 	 	(i)	Copies of [*] related to manufacturing
          the Collaboration Product;  
	 	 	 	 
	 	 	 (ii) 	A list of all [*] in the production of the Collaboration Product;
	 	 	 	 
	 	 	(iii)	 Copies of all [*], for the Collaboration Product;
	 	 	 	 
	 	 	(iv) 	Copies of all [*] 
	 	 	 	 
	 	 	(v)	All necessary [*] necessary to manufacture
          the Collaboration Product and copies of any [*]; and 
	 	 	 	 
	 	 	(vi) 	Such other documentation as the Parties
          may agree. 
	 	 	 	 
	 	(c) 	Audit of New River Procedures.
                    The Supply Agreement will contain reasonable and customary
                    provisions allowing Shire to inspect and audit those portions
                    of the sites at which the Collaboration Product is manufactured
                    in connection with the transfer of manufacturing technology
                    for a particular Collaboration Product. Any information obtained
                    by Shire through such inspections and audits or reviews of
                    documentation shall be treated as confidential information
                    of New River, subject to the confidentiality obligations
          under Article 9.
	 	 	 
	 	(d)	Access to New
                    River Personnel.
                    New River shall make available to Shire, for a reasonable
                    period of time, all manufacturing and operations [*] necessary
                    to support the transfer of the manufacturing technology to
                    Shire, including the [*] [*] for the validation and qualification
                    of the transferred manufacturing protocol. These [*] in the
                    implementation of the manufacturing technology until all
                    Installation Qualification, Operation Qualification and Process
          Qualification procedures have been completed successfully. 

7. Forecasts.
Following the execution of the Supply Agreement, Shire will give to New River
a [*] rolling forecast of Shire’s estimated monthly requirements of Compound
or Collaboration Product. The first [*] of the forecast shall be binding and
the remainder shall be a good faith estimate of Shire’s
requirements. However, for each of the [*] in each such forecast, although the
quantities forecast may exceed [*] the supply obligations of New River shall
not exceed [*] of the amount forecast for such month in the previous forecast.
Shire will  provide New River with monthly binding purchase orders for Compound
or Collaboration Product in accordance with the binding portion of the rolling
forecast. 

8. Quality Complaints.  New River shall be primarily responsible for handling product quality complaints related to Compound or Collaboration Product. Each Party shall
promptly advise the other of any such quality complaints with respect to Compound or Collaboration Product. 

9. Representations and Warranties. New River shall make, and shall cause its Affiliates to make, representations and warranties regarding the Compound or Collaboration
Product supplied under the Supply Agreement, including, without limitation, the following representations and warranties: 

	 	(a)	All Compound or Collaboration Product
                    shall (i) be manufactured in accordance with the then-current
                    good manufacturing practices of all applicable Regulatory
                    Authorities in countries reasonably designated by Shire from
                    time to time, and all other applicable laws, at the time
                    of delivery of Compound or Collaboration Product, (ii) comply
          with the specifications at the time of delivery.

In addition, for purposes of avoiding prosecution under the FD&C Act only, New River will guarantee that any Compound or Collaboration Product delivered under the Supply Agreement (i) shall not be adulterated or misbranded
within the meaning of the Act and applicable foreign equivalents at the time of delivery to Shire, and (ii) is not an article that may not, under the Act (or applicable foreign equivalents), be introduced into interstate commerce. 

10. Covenants.  New River shall make, and shall cause its Affiliates to make, covenants relating to Compound or Collaboration Product supplied under the Supply Agreement,
including, without limitation, the following covenants: 

	 	(a) 	New River shall, and require its Affiliates
                    and Third Party contract manufacturers, if any, to maintain
                    all regulatory and governmental permits, licenses and approvals
                    that may be necessary to manufacture and ship Compound or
          Collaboration Product.
	 	 	 
	 	(b)	New River shall advise Shire of any information
                    that arises out of New River’s or its Affiliates’ or
                    Third Party contract manufacturers’ activities of which
                    it is aware, that have adverse regulatory compliance and/or
                    reporting consequences concerning Compound or Collaboration
          Product.

	 	(c)	New River shall promptly advise Shire
                    of any requests by any Regulatory Authority for inspections
                    at the premises of New River or its Affiliates or Third Party
                    contract manufacturers, with respect to Compound or Collaboration
          Product.
	 	 	 
	 	(d)	In the event New River or its Affiliates
                    or Third Party contract manufacturers are inspected by any
                    Regulatory Authority relating to Compound or Collaboration
                    Product, [*]. New River shall promptly notify Shire of any
                    alleged violations or deficiencies relating to a facility
                    at which Compound or Collaboration Product is manufactured,
                    packaged or stored, and shall promptly disclose to Shire
                    all relevant portions of any notice of observations or potential
                    violations as well as a copy of its or its Affiliates’ or
          Third Party contract manufacturers’ response thereto. 
	 	 	 
	 	(e)	For the purpose of permitting a quality
                    and compliance audit, New River shall grant to authorized
                    representatives of Shire (or a Third Party hired on behalf
                    of Shire who is reasonably acceptable to New River), upon
                    reasonable notice, access to areas of each of its plants,
                    and permit Shire access to areas of New River’s and
                    its Affiliates’ and, to the extent practicable, Third
                    Party contract manufacturers’ plants, at such times
                    as Compound or Collaboration Product is being manufactured,
                    packaged or tested; provided, that Shire’s audit of
                    any Third Party facilities will be subject to reasonable
          and customary confidentiality and non-use obligations.
	 	 	 
	 	(f)	Shire shall have the right to examine
                    those technical records made by New River or its Affiliates
                    or Third Party contract manufacturers that relate to the
                    manufacture of Compound or Collaboration Product; provided,
                    that such records will be subject to reasonable and customary
          confidentiality and non-use obligations.
	 	 	 
	 	(g) 	New River shall ensure that its Third
          Party contract manufacturers agree [*]

11. Nonconforming Goods. If a shipment of Compound or Collaboration Product fails, at the time of delivery, to comply with the applicable specifications, and Shire
notifies New River of such nonconformity [*] within [*] following Shire’s receipt of such shipment, then New River will replace, at no additional expense to Shire, such Compound or Collaboration Product as soon as reasonably practicable after
receipt of notification of nonconformity. Any dispute regarding whether a shipment of Compound or Collaboration Product conforms with the applicable specifications will be submitted to an independent laboratory mutually acceptable to the Parties for
final resolution. The costs of retaining the laboratory will be included in Cost of Goods for the US Territory and will be borne by the Party whose evaluation of the applicable shipment of Compound or Collaboration Product is mistaken in the ROW
Territory. 

12. Payment Terms.  Shire will pay New River [*] for any quantity of Compound and Collaboration Product provided under the Supply Agreement.  At the time of each shipment,
New River shall invoice Shire, and Shire shall pay for such shipment within [*] [*] of receipt of each such invoice. 

13. Additional Provisions.  In addition to more detailed terms regarding the matters specified above in this Exhibit B, the Supply Agreement shall contain other customary supply agreement provisions. 

EXHIBIT C 

JOINT PRESS RELEASE

	Shire Pharmaceuticals
                         Group plc 

Hampshire International Business Park, 

Chineham, Basingstoke RG24 8EP UK 

Tel +44 1256 894000 

Fax +44 1256 894708 

http://www.shire.com 

New River Pharmaceuticals 

1881 Grove Avenue Radford, VA 24141 

Tel +1 540 633 7978 Fax: +1 540 633 7979

http://www.nrpharma.com	

For immediate release 

 * (ET) * (GMT) 

Shire and New River announce collaboration on Phase 3 ADHD drug 

candidate 

BASINGSTOKE, UK, PHILADELPHIA, PA, US and RADFORD, Va., US January 31, 2005— Shire Pharmaceuticals Group plc (LSE: SHP; NASDAQ: SHPGY; TSX: SHQ) and New River Pharmaceuticals Inc.
(NASDAQ: NRPH) announced today the signing of an agreement for the global commercialization of NRP104, New River’s Phase 3 compound for treatment of Attention Deficit Hyperactivity Disorder (ADHD), as well as for other potential
indications.

Under the terms of the agreement the parties will collaborate on NRP104 development, manufacturing, marketing and sales in the US. Shire will book the product sales and New River may supply up to 25% of the sales effort under a
co-promotion right.  New River will be financially and operationally responsible for clinical and manufacturing development. 

Upon U.S. Food and Drug Administration (FDA) approval, the parties will divide operating profit in accordance with the following general principles: Shire will retain 75% of profits for the first two years following launch
and the parties will share the profits equally thereafter.

In the rest of the world, Shire has a license to develop and commercialize NRP104 and New River will receive a low double-digit royalty on net sales. 

Shire pays an initial sum of US$50 million on signing, a further US$50 million upon acceptance of filing of the New Drug Application by the FDA and up to US$300 million in milestone payments depending on the characteristics
of the FDA-approved product labeling. An additional US$100 million milestone would be payable as a sales bonus upon achieving a significant sales target. Shire currently plans to expense the first two US$50 million payments, and to capitalize and
amortize the milestone payments and the sales bonus over the life of the product.

Shire may be entitled to refunds of amounts previously paid in the event of a delayed product approval, or upon FDA approval depending on the characteristics of the approved product labeling.

Matthew Emmens, Chief Executive of Shire, said:

“This is a strong addition to our ADHD portfolio and complements the development strategy of Shire and its pipeline. NRP104 is in late stage development and we are encouraged by the data that we have seen to date and hope
that the new drug has similar efficacy of currently marketed ADHD treatments with potential additional advantages. Importantly, NRP104 could become a global ADHD product.  We have structured the financial payments for this collaboration to reflect
the potential of the new drug and look forward to progressing this product with New River.” 

R.J. Kirk, Chairman and Chief Executive Officer of New River, said:

“We are delighted to announce this collaboration with Shire, a company that we believe will bring substantial value to this project as we plan and hopefully execute the commercialization of NRP104.  Shire’s CNS
expertise and leadership position in the ADHD market allows them to significantly contribute to this collaboration in a manner that we believe will optimally serve the interests of our shareholders.  We therefore believe that Shire will be our ideal
partner for this product and we look forward to working with their outstanding team to fully realize the potential of NRP104.”

For further information please contact: 

	
Shire Pharmaceuticals Group plc
        	

        	

        
	 		
	
Investor Relations
        	

        	

        
	 	 	 
	
Cléa Rosenfeld (UK and Europe)
        	
+
        	
  44 1256 894 160
        
	 	 	 
	
Brian Piper (US and Canada)
        	
+
        	
  1 484 595 8252
        

	
Media
        	

        	

        
	 	 	 
	
Jessica Mann (UK and Europe)
        	
+
        	
  44 1256 894 280
        
	 	 	 
	
Matthew Cabrey (US)
        	
+
        	
  1 484 595 8248
        
	 	 	 
	 

        	 	 
	
New River Pharmaceuticals Inc.
        	

        	

        
	 		
	
Investor Relations
        	

        	

        
	 	 	 
	
John Quirk
        	
+
        	
  1 646 536 7029
        
	 		
	
jquirk@theruthgroup.com
        	

        	

        
	 		
	
Media
        	

        	

        
	 	 	 
	
Zack Kubow
        	
+
        	
  1 646 536 7020
        
	 		
	
zkubow@theruthgroup.com
        	

        	

        

Notes to editors 

Shire 

Shire Pharmaceuticals Group Plc is a global pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of
central nervous system, gastrointestinal and renal diseases. Shire has operations in the world’s key pharmaceutical markets (U.S., Canada, U.K., France, Italy, Spain and Germany).

For further information on Shire, please visit the Company’s website: www.shire.com 

“SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such
risks or uncertainties materialize, Shire’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development,
manufacturing and commercialization, the impact of competitive products, including, but not limited to, the impact of those on Shire’s Attention Deficit & Hyperactivity Disorder (ADHD) franchise, patents, including but not limited to, legal
challenges relating to Shire’s ADHD franchise, government regulation and approval, including but not limited to the expected product approval dates of METHYPATCH® (methylphenidate) and NRP104, including its scheduling classification by the
Drug Enforcement Agency in the United States, Shire’s ability to secure new products for development, the implementation of the current reorganization and other risks and uncertainties detailed from time to time in Shire’s filings,
including its Annual Report on Form 10-K for the year ended December 31, 2003, with the Securities and Exchange Commission. 

New River 

New River Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing novel pharmaceuticals that are safer and improved versions of widely-prescribed drugs, including amphetamines and opioids. 

For further information on New River, please visit the company’s website at www.nrpharma.com. 

“SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 

This press release contains certain forward-looking information that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private 

Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as “expect(s),” “feel(s),” “believe(s),” “will,”
“may,” “anticipate(s)” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions;
statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are
difficult to predict and generally beyond the control of New River Pharmaceuticals, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks
and uncertainties include: those discussed and identified in the New River Pharmaceuticals Inc. final prospectus filed on August 5, 2004, under Rule 424(b) of the Securities Act of 1933, as amended; the ability to successfully execute the
collaboration with Shire within a reasonable timeframe or at all; the progress of our product development programs; the status of our preclinical and clinical development of potential drugs, the likely success of our drug products in clinical trials
and the regulatory approval process, particularly whether and under what circumstances NRP104 will be approved by the FDA; the ability to develop, manufacture, launch and market NRP104; our projections for future revenues, profitability and ability
to achieve certain sales targets; our estimates regarding our capital requirements and our needs for additional financing; the likely scheduling and labeling of NRP104; our ability to attract partners with acceptable development, regulatory and
commercialization expertise; the likelihood of regulatory approval under Section 505(b)(2) under the Federal Food, Drug, and Cosmetic Act; the expected benefits of NRP104 such as efficacy and potential advantages; our ability to develop safer and
improved versions of widely-prescribed drugs; and our ability to obtain favorable patent claims. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. New River Pharmaceuticals
does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider
the various disclosures in New River Pharmaceuticals’ final prospectus filed with the SEC on August 5, 2004, under Rule 424(b) of the Securities Act of 1933, as amended, as well as other public filings with the SEC. 

EXHIBIT D 

TECHNICAL TRADE SECRETS 

     Compound means the compound currently identified by New River as NRP104 with the chemical structure [*] and any isomers, salts, solvates, polymorphs, esters and
derivatives of any of the foregoing, in each case where an active moiety of such compound is [*]. 

EXHIBIT E 

CERTAIN PRODUCTS OF SHIRE 

Development Projects

 [*]

 Marketed Stimulant Products

 [*] 

SCHEDULE 5.1.1 

NEW RIVER MANUFACTURING CONTRACTORS AND ACTIVITIES 

	 NAME
                         OF THIRD PARTY 	 ACTIVITIES PERFORMED /
                         TO BE PERFORMED 
	[*] 	 Manufacture of
                    Drug Substance (API) 
	[*] 	 Manufacture of
                    Drug product (formulation and encapsulation) 

SCHEDULE 11.1.3(b) 

INDs and DRUG APPROVAL APPLICATIONS 

United States IND #67482 

United States IND #70109 

SCHEDULE 11.1.3(c)(i)(I) 

LICENSED PATENTS [*] 

	
Serial No.
(Filing
Date)
        	
Next Action Date

(Official fees to be paid within
180 days) 1
        
	
[*]
        	
[*]
        

__________

1 Official fees do not include Attorney or Foreign Associate Fees. 

SCHEDULE 11.1.3(c)(i)(II) 

LICENSED PATENTS THAT DO NOT CLAIM COMPOUND OF COLLABORATION PRODUCTS

	
Serial No.
(Filing
Date)
        	
Next Action Date

(Official fees to be paid within
180 days) 
	
[*]
        	
[*]<PAGE>
                                                                     EXHIBIT 4.2

--------------------------------------------------------------------------------

                            6.92% DEBENTURES DUE 2028

                          SECOND SUPPLEMENTAL INDENTURE

                                     between

                        CINCINNATI FINANCIAL CORPORATION

                                       and

                    THE BANK OF NEW YORK TRUST COMPANY, N.A.

                                   as Trustee

                             Dated as of May 9, 2005

--------------------------------------------------------------------------------
<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                             PAGE
                                                                                             ----
<S>      <C>               <C>                                                               <C>
ARTICLE 1         DEFINITIONS...................................................................2

         Section 1.01.     Definition of Terms..................................................2

ARTICLE 2         THE SECURITIES................................................................2

         Section 2.01.     Designation..........................................................2
         Section 2.02.     Principal Amount.....................................................3
         Section 2.03.     Form of Securities; Global Form......................................3
         Section 2.04.     Restrictive Legends..................................................4
         Section 2.05.     Transfer Restrictions................................................4

ARTICLE 3         DEFEASANCE....................................................................6

         Section 3.01.     Defeasance By The Company............................................6

ARTICLE 4         MISCELLANEOUS.................................................................7

         Section 4.01.     Ratification Of Indenture............................................7
         Section 4.02.     Trustee Not Responsible For Recitals.................................7
         Section 4.03.     Governing Law........................................................7
         Section 4.04.     Separability.........................................................7
         Section 4.05.     Counterparts.........................................................7
</TABLE>
<PAGE>
         SECOND SUPPLEMENTAL INDENTURE dated as of May 9, 2005 (the "SECOND
SUPPLEMENTAL INDENTURE") between Cincinnati Financial Corporation, an Ohio
corporation (the "COMPANY"), and The Bank of New York Trust Company, N.A., a
national banking association, as trustee (the "TRUSTEE") under the Indenture
dated as of November 1, 2004 (the "2004 INDENTURE") between the Company and the
Trustee.

         WHEREAS, the Company executed and delivered the 2004 Indenture to the
Trustee to provide, among other things, for unsecured debentures, notes or other
evidences of indebtedness to be issued by the Company from time to time in one
or more series under the 2004 Indenture;

         WHEREAS, Section 9.01(g) of the 2004 Indenture provides that the
Company and the Trustee may enter into an indenture supplemental to the 2004
Indenture to establish the form or terms of Securities (as defined in the 2004
Indenture) of any series as provided by Sections 2.01 and 2.02 of the 2004
Indenture;

         WHEREAS, the Company executed and delivered a Supplemental Indenture
dated as of November 1, 2004 (the "FIRST SUPPLEMENTAL INDENTURE" and the 2004
Indenture as supplemented by the First Supplemental Indenture and by this Second
Supplemental Indenture, the "INDENTURE") to the Trustee in connection with the
issuance of the Company's 6.125% senior notes due 2034, a series of securities
under the Indenture;

         WHEREAS, the Board of Directors of the Company has duly adopted
resolutions authorizing the Company to execute and deliver this Second
Supplemental Indenture;

         WHEREAS, pursuant to the terms of the Indenture, the Company desires to
enter into this Second Supplemental Indenture to provide for the establishment
of a new series of its Securities to be known as its 6.92% Debentures due 2028
(the "6.92% NOTES");

         WHEREAS, the Company has requested that the Trustee execute and deliver
this Second Supplemental Indenture and all things necessary to make (i) this
Second Supplemental Indenture a valid instrument in accordance with its terms,
and (ii) the 6.92% Notes, when executed by the Company and authenticated and
delivered by the Trustee, the valid obligations of the Company, have been done;

         NOW THEREFORE, in consideration of the purchase and acceptance of the
6.92% Notes by the Holders thereof, and for the purpose of setting forth, as
provided in the Indenture, the form and terms of the 6.92% Notes, the Company
covenants and agrees with the Trustee as follows:
<PAGE>
                                   ARTICLE 1

                                   DEFINITIONS

         Section 1.01. Definition of Terms.

         Unless the context otherwise requires:

         (a) a term defined in the 2004 Indenture has the same meaning when used
in this Second Supplemental Indenture unless the definition of such term is
amended and supplemented pursuant to the First Supplemental Indenture or this
Second Supplemental Indenture;

         (b) a term defined anywhere in this Second Supplemental Indenture has
the same meaning throughout;

         (c) the singular includes the plural and vice versa;

         (d) a reference to a Section or Article is to a Section or Article of
this Second Supplemental Indenture; and

         (e) headings are for convenience of reference only and do not affect
interpretation.

                                   ARTICLE 2

                                 THE SECURITIES

         Section 2.01. Designation. (a) The Company hereby establishes a series
of Securities designated the "6.92% Debentures due 2028" for issuance under the
Indenture. Their Stated Maturity shall be May 15, 2028 and they shall bear
interest at the rate of 6.92% per annum from the Issue Date or from the most
recent Interest Payment Date to which interest has been paid or duly provided
for, as the case may be, payable semi-annually in arrears on each May 15 and
November 15 (each, an Interest Payment Date), commencing May 15, 2005, until the
principal thereof is paid or made available for payment.

         The 6.92% Notes are not subject to any sinking fund. The 6.92% Notes
may not be redeemed prior to the Stated Maturity.

         Interest on the 6.92% Notes shall be computed on the basis of a 360 day
year comprised of twelve 30 day months.

         (b) The 6.92% Notes shall be issuable in registered form without
coupons in denominations of $1,000 and any integral multiple thereof.

                                       2
<PAGE>
         (c) The principal of, premium, if any, and interest on the 6.92% Notes
shall be payable at the office or agency of the Company designated for that
purpose as the Place of Payment, as provided in Section 4.02 of the Indenture;
provided, however, that interest may be payable at the option of the Company by
check mailed to the address of the Person entitled thereto as such address shall
appear on the Security Register on the record date for such interest payment.

         Section 2.02. Principal Amount. The 6.92% Notes shall be limited to an
aggregate principal amount of $392,249,000, except for 6.92% Notes authenticated
and delivered upon registration of transfer of, or in exchange for, or in lieu
of, other Securities of this same series pursuant to Sections 3.02, 3.03, 3.04
or 10.02 of the Indenture.

         Section 2.03. Form of Securities; Global Form.

         (a) The 6.92% Notes shall be substantially in the forms of Exhibit A
hereto. The terms and provisions contained in the form of 6.92% Notes set forth
in Exhibit A shall constitute, and are hereby expressly made, a part of the
Indenture as supplemented by this Second Supplemental Indenture.

         Any of the 6.92% Notes may have such letters, numbers or other marks of
identification and such notations, legends, endorsements or changes as the
officers executing the same may approve (execution thereof to be conclusive
evidence of such approval) and as are not inconsistent with the provisions of
the Indenture, or as may be required by the Depository or as may be required to
comply with any applicable law or with any rule or regulation made pursuant
thereto or with any rule or regulation of any securities exchange or automated
quotation system on which the 6.92% Notes may be listed, or to conform to usage,
or to indicate any special limitations or restrictions to which any particular
6.92% Notes are subject.

         (b) So long as any 6.92% Notes are eligible for book-entry settlement
with the Depository, or unless otherwise required by law, or otherwise
contemplated by Section 2.05(b), all of the 6.92% Notes of this series shall be
represented by one or more 6.92% Notes in global form registered in the name of
the Depository or the nominee of the Depository (each and collectively, the
"GLOBAL NOTE"). The transfer and exchange of beneficial interests in any such
Global Note shall be effected through the Depository in accordance with the
Indenture and the applicable procedures of the Depository. Except as provided in
Section 2.05, beneficial owners of a Global Note shall not be entitled to have
certificates registered in their names, will not receive or be entitled to
receive physical delivery of certificates in definitive form and will not be
considered Holders of such Global Note.

         Any Global Note shall represent such of the outstanding 6.92% Notes as
shall be specified therein and shall provide that it shall represent the
aggregate amount of outstanding 6.92% Notes from time to time endorsed thereon
and that the aggregate amount of outstanding 6.92% Notes represented thereby may
from

                                       3
<PAGE>
time to time be increased or reduced to reflect redemptions, transfers or
exchanges permitted hereby. Any endorsement of a Global Note to reflect the
amount of any increase or decrease in the amount of outstanding 6.92% Notes
represented thereby shall be made by the Trustee in such manner and upon
instructions given by the Holder of such 6.92% Notes in accordance with the
Indenture. Payment of principal of and interest and premium, if any, on any
Global Note shall be made to the Holder of such note.

         Section 2.04. Restrictive Legends. Each Global Note shall bear the
following legend on the face thereof:

THIS 6.92% NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREAFTER
REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITORY OR A NOMINEE
THEREOF. UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN
DEFINITIVE FORM, THIS 6.92% NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE
DEPOSITORY TO A NOMINEE OF THE DEPOSITORY OR BY A NOMINEE OF THE DEPOSITORY TO
THE DEPOSITORY OR ANOTHER NOMINEE OF THE DEPOSITORY OR BY THE DEPOSITORY OR ANY
SUCH NOMINEE TO A SUCCESSOR DEPOSITORY OR A NOMINEE OF SUCH SUCCESSOR
DEPOSITORY.

         Each Global Note for which The Depository Trust Company is the
Depository shall also bear the following legend on the face thereof:

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION ("DTC"), TO THE COMPANY OR ITS
AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE
ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS REQUESTED
BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR
TO SUCH OTHER ENTITY AS IS REQUIRED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY
TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON
IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST
HEREIN.

         Section 2.05. Transfer Restrictions.

         (a) The Trustee shall have no obligation or duty to monitor, determine
or inquire as to compliance with any restrictions on transfer imposed under this
Supplemental Indenture or under applicable law with respect to any transfer of
any interest in any Security (including any transfers between or among members
of, or participants in, the Depository or beneficial owners of interests in any
Global Note) other than to require delivery of such certificates and other
documentation or evidence as are expressly required by, and to do so if and when

                                       4
<PAGE>
expressly required by the terms of, this Second Supplemental Indenture, and to
examine the same to determine substantial compliance as to form with the express
requirements hereof.

         (b) The following provisions shall apply only to Global Notes:

            (i) Each Global Note authenticated under this Second Supplemental
         Indenture shall be registered in the name of the Depository or a
         nominee thereof and delivered to such Depository or a nominee thereof
         or the Trustee if the Trustee is acting as custodian for the Depository
         or its nominee with respect to such Global Note, and each such Global
         Note shall constitute a single Security for all purposes of the
         Indenture and this Second Supplemental Indenture.

            (ii) Notwithstanding any other provision in the Indenture, no Global
         Note may be exchanged in whole or in part for 6.92% Notes registered,
         and no transfer of a Global Note in whole or in part may be registered,
         in the name of any Person other than the Depository or a nominee
         thereof unless (A) the Depository (x) has notified the Company that it
         is unwilling or unable to continue as Depository for such Global Note
         or (y) has ceased to be a clearing agency registered under the
         Securities Exchange Act of 1934, (B) an Event of Default has occurred
         and is continuing with respect to the 6.92% Notes or (C) the Company,
         in its sole discretion, notifies the Trustee in writing that it no
         longer wishes to have the 6.92% Notes represented by a Global Note. Any
         Global Note exchanged pursuant to clause (A) or (B) above shall be so
         exchanged in whole and not in part and any Global Note exchanged
         pursuant to clause (C) above may be exchanged in whole or from time to
         time in part as directed by the Company. Any 6.92% Note issued in
         exchange for a Global Note or any portion thereof shall be a Global
         Note; provided that any such 6.92% Note so issued that is registered in
         the name of a Person other than the Depository or a nominee thereof
         shall not be a Global Note.

            (iii) 6.92% Notes issued in exchange for a Global Note or any
         portion thereof pursuant to clause (ii) above shall be issued in
         definitive, fully registered form, without interest coupons, shall have
         an aggregate principal amount equal to that of such Global Note or
         portion thereof to be so exchanged, shall be registered in such names
         and be in such authorized denominations as the Depository shall
         designate and shall bear any legends required hereunder. Any Global
         Note to be exchanged in whole shall be surrendered by the Depository to
         the Trustee, as Securities registrar. With regard to any Global Note to
         be exchanged in part, either such Global Note shall be so surrendered
         for exchange or, if the Trustee is acting as custodian for the
         Depository or its nominee with respect to such Global Note, the
         principal amount thereof shall be reduced, by an amount equal to the
         portion thereof to be so exchanged, by means of an appropriate
         adjustment made on the records of the Trustee. Upon any

                                       5
<PAGE>
         such surrender or adjustment, the Trustee shall authenticate and make
         available for delivery the 6.92% Note issuable on such exchange to or
         upon the written order of the Depository or an authorized
         representative thereof.

            (iv) In the event of the occurrence of any of the events specified
         in clause (ii) above, the Company will promptly make available to the
         Trustee a reasonable supply of certificated 6.92% Notes in definitive,
         fully registered form, without interest coupons.

            (v) Neither any members of, or participants in, the Depository
         ("AGENT MEMBERS") nor any other Persons on whose behalf Agent Members
         may act shall have any rights under the Indenture with respect to any
         Global Notes registered in the name of the Depository or any nominee
         thereof, and the Depository or such nominee, as the case may be, may be
         treated by the Company, the Trustee and any agent of the Company or the
         Trustee as the absolute owner and Holder of such Global Notes for all
         purposes whatsoever. Notwithstanding the foregoing, nothing herein
         shall prevent the Company, the Trustee or any agent of the Company or
         the Trustee from giving effect to any written certification, proxy or
         other authorization furnished by the Depository or such nominee, as the
         case may be, or impair, as between the Depository, its Agent Members
         and any other Person on whose behalf an Agent Member may act, the
         operation of customary practices of such Persons governing the exercise
         of the rights of a Holder of any 6.92% Note.

            (vi) At such time as all interests in a Global Note have been
         redeemed, repurchased, converted, canceled or exchanged for 6.92% Notes
         in certificated form, such Global Note shall, upon receipt thereof, be
         canceled by the Trustee in accordance with standing procedures and
         instructions existing between the Depository and the Trustee. At any
         time prior to such cancellation, if any interest in a Global Note is
         redeemed, repurchased, converted, canceled or exchanged for 6.92% Notes
         in certificated form, the principal amount of such Global Note shall,
         in accordance with the standing procedures and instructions existing
         between the Depository and the Trustee, be appropriately reduced, and
         an endorsement shall be made on such Global Note, by the Trustee, at
         the direction of the Trustee, to reflect such reduction.

                                   ARTICLE 3

                                   DEFEASANCE

         Section 3.01. Defeasance By The Company. The 6.92% Notes shall be
subject to defeasance at the option of the Company in accordance with the terms
and conditions set forth in Article 11 of the 2004 Indenture.

                                       6
<PAGE>
                                   ARTICLE 4

                                  MISCELLANEOUS

         Section 4.01. Ratification Of Indenture.

         The 2004 Indenture is in all respects ratified and confirmed, and this
Second Supplemental Indenture shall be deemed part of the 2004 Indenture in the
manner and to the extent herein and therein provided.

         Section 4.02. Trustee Not Responsible For Recitals.

         The recitals herein contained are made by the Company and not by the
Trustee, and the Trustee assumes no responsibility for the correctness thereof.
The Trustee makes no representation as to the validity or sufficiency of this
Second Supplemental Indenture.

         Section 4.03. Governing Law.

         This Second Supplemental Indenture and each 6.92% Note shall be
governed by and construed in accordance with the laws of the State of New York
without regard to the principles of conflicts of laws thereof.

         Section 4.04. Separability.

         In case any one or more of the provisions contained in this Second
Supplemental Indenture or in the 6.92% Notes shall for any reason be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall not affect any other provisions of this Second
Supplemental Indenture or of the 6.92% Notes, but this Second Supplemental
Indenture and the 6.92% Notes shall be construed as if such invalid or illegal
or unenforceable provision had never been contained herein or therein.

         Section 4.05. Counterparts.

         This Second Supplemental Indenture may be executed in any number of
counterparts each of which shall be an original; but such counterparts shall
together constitute but one and the same instrument.

                                       7
<PAGE>
         IN WITNESS WHEREOF, the Company has caused this Second Supplemental
Indenture to be signed and acknowledged by its duly authorized officers, and The
Bank of New York Trust Company, N.A., has caused this Second Supplemental
Indenture to be signed by one of its duly authorized officers, as of the day and
year first above written.

                       CINCINNATI FINANCIAL CORPORATION

                       By:      /s/ John J. Schiff, Jr.
                                ---------------------------------------------
                                Name:          John J. Schiff, Jr.
                                Title:         President and Chief
                                               Executive Officer

                       By:      /s/ Kenneth W. Stecher
                                ---------------------------------------------
                                Name:          Kenneth W. Stecher
                                Title:         Treasurer

                       THE BANK OF NEW YORK TRUST
                         COMPANY, N.A., as Trustee

                       By:      /s/ Geoffrey D. Anderson
                                ---------------------------------------------
                                Name:          Geoffrey D. Anderson
                                Title:         Assistant Vice President
<PAGE>
                                                                       EXHIBIT A

                                 [FACE OF NOTE]

THIS 6.92% NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREAFTER
REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITORY OR A NOMINEE
THEREOF. UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN
DEFINITIVE FORM, THIS 6.92% NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE
DEPOSITORY TO A NOMINEE OF THE DEPOSITORY OR BY A NOMINEE OF THE DEPOSITORY TO
THE DEPOSITORY OR ANOTHER NOMINEE OF THE DEPOSITORY OR BY THE DEPOSITORY OR ANY
SUCH NOMINEE TO A SUCCESSOR DEPOSITORY OR A NOMINEE OF SUCH SUCCESSOR
DEPOSITORY.

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE
DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION ("DTC"), TO THE COMPANY OR ITS
AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE
ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS REQUESTED
BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR
TO SUCH OTHER ENTITY AS IS REQUIRED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY
TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON
IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST
HEREIN.

                                      A-1
<PAGE>
                                                             CUSIP No. 172062AF8

                        CINCINNATI FINANCIAL CORPORATION
                            6.92% Debentures Due 2028

No. 1
$392,249,000

         CINCINNATI FINANCIAL CORPORATION, a corporation duly organized and
existing under the laws of Ohio (herein called the "COMPANY", which term
includes any successor Person under the Indenture referred to herein), for value
received, hereby promises to pay to CEDE & Co., or registered assigns, the
principal sum of THREE HUNDRED NINETY TWO MILLION, TWO HUNDRED FORTY NINE
DOLLARS ($392,249,000) on May 15, 2028, and to pay interest thereon from April
29, 2005, or from the most recent Interest Payment Date to which interest has
been paid or duly provided for, semiannually in arrears on May 15 and November
15 in each year commencing May 15, 2005, at the rate of 6.92% per annum, until
the principal hereof is paid or made available for payment. The interest so
payable, and punctually paid or duly provided for, on any Interest Payment Date
will, as provided in such Indenture, be paid to the Person in whose name this
6.92% Note (or one or more predecessor 6.92% Notes) is registered at the close
of business on the Regular Record Date for such interest, which shall be the May
1 or November 1 (whether or not a Business Day), as the case may be, next
preceding such Interest Payment Date; provided, however, that interest at Stated
Maturity will be payable to the Person to whom principal shall be payable.
Except as otherwise provided in the Indenture, any such interest not so
punctually paid or duly provided for will forthwith cease to be payable to the
Holder on such Regular Record Date and may either be paid to the Person in whose
name this 6.92% Note (or one or more predecessor 6.92% Notes) is registered at
the close of business on a Special Record Date for the payment of such Defaulted
Interest to be fixed by the Trustee, notice whereof shall be given to Holders of
6.92% Notes not less than 10 days prior to such Special Record Date, or be paid
at any time in any other lawful manner not inconsistent with the requirements of
any securities exchange on which the 6.92% Notes may be listed, and upon such
notice as may be required by such exchange, all as more fully provided in said
Indenture. Payment of the principal of and interest on this 6.92% Note will be
made at the Place of Payment which, subject to the right of the Company to vary
or terminate the appointment of such agency, shall initially be the principal
office of the Trustee, in such coin or currency of the United States of America
as at the time of payment is legal tender for payment of public and private
debts; provided, however, that, at the option of the Company, payment of
interest may be made by check mailed to the address of the Person entitled
thereto as such address shall appear in the Security Register.

                                      A-2
<PAGE>
         Reference is hereby made to the further provisions of this 6.92% Note
set forth on the pages following the certificate of authentication hereon, which
further provisions shall for all purposes have the same effect as if set forth
at this place.

         Unless the certificate of authentication hereon has been executed by
the Trustee referred to below, directly or through an Authenticating Agent, by
manual signature of an authorized signatory, this 6.92% Note shall not be
entitled to any benefit under the Indenture or be valid or obligatory for any
purpose.

                                      A-3

<PAGE>
      IN WITNESS WHEREOF, Cincinnati Financial Corporation has caused this
instrument to be signed by its duly authorized officers.

Dated: May ____, 2005
                               CINCINNATI FINANCIAL CORPORATION

                               By:
                                     ------------------------------------
                                     Title:

                               By:
                                     ------------------------------------
                                     Title:

                                      A-4
<PAGE>
                          CERTIFICATE OF AUTHENTICATION

      This is one of the 6.92% Notes of the series designated herein and
referred to in the within-mentioned Indenture.

                                    The Bank of New York Trust Company,
                                       N.A., as Trustee

                                    By:
                                          ------------------------------------
                                          Authorized Signatory

                                      A-5
<PAGE>
                              [REVERSE OF SECURITY]
                        CINCINNATI FINANCIAL CORPORATION
                            6.92% Debentures Due 2028

      This note is one of a duly authorized issue of Securities of the Company
(herein called the "6.92% NOTES"), issued and to be issued in one or more series
under the Indenture, dated as of November 1, 2004 as supplemented by the
Supplemental Indenture, dated as of November 1, 2004, and by the Second
Supplemental Indenture, dated as of May 9, 2005 (collectively herein called the
"INDENTURE"), between the Company and The Bank of New York Trust Company, N.A.
(herein called the "TRUSTEE," which term includes any successor trustee under
the Indenture), to which Indenture and all indentures supplemental thereto
reference is hereby made for a statement of the respective rights, limitations
of rights, duties and immunities thereunder of the Company, the Trustee and the
Holders of the 6.92% Notes and of the terms upon which the 6.92% Notes are, and
are to be, authenticated and delivered. This 6.92% Note is one of the 6.92%
Notes of the series designated herein, limited in aggregate principal amount to
$392,249,000.

      This 6.92% Note is not subject to any sinking fund. The 6.92% Notes may
not be redeemed prior to the Stated Maturity.

      As provided in the Indenture, defeasance may occur at any time of (a) the
entire indebtedness of the Company on this 6.92% Note and (b) certain
restrictive covenants and the related defaults and Events of Default, upon
compliance by the Company with certain conditions set forth therein, which
provisions apply to this 6.92% Note.

      If an Event of Default with respect to 6.92% Notes shall occur and be
continuing, the principal of the 6.92% Notes may be declared due and payable in
the manner and with the effect provided in the Indenture.

      The Indenture permits, with certain exceptions as therein provided, the
amendment thereof and the modification of the rights and obligations of the
Company and the rights of the Holders of the Securities of each series
(including these 6.92% Notes) to be affected under the Indenture at any time by
the Company and the Trustee with the consent of the Holders of greater than 50%
in principal amount of the Securities at the time Outstanding of each series
affected. The Indenture also contains provisions permitting the Holders of
specified percentages in principal amount of the Securities at the time
Outstanding of each series affected, on behalf of the Holders of all Securities
of such series, to waive compliance by the Company with certain provisions of
the Indenture and certain past defaults under the Indenture and their
consequences. Any such consent or waiver by the Holder of this 6.92% Note shall
be conclusive and binding upon such Holder and upon all future Holders of this
6.92% Note and of any 6.92%

                                      A-6
<PAGE>
Note issued upon the registration of transfer hereof or in exchange herefor or
in lieu hereof, whether or not notation of such consent or waiver is made upon
this 6.92% Note.

      As set forth in, and subject to, the provisions of the Indenture, no
Holder of any 6.92% Note will have any right to institute any proceeding with
respect to the Indenture or for any remedy thereunder, unless such Holder shall
have previously given to the Trustee written notice of a continuing Event of
Default with respect to such Security, the Holders of not less than 25% in
principal amount of the Outstanding 6.92% Notes shall have made written request,
and offered indemnity, to the Trustee to institute such proceeding as trustee,
and the Trustee shall not have received from the Holders of a majority in
principal amount of the Outstanding 6.92% Notes a direction inconsistent with
such request and shall have failed to institute such proceeding within 60 days;
provided, however, that such limitations do not apply to a suit instituted by
the Holder hereof for the enforcement of payment of the principal of or interest
on this 6.92% Note on or after the respective due dates expressed herein.

      No reference herein to the Indenture and no provision of this 6.92% Note
or of the Indenture shall alter or impair the obligation of the Company, which
is absolute and unconditional, to pay the principal of and interest on this
6.92% Note at the times, places, and rate, and in the coin or currency, herein
prescribed.

      As provided in the Indenture and subject to certain limitations therein
set forth, the transfer of this 6.92% Note is registrable in the Security
Register, upon surrender for registration of transfer at the office or agency of
the Company maintained for that purpose, duly endorsed by, or accompanied by a
written instrument of transfer in form satisfactory to the Company and the
Security Registrar duly executed by, the Holder hereof or his attorney duly
authorized in writing, and thereupon one or more new 6.92% Notes of this series
and of like tenor, of authorized denominations and for the same aggregate
principal amount, will be issued to the designated transferee or transferees.

      The 6.92% Notes of this series are issuable only in global or definitive
registered form, without coupons, in denominations of $1,000 and integral
multiples thereof. As provided in the Indenture and subject to certain
limitations therein set forth and to the limitations described below, if
applicable, 6.92% Notes are exchangeable at the office or agency of the Company
for a like aggregate principal amount of 6.92% Notes of a different authorized
denomination, as requested by the Holder surrendering the same.

      This 6.92% Note is exchangeable for 6.92% Notes in definitive registered
form only if (A) the Depository (x) notifies the Company that it is unwilling or
unable to continue as Depository for this Global Note or (y) ceases to be a
clearing agency registered under the Securities Exchange Act of 1934, as

                                      A-7
<PAGE>
amended, (B) an Event of Default has occurred and is continuing with respect to
this 6.92% Note, or (C) the Company, in its sole discretion, determines that
this 6.92% Note shall be exchangeable for definitive 6.92% Notes in registered
form and so notifies the Trustee in writing; provided that the definitive 6.92%
Notes so issued in exchange for this Global Note shall be in denominations of
$1,000 and integral multiples thereof and be of like aggregate principal amount
and tenor as the portion of this Global Note to be exchanged, and provided
further that, unless the Company agrees otherwise, 6.92% Notes of this series in
definitive registered form will be issued in exchange for this Global Note, or
any portion hereof, only if such 6.92% Notes in definitive registered form were
requested by written notice to the Trustee or the Security Registrar by or on
behalf of a Person who is beneficial owner of an interest hereof given through
the Holder hereof. Except as provided above, owners of beneficial interests in
this Global Note will not be entitled to receive physical delivery of 6.92%
Notes in definitive registered form and will not be considered the Holders
thereof for any purpose under the Indenture.

      No service charge shall be made for any such registration of transfer or
exchange, but the Company may require payment of a sum sufficient to cover any
tax or other governmental charge payable in connection therewith.

      Prior to the due presentment of this 6.92% Note for registration of
transfer, the Company, the Trustee and any agent of the Company or the Trustee
may treat the Person in whose name this 6.92% Note is registered as the owner
hereof for all purposes, whether or not this 6.92% Note is overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the
contrary.

      The Indenture and the 6.92% Notes shall be governed by and construed in
accordance with the laws of the State of New York.

      All terms used in this 6.92% Note which are defined in the Indenture shall
have the meanings assigned to them in the Indenture.

                                      A-8
<PAGE>
                                  ABBREVIATIONS

      The following abbreviations, when used in the inscription on the face of
this instrument, shall be construed as though they were written out in full
according to applicable laws or regulations:

TEN COM  --             as tenants in common
TEN ENT  --             as tenants by the entireties
JT TEN  --              as joint tenants with right of survivorship and not as
                        tenants in common

UNIF GIFT MIN ACT  --   Custodian
                        Under Uniform
                        Gifts to
                        Minors Act

                        (Cust)         (Minor)        (State)

      Additional abbreviations may also be used though not in the above list.

                                      A-9
<PAGE>
                            [FORM OF TRANSFER NOTICE]

      FOR VALUE RECEIVED, the undersigned hereby sell(s), assign(s) and
transfer(s) unto

PLEASE INSERT SOCIAL SECURITY OR
OTHER IDENTIFYING NUMBER OF ASSIGNEE

-----------------------

PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS INCLUDING
POSTAL ZIP CODE OF ASSIGNEE

-----------------------

-----------------------

-----------------------

the within 6.92% Note and all rights thereunder, hereby irrevocably constituting
and appointing ____________ attorney to transfer said Security on the books of
the Company, with full power of substitution in the premises.

Dated:

                                             -----------------------
                                             Signature

      NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS
WRITTEN UPON THE FACE OF THE WITHIN INSTRUMENT IN EVERY PARTICULAR, WITHOUT
ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATEVER.

                                      A-10
<PAGE>
                                                                      Schedule I

                 [Include as Schedule I only for a Global Note]

                    SCHEDULE OF EXCHANGES OF DEFINITIVE NOTES

                        CINCINNATI FINANCIAL CORPORATION
                            6.92% Debentures due 2028

No. [   ]

      The following exchanges of a part of this Global Note for Definitive Notes
have been made:

<TABLE>
<CAPTION>
                                                       PRINCIPAL       SIGNATURE OF
                     AMOUNT OF        AMOUNT OF      AMOUNT OF THIS     AUTHORIZED
                    DECREASE IN      INCREASE IN      GLOBAL NOTE      SIGNATORY OF
                     PRINCIPAL        PRINCIPAL      FOLLOWING SUCH     TRUSTEE OR
                   AMOUNT OF THIS   AMOUNT OF THIS    DECREASE (OR       SECURITY
DATE OF EXCHANGE    GLOBAL NOTE      GLOBAL NOTE       INCREASE)        CUSTODIAN
----------------    -----------      -----------       ---------        ---------
<S>                <C>              <C>              <C>               <C>
</TABLE>

                                      A-11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]